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Abstract 
The deregulation of FGF signalling is closely linked to many human diseases, including 
cancer. Through phosphorylation and dephosphorylation processes, FGF signalling is 
finely controlled. The thesis presented focuses on applying mass spectrometry tools to 
investigate FGF signalling using the breast carcinoma SUM52 cell line. 
High-Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS) is a technique 
that separates and focuses ions at atmospheric pressure. It has been demonstrated that 
the application of LC-FAIMS-MS/MS results in increased signal-to-noise ratios and 
improved dynamic range in the analysis of complex proteomics samples. The LC-
FAIMS-MS/MS method for large-scale quantitative analysis was optimized and the 
performance of LC-MS/MS and LC-FAIMS-MS/MS was compared. Results showed 
the two techniques shared good complementarity. The incorporation of FAIMS resulted 
in an increase in identifications of novel phosphosites and an increase in the 
identification of multiply-phosphorylated peptides. Next, a modified FAIMS interface 
was evaluated for proteomic analyses. This novel FAIMS device exhibited potential in 
enhancing proteomic analysis showing an increase in peak capacity and proteome 
coverage and a lower level of redundancy. Next, SRM was applied for accurate 
quantitation of 75 phosphopeptides in a time-resolved way. These candidates were 
selected from kinases in response to FGFR inhibition in a SILAC experiment performed 
on SUM52 and MFM233 cells, with peptides containing multiple sites of 
phosphorylation also included. The data revealed that these phosphorylation sites 
showed different associations with FGF1 stimulation. Expression patterns were 
clustered into early, mid- and late stage response. 
Results presented in this work range from the large-scale investigation of 
phosphorylation events involved in FGF signalling, the application of a novel FAIMS 
interface and a targeted quantitation profile of the key phosphorylation events in FGF 
signalling, which would benefit both understanding and the potential mechanisms of 
FGF signalling. 
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INTRODUCTION 
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1.1 Overview 
Fibroblast growth factor (FGF) ligands and receptors play important roles in the regulation of 
cell growth, cell division, angiogenesis and tumour growth. Accumulating evidence 
demonstrates that deregulation of FGF signalling is closely related to many human diseases 
including cancer. Through phosphorylation and dephosphorylation processes, FGF signalling 
is propagated through a series of receptor proteins, scaffolding proteins and signal mediators, 
leading to activation of multiple downstream pathways. 
Tandem mass spectrometry (MS/MS) combined with pre-fractionation and phosphoenrichment 
is a well-established workflow for large-scale quantitative phosphoproteomic analysis. One of 
the major challenges in phosphoproteomic research is to map sites of modification in multiply-
phosphorylated peptides. In recent years, ion mobility spectrometry has emerged as an 
attractive technique for specific and global proteome profiling. Field asymmetric waveform 
ion mobility spectrometry (FAIMS) is a gas phase separation technique based on the 
differences in ion mobility in high and low electric fields. Coupled with liquid chromatography 
(LC)-MS/MS, FAIMS has been shown to enhance proteomic analyses by extending proteome 
coverage, improving signal-to-noise and separating isomeric peptides.  
Following the discovery phase provided by a shotgun strategy, a targeted quantitation method 
is needed for biological interpretation. For sensitive detection and accurate quantitation of 
selected peptides, selected reaction monitoring (SRM) has emerged as the method of choice 
that complements the discovery capabilities of shotgun approach. Consistently identified and 
precisely quantified data across multiple samples provide the basis for a system biology 
interpretation, a requirement that can be achieved by SRM. 
The aim of this chapter is to provide background on current research and development in FGF 
signalling (section 1.2), an overview of mass spectrometry (section 1.3), proteomics by mass 
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spectrometry (section 1.4) and FAIMS (section 1.5), which forms the basis for the work 
presented in this thesis: investigation of the application of FAIMS to increase 
phosphoproteomic coverage in FGF signalling (Chapter 4) and the employment of targeted 
approaches for accurate quantitation (Chapter 6). 
 
1.2 Fibroblast growth factor (FGF) and FGF signalling 
Fibroblast growth factor was first discovered in bovine pituitary extracts by Armelin et al. in 
1973 and it was found to introduce the proliferation of fibroblasts1. Over forty years, extensive 
research has been carried out in order to reveal the functions of FGF and the signal transduction 
of FGF pathway2. It has been shown that FGF and the FGF signalling pathway play diverse 
roles in cell division, cell growth and maturation, angiogenesis, wound healing and tumour 
growth3. Accumulating evidence suggests the deregulation of FGF signalling has been 
associated with many human diseases, including cancer4. 
 
1.2.1 FGFs 
FGFs are glycoproteins that bind to cell surface receptors to initiate signalling. The mammalian 
FGF family comprises 23 members5. They are structurally related and all share a highly 
conserved region of 120 amino acids, which is responsible for the interaction with FGF 
receptors2. This conserved region forms 12 anti-parallel β-strands, which fold into a cylindrical 
barrel. Many FGFs contain a signal peptide region for secretion into the extracellular 
environment. 
An important feature of FGF family is that they have a strong affinity for heparin and heparin-
like glycosaminoglycans (HLGAGs). Current understanding holds that the binding to heparin 
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and HLGAGs could protect FGFs from degradation, leading to FGFR dimerization and 
subsequent activation of the intracellular kinase domain6. Although not all members are 
receptor activating (except FGF11, 12, 13 and 14), or have fibroblast stimulation activities 
(FGF-7), they are still clustered as FGF family members as they are structurally related. 
Generally, FGFs are secreted glycoproteins that are localized to the extracellular matrix7. Most 
FGFs (except FGF1 and FGF2) are produced in endoplasmic reticulum (ER) and utilize the 
signal peptide for secretion into extracellular matrix. In order to signal, FGFs are released from 
the extracellular matrix and free FGFs can bind with low-affinity receptors, such as heparin. 
Heparin can guide FGFs to FGFR and stabilize the ligand-receptor complex. Some FGF 
members, such as FGF1 and FGF2, have also been found in nucleus and nucleolus in addition 
to their extracellular and transmembrane locations8. FGF1 and FGF2 contain a nuclear 
localization signal (NLS), which regulates their translocation of FGFs after internalization. 
This provides a novel mechanism for FGF-mediated nuclear events, which are regulated 
through a direct interaction with nuclear effectors9. 
 
1.2.2 FGFR 
1.2.2.1 Structure 
FGFs activate FGF signalling by binding with four tyrosine kinase receptors (FGFR1, FGFR2, 
FGFR3 and FGFR4), which are responsible for transmitting the extracellular signal to 
cytoplasmic environment. The members of FGFR family are composed of an extracellular 
ligand-binding domain, a transmembrane spanning domain, and an intracellular domain 
containing a protein tyrosine kinase (TK) core. The extracellular portion contains three 
immunoglobulin (Ig)-like domains. The second and third Ig domains interact directly with the 
FGF ligand10. The intracellular region possesses a juxtamembrane domain, two tyrosine kinase 
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domains (which are split by a kinase insert sequence) and a C-terminal tail. This protein 
structure places FGFR in the Ig superfamily of receptors and the family of receptor tyrosine 
kinase (RTK), such as EGFR family (epidermal growth factor receptor), PDGF family 
(platelet-derived growth factor receptor)11. 
 
Figure 1.1 Schematic structure of FGFRs (Adapted from Turner et al.12) 
FGFR consists of extracellular domain, transmembrane domain and tyrosine kinase (TK) domain. The dotted lines 
indicates FGFR in monomer status. 
 
1.2.2.2 FGFR specificity 
FGFR isoforms, arising from various alternative splicing events occurring both in the 
extracellular and the intracellular domain of receptors, are crucial in modulating ligand-binding 
specificity and receptor activity13. Generally, each receptor can be activated by different FGFs 
and most of the FGFs can bind with multiple receptors (with the exception of FGF3, 7 and 9 
which can bind with one FGFR member). Differences in splice variants in the extracellular 
domain are often associated with the specificity of the receptor. For instance, shortened FGFR2 
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splice variants in the C-terminal tail were observed in several cancer cell lines. It was 
established that the C-terminal deletion is able to induce conformational changes in the receptor, 
leading to accumulated level of the receptor at cell surface and thus enhanced signalling 
capacity14. 
Also, the spatial and temporal expression patterns of FGF and FGFR are jointly responsible for 
regulation of the specificity of the FGF-FGFR interaction15. For instance, the FGFR IIIb and 
FGFR IIIc splice isoforms in Ig-like domain III are regulated in a tissue-specific manner. The 
FGFR IIIb isoform is expressed exclusively in epithelial tissues and the FGFR IIIc isoform is 
preferentially expressed in mesenchymal tissues16.  
 
1.2.2.3 Phosphorylation of receptor 
Receptor tyrosine kinase (RTK) represents a family of cell-surface proteins that can be 
activated by ligands in cell signalling processes. Like other RTKs, the intracellular tyrosine 
domain of FGFR catalyses autophosphorylation of the receptor itself and phosphorylation of 
RTK substrates (see Figure 1.2). For FGFR, this was first suggested by the finding that an 
elevated expression level of tyrosine phosphorylation was observed upon FGF-1 and FGF-2 
stimulation in 3T3 fibroblasts, by Western blot using phosphotyrosine antibody17. FGF 
stimulation is able to induce an immediate response in phosphorylation of the receptor and 
tyrosine phosphorylation of FGFR was found to occur within 30 seconds of FGF stimulation18.  
In FGFR1, seven phosphotyrosine sites have been identified in the cytoplasmic domain 
(Figure1.2): Y463 in juxtamembrane (JM) domain, Y583 and Y585 in the kinase insert (KI) 
domain, Y653 and Y654 in the activation loop of the second tyrosine kinase domain19, Y730 
and Y766 in the C-terminal tail20. The activation of FGFR1 has been described as a temporal 
phosphorylation mechanism occurring in the intracellular domain21. Of these seven tyrosine 
7 
 
sites, the phosphorylation of Y653 serves as the initiation reaction, which activates the kinase 
by 50-100 fold, and the phosphorylation of Y654 can increase kinase activity by up to 500-
1000 fold. Followed by the activation of two tyrosine sites in the activation loop, 
juxtamembrane region Y463, kinase insert Y586/Y588, and in the C-terminal region Y769 are 
also phosphorylated to promote further receptor activation or serve as the recruitment site for 
downstream signalling proteins. 
 
Figure 1.2 Structure and phosphorylation sites of FGFR1 
FGFR1 comprises an extracellular domain, a transmembrane domain (TM) and a cytoplasmic domain. Signal 
peptide (SP) sits in N-terminal. There are 2 or 3 Ig-like domains in the extracellular domain. The acid box (AB) 
locates between Ig-I and Ig-II. Heparin binding domain is in Ig-II. Followed by juxtamembrane domain (JM) are 
two tyrosine kinase (TK) subdomains, including a nuclear binding domain (NB) and a short kinase insert (KI). 
Seven tyrosine phosphorylation sites have been identified so far: Tyr463 in JM, Tyr582 and Tyr585 in KI, Tyr653 
and Tyr654 in TK2, Tyr730 and Tyr766 in C-terminal tail. 
 
1.2.3 FGF signalling 
1.2.3.1 Activation of FGF signalling 
The FGF signalling is a typical RTK-induced signalling cascade (see Figure 1.3). The FGFs 
exert their biological functions through the binding with Ig-like domain (II and III) of FGFR, 
with the assistance of heparin22. Binding of FGFs to receptors induces dimerization of the 
receptors, which will cause a conformational shift in the intracellular domain of the receptor. 
In contrast to the non-dimerized form, the conformational change opens the kinase domain for 
ATP binding. It activates FGFR and leads to trans-autophosphorylation reaction in the receptor, 
where phosphorylation occurs through the other kinase in the dimer. Following 
phosphorylation in the activation loop (e.g. Y653 and Y654 in FGFR1), the activated FGFR is 
capable of catalysing the phosphorylation of multiple tyrosine residues in the kinase domain. 
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The phosphorylated tyrosine residues on the receptor can function as regulation sites or docking 
sites for adaptor proteins. FGFR substrate 2 (FRS2), a key adapter protein in FGF signalling, 
are recruited to the FGF-FGFR complex in this step23. FRS2 binds with the juxtamembrane 
region of FGFR. The recruitment of FRS2 initiates the phosphorylation of itself and FRS2 can 
further recruit downstream molecules and adaptor proteins via phosphorylation events.  
 
Figure 1.3 FGFR signalling network (Adapted from Turner and Grose12) 
Upon ligand binding, FGFRs at plasma membrane dimerise and trans-autophosphorylate, thus triggering series of 
phosphorylation and dephosphorylation events in various signalling proteins. 
 
Phosphorylation events hold the key to understand the signalling events downstream of FGFR. 
For instance, phosphorylation of the active sites of kinases often significantly alter the binding 
capacity for substrates24. At the next level, specificity is regulated by the interaction between 
the docking motif of the substrate and the kinase. In some cases, recruitment of substrates to 
kinases require phosphorylation of an adjacent or distant residue from the active site25. 
One of the most widely accepted models for FGF signal transduction is the diffusion-based 
model (also termed canonical model)26. It proposes the receptors are monomers in the absence 
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of ligands, and dimerise and trans-phosphorylated each other upon ligand binding. The other 
model postulates that FGF receptors form dimers even in the absence of ligands, but ligand 
binding triggers the structural changes of the dimers and significantly increases FGFR 
phosphorylation. Also, different ligand binding (e.g. FGF1 and FGF2) can cause different 
effects on the receptor structure, therefore induce specific biological responses27. 
 
1.2.3.2 Downstream of FGF signalling 
The main downstream pathways of FGF signalling include the Ras/MAPK (rat sarcoma 
mitogen-activated protein kinase) pathway whose activation is mediated by growth-factor-
receptor-bound protein 2 (GRB2) and Son of Sevenless (SOS), the PI3K (phosphoinositide 3-
kinase)/AKT pathway activated by GRB2, and the Src pathway that initiated directly by 
FRS228–30. In addition, instead of propagating the signal through FRS2, the tyrosine site (e.g. 
Y766 in FGFR1) in the kinase domain of FGFR can directly act as the recruiting site for PLCγ 
(phospholipase Cγ), leading to the recruitment of more partner proteins. These signalling 
cascades form a complex network, which regulates a wide array of biological processes and 
also mediates the FGF signal transduction by regulation of phosphorylation of downstream 
signalling molecules.  
In humans, the activation of the Ras/MAPK pathway is a highly conserved mechanism in 
response to FGFs, while activation of other downstream pathways is subject to cell type or 
tissue. The maintenance of certain levels of phosphorylation of Ras and MAPKs is critical to 
enable phosphorylation of target substrates. A number of inhibitors, targeting upstream 
proteins (e.g. FGFRs or Ras), were developed to block the activation of Ras/MAPK pathway.  
Another complex activated through GRB2 is the PI3K/AKT pathway, which further activates 
AKT-dependent anti-apoptotic pathway. The PI3K/AKT pathway also responds to a wide 
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variety of stimuli, such as RTKs, B/T cell receptors, integrin, G-protein-coupled receptors and 
other receptors that catalyse the production of phosphatidylinositol (3,4,5) trisphosphate (PIP3) 
by PI3K31. Downstream effects of AKT are primarily associated with the regulation of cell 
cycle, cell survival and metabolism via mTOR pathway32. 
Non receptor Src family kinases (SFKs) are regulators of FGF signalling33. Of Src family, Src, 
Fyn and Yes are found universally expressed in human cells while other members are expressed 
in specific tissues or particular development stages. In addition to FGF signalling, SFKs are 
involved in signalling by many RTKs, including PDGF receptor (PDGF-R)34, epidermal 
growth factor receptor (EGFR)35 and insulin-like growth factor-1 receptor (IGF-1R)36. Their 
participation is particularly important in the regulation of DNA synthesis and endocytosis. It 
has been shown the elevated levels of dephosphorylation of Tyr527 in Src, which has been 
detected in various cell lines, transforms Src to become abnormally active. 
An important aspect of FGFR-induced cellular events is through PLCγ-mediated mitogenesis. 
Activation of PLCγ is through direct binding to a conserved phosphotyrosine residue in C-
terminal tail of FGFR37.  PLC then hydrolyses phosphotidylinositol-4,5-diphosphate to 
inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 stimulates intracellular 
calcium release, while DAG activates protein kinase C (PKC)38. 
 
1.2.4 FGF signalling and cancer 
1.2.4.1 Current understanding of FGF signalling and cancer 
FGFR2 has been extensively examined in its relationship with breast, gastric and bladder 
cancer 39–42. The FGFR2 gene is located on human chromosome 10 and it encodes FGFR2 
protein which shares highly conservative sequence with the FGFR family members. Due to 
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splicing of the third Ig-like domain, there are two natural isoforms of FGFR2: FGFR2IIIb and 
FGFR2IIIc. The IIIb isoform is expressed exclusively in epithelial tissue and the IIIc isoform 
is preferentially expressed in mesenchymal tissue. Triple-negative breast cancer (TNBC) cell 
lines, for example SUM52 and MFM223, show FGFR2 amplification. FGFR2 amplifications 
have also been described in approximately 3% -10% of primary gastric cancers patients and 
usually associated with the poor prognosis and low survival rate43. Decreased levels of FGFR2-
IIIb have also been reported in a number of bladder cancer cases, which suggests the potential 
role of FGFR2 as a tumour suppressor in bladder carcinomas44,45.  
A genome-wide association study (GWAS) has identified several SNPs (single nucleotide 
polymorphism) in FGFR family as novel breast cancer susceptibility loci46. Eight SNPs located 
in intron 2 of FGFR2 have attracted extensive attention. They change binding affinity of 
transcription factors directly downstream of FGFR47.  A SNP in FGFR4 has been shown to 
contribute to more aggressive behaviour and poor prognosis in several types of cancer, 
including breast cancer48. 
Mutated FGFRs have also been found to be associated with several developmental syndromes, 
including cancer49. Mutations in cytoplasmic and tyrosine kinase domain of FGFR1 and 
FGFR2 have been discovered in endometrial cancer, which alter the ligand specificity and 
kinase activity respectively50. In some circumstances, mutation can cause loss-of-function51. 
As a result of gene splicing, novel splice variants of FGF family are identified to be associated 
with cancer. For example, an FGFR2 variant with a shortened C-terminus has been identified 
in several cancer cell lines. The study of rat osteosarcoma cell line has shown the alteration of 
C-terminus resulted from the fusion of FGFR2 to a novel protein due to chromosomal 
rearrangement. The fusion protein acts as dimer leading to the autophosphorylation of tyrosine 
domain. Therefore this protein can cause continuous signalling  in the absence of FGFs and 
thus enhanced signalling capacity52.  
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1.2.4.2 Therapeutic development 
Upstream intervention of FGF signalling primarily involves inhibiting ligand-receptor binding. 
FGF ligand traps (e.g. FP1039), a fusion protein comprised of the extracellular domain of 
FGFR fused with the Fc region of IgG, was developed and is being tested for clinical 
application53. Another approach to inhibit ligand binding is to use peptide mimics, which is 
particularly useful for patients with FGFR amplification54. 
A number of tyrosine kinase inhibitors targeting FGFR activity are in early clinical 
development. These inhibitors are multi-targeting ATP-competitive inhibitors. As kinase 
domains of RTKs are similar in structure, these inhibitors are not specific and activity of 
VEGFRs and PDGFRs could also be affected51. Dovitinib is a potent TKI with anti-angiogenic 
activity through the inhibition of FGFR, VEGFR, and PDGFR. Dovitinib is in phase II clinical 
trials for advanced breast and endometrial cancers and phase III clinical trial for renal cell 
carcinoma. The second generation inhibitors target FGFRs with selectivity over other kinases. 
For example, AZD 4547 shows affinity with FGFRs approximately 120-fold higher than 
VEGFRs. AZD4547 is in phase II clinical trial for breast cancer55. SU5402 is one of the 
compounds that have been designed as FGFR specific inhibitors56. SU5402 occupies the same 
region in FGFRs as ATP to inhibit FGFR tyrosine phosphorylation and does not affect kinase 
activity of VEGFRs and PDGFRs. It should be noted that the selective inhibitors also exhibits 
toxicities, including hypertension, cardiovascular events and some FGFR-specific toxicities57. 
The development of specific toxicity management protocols is required and a few projects are 
on the way58. Monoclonal antibodies are an alternative to avoid the side effects of multi-
targeting inhibitors. Antibodies targeting FGFR1-IIIc and FGFR3 are in preclinical 
development55. 
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Proteins downstream of FGFRs also participate in multiple signalling, therefore it is difficult 
to target them to inhibit FGF signalling. Thus, targeting downstream effectors is aiming at more 
specific processes or pathways. In this thesis, to inhibit Src family kinase, dasatinib is used. 
Dasatinib is a small molecule inhibitor of Src and Abl proteins and has already been used in 
treatment of imatinib refractory chronic myelogenous leukemia (CML)59. It is not clear whether 
it can be used as breast tumour suppressor, but its association with FGF signalling has made it 
promising for clinical trial for breast cancer patients. 
 
Figure 1.4 Chemical structures of (A) SU5402 and (B) dasatinib 
Previous studies have provided a valid rationale to further explore the potency of FGFR-
targeting drugs in their targeting specificity, toxicity and anti-tumour activity. Although the 
most effective anti-tumour activity was observed with multi-targeting kinase inhibitors, 
selective inhibitors present less toxicity and non-FGF related problems. In addition to small 
molecule inhibitor, the application of small interfering RNAs, the combination of FGFR and 
other kinase inhibitors has shown preliminary progress in targeting specific FGFR events60. 
 
1.2.4.3 Future prospects 
Progress is being made in understanding the association between FGF signalling and 
development of cancer, and therapeutic strategy, e.g. key signalling molecules responsible for 
cancer pathogenesis and progression, response of FGF signalling to chemotherapy and 
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development of FGFR inhibitor in combination with conventional therapies. However, this is 
still the early phase of understanding of how FGF signalling can be targeted in development of 
cancer. Understanding the mechanism underlying intracellular responses induced by FGF 
signalling requires knowledge of receptor activation, signal transduction cascades and the 
downstream regulation of gene expression, which are modulated by phosphorylation and 
dephosphorylation at different levels. 
Functional interpretation of these phosphorylation events requires detailed analysis of specific 
residues or combinations of residues. Much attention has been focused on individual residues 
and multiple/combinatorial phosphorylation events have attracted less attention because it is 
harder to identify these peptides. Current understanding suggests that it is more challenging to 
detect doubly- and multiply-phosphorylated peptides than singly-phosphorylated peptides due 
to their low stoichiometry and poor binding ability to chromatographic columns. Whereas, 
deciphering the mechanisms of FGFR signalling requires knowledge of multiply-
phosphorylated peptides as the adjacent phosphosites may play regulatory roles. Thus, one of 
the major challenges in intracellular cell signalling research is to map sites of modification in 
multiply-phosphorylated peptides.  
Liquid chromatography coupled with tandem mass spectrometry, combined with pre-
fractionation and phosphoenrichment is a well-established workflow for large-scale 
quantitative phosphoproteomic analysis61. Although progress has been made, low 
phosphoproteome coverage, limited dynamic range and co-elution of peptide isomers still 
remain a challenge. With the development in phosphopeptide enrichment protocols, liquid 
chromatography, combinations of MS/MS approaches and development of novel data handling 
software, a more profound understanding of FGF signalling and its role in cancer development 
will emerge. 
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1.3 Mass spectrometry 
Mass spectrometry (MS) is an analytical technique that enables identification and quantitation 
of molecules by their measuring mass-to-charge ratio (m/z)62. As it is a sensitive technique that 
offers both low detection limits and high mass accuracy, mass spectrometry is an invaluable 
tool for study in a range of fields, including organic chemistry, proteomics, metabolomics and 
clinical testing etc. In addition, high throughput analysis is possible by mass spectrometry63. 
In mass spectrometric analysis, samples are ionised and subject to gas phase environment for 
separation based on m/z values. Tandem mass spectrometry (MS/MS) technique allows the 
multiple stages of isolation and fragmentation in time and space. Charged ions (termed 
precursor ions) are isolated according to their m/z values, typically by subjecting them and 
accelerating them into an electric field. Therefore, the isolation and fragmentation of the 
precursor ions occurs in multiple stages. MS/MS results will be displayed in spectra with the 
relative abundance of detected fragment ions and a function of the m/z ratio. Mass 
spectrometers comprise three parts: an ion source that ionizes the sample, mass analyser that 
separates ions based on m/z ratios and detector that records the signal. Modern mass 
spectrometers have undergone immense technological innovations during recent decades 
allowing for applications in analyses of drugs, peptides, proteins, carbohydrates, DNA and 
many other biologically relevant molecules64–66. Separation techniques combined with mass 
spectrometry have been widely used to enhance resolving power in the analysis of complex 
samples. Increasing application of mass spectrometry to complex biological samples has driven 
data analysis software development. In the following text, instrumentations and applications of 
mass spectrometry will be introduced in more detail. 
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1.3.1 Ionization 
The ionization process enables molecules to acquire a negative or positive charge through 
interactions with chemicals, light or electrons. The earliest ionization techniques were electron 
ionization (EI)67 and chemical ionisation (CI)68, which tend to induce fragmentation thus 
limiting formation of stable molecular ions. These two techniques are primarily used in the 
analysis of organic molecules. Fast atom bombardment (FAB) is a soft ionization technique, 
which yield little or no fragmentation, thus allowing the analysis of molecules larger than 
25,000 Da. It uses a beam of high energy atoms to desorb ions from a surface69. When highly 
energetic ions are used instead of atoms, this method is also known as liquid secondary ion 
mass spectrometry (LSIMS)70. More recent techniques, matrix-assisted laser desorption 
ionization (MALDI)71 and electrospray ionization (ESI)72 are also soft ionization techniques, 
similar to FAB.  The key feature of MALDI is the use of a matrix to assist desorption. Prior to 
MALDI ionization, the sample is mixed with an organic matrix on a metal plate. The mixture 
is dried and the matrix co-crystallised with the sample. A laser beam at a specific wavelength 
is then directed at the sample-matrix mixture, causing the matrix to absorb energy, which 
enables protons to be transferred from matrix to the sample and ionise the sample. In 2002, the 
developers of MALDI (Koichi Tanaka) and ESI (John Fenn) were awarded Nobel Prize in 
Chemistry ‘for their development of soft ionization methods for mass spectrometric analyses 
of biological macromolecules’. Currently, MALDI is routinely used in tissue imaging and 
identification of a wide variety of analytes in tissues73.  
ESI is suitable for both organic and biological molecules and was used in the work presented 
herein. In ESI, samples are usually dissolved in a mixture containing volatile organic solvents 
(e.g. methanol or acetonitrile) and an acidic buffer. Typically, the sample will go through three 
major stages. First, the sample solution becomes charged when passing through a thin metal 
capillary at a certain voltage. Second, as the surface tension of the droplet overcome the 
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electrostatic repulsion, the charged droplets become unstable when Rayleigh limits is reached, 
leading to evaporation of solvent from the charged droplets and formation of decreasing 
charged droplets. There are two main models describing the third stage of ESI process (see 
Figure 1.5): the charge residue model (CRM)74 and the ion evaporation model (IEM)75. The 
CRM model suggests as the remaining solvent evaporates, the gas phase ions are produced as 
the size of the droplet decreases into a droplet containing only one macromolecule. The IEM 
model proposes that as the droplet decreases to a radius of 10 nM, the strength at the surface 
of the droplet can assist the field desorption and allow the formation of gas phase ions. The 
exact mechanism of ESI is still under debate. However, there is a consensus among scientists 
that a combination of these two models occur during ESI.  
ESI is able to preserve multiply charged ions, facilitating the identification of large molecules. 
Due to multiple charging, the m/z values of multiple charged ions become lower and fall into 
the mass range of common mass analysers. Thus, analysis of protein and macromolecules is 
made possible by applying ESI in modern mass spectrometer.  
 
Figure 1.5 Electrospray ionisation: the proposed model of CRM and IEM、 
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1.3.2 Mass analysers 
Once in the gas phase, ions are transferred to the mass analyser for isolation or/and separation 
based on m/z values. Several types of mass analysers that utilise different mechanisms to 
separate ions, either by static or dynamic electric or/and magnetic fields or in combination, 
have been developed. There are three main classes of mass analyser. One type of mass analyser 
separates ions in space according to their m/z values, i.e., the time-of-flight (TOF)76 analyser. 
Another type of mass analyser scans for a particular m/z value while removing all the other 
ions, such as the quadrupole mass analyser77. Thirdly, mass analysers can measure the resonant 
oscillations of ions in electric/magnetic fields, such as the linear ion trap78, 3D ion trap79, 
Fourier transform ion cyclotron resonance (FTICR)80 and orbitrap81 mass analyser. The mass 
analysers which have been employed in this work are the dual-pressure linear ion trap, the 
Orbitrap mass analyser and the triple-quadrupole mass analyser and a detailed introduction is 
given in Section 1.3.4.1 and 1.3.4.2. 
 
1.3.3 Tandem mass spectrometry 
Tandem mass spectrometry (MS/MS) enables characterisation of the structure of an analyte, 
and is especially useful in the analysis of peptides, intact proteins and post-translational 
modifications. In mass spectrometry-based proteomic analyses, MS/MS of a peptide provides 
information on peptide sequence and structure. There are different fragmentation techniques 
available. The most commonly used are collision induced dissociation (CID)82,83, electron 
capture dissociation (ECD)84 and electron transfer dissociation (ETD)85. CID and ETD are the 
most widely used fragmentation techniques in proteomics and solely used in this thesis, and 
therefore are discussed further below. 
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1.3.3.1 Collision induced dissociation  
In CID (also referred to as collision activated dissociation, CAD), precursor ions are 
accelerated by electric potentials to high kinetic energy and collided with inert gas (typically 
helium, nitrogen or argon). During the collision, a certain amount of kinetic energy is converted 
into internal energy resulting in bond breakage and fragmentation of molecules. The mobile 
proton model proposed by Gaskell and Wysocki best describes the mechanism of CID 
fragmentation on peptides and proteins86,87. The model proposes that a proton is mobile 
between various protonation sites and the actual fragmentation site is the result of competition 
between various fragmentation pathways. The energy required for proton mobility depends on 
gas-phase basicity of the group. The proton is preferentially mobilised to N-terminal or basic 
site, e.g. lysine or arginine, over non-basic amino acid, leading to charge-directed 
fragmentation. Therefore, as the proton migrates to amide nitrogen, which leads to weakening 
of the amide bond and makes the adjacent carbonyl group susceptible to attack, peptides tend 
to undergo N-Co breakage along the peptide backbone, which produces a series of b and y 
fragment ions (Figure 1.6)88,89. 
 
Figure 1.6 Dissociation products of protonated peptides 
CID produces b and y type anions by heterolytic amide bond breakage. ETD and ECD produces c and z type ions 
by homolytic bond cleavage. 
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1.3.3.2 Electron transfer dissociation 
ETD induces fragmentation by transferring electrons to positively charged precursor ions to 
induce specific N-Cα breakage along the peptide backbone, while the side chains and peptide 
modifications are left intact85,90. The ETD radical anions (e.g. anthracene or fluoranthene) are 
required as strong bases or/and reagents for proton abstraction.  
The ETD fragmentation mechanism can be described by the Utah-Washington mechanism, 
developed independently by two groups91,92. In a peptide, the electron attachment to amide π* 
orbital makes it a strong base with a strong affinity to protons. The amide group is then able to 
participate in proton abstraction, leading to the breakage of N-Cα bond and generation of c and 
z ions, as shown in Figure 1.7. The proton abstraction is where the two mechanisms differ. The 
Washington mechanism proposes the initial electron capture takes place at a charge site. 
However, the Utah mechanism suggests that capture occurs directly in a stabilised orbital (S-S 
σ* or amide π* orbital), leading to peptide fragmentation. 
ETD has been seen as a complementary technique to CID fragmentation, as ETD (a) favours 
fragmentation of large peptides and intact proteins, and (b) is able to preserve labile PTMs on 
backbone fragments for PTM characterisation. Combinations of CID and ETD fragmentation 
and alternating CID/ETD fragmentation methods both proved to improve sequence coverage 
and PTM identification than individual CID and ETD fragmentation alone93. 
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1.3.4 Hybrid instruments 
1.3.4.1 Hybrid Orbitrap mass spectrometer 
The LTQ Orbitrap Velos ETD mass spectrometer is a hybrid mass spectrometer comprising a 
dual-pressure linear ion trap (the linear trap quadrupole, LTQ) and the Orbitrap analyser94. 
Figure1.8 shows the schematic diagram of an LTQ Orbitrap Velos ETD mass spectrometer. 
The LTQ is used for for ion trapping, ion selection, ion fragmentation and low resolution 
scanning. In the LTQ, ions are trapped (and fragmented) in the first ion trap with high gas 
(helium) pressure (-5×10-3 Torr) before passed to the second ion trap with low gas pressure (-
4×10-4 Torr) for fast scanning. The LTQ comprises linear ion traps (LIT) which create two 
dimensional (2-D) quadrupole fields95. The 2-D ion trap uses an oscillating field (radio 
frequency field, RF field) to trap ions radially and a static electric field applied to the tip of the 
rods to trap ions axially in two dimensions. A 2-D ion trap comprises of four parallel electrode 
rods and an opposite electrical potential applied to the end electrodes with the same polarity. 
In the 2-D trap, the ions collide with inert gas and travel along the z axis through the centre of 
rods owing to the application of a balanced dipolar field. In the xy plane, the ions are oscillated 
due to a RF potential on the rods. The application of DC voltage to the rods allows the ions to 
be trapped. Within an LIT, ions can be ejected between the rods and the exit lens either axially 
or radially by applying an AC voltage. The toroidal shape of the ion trap increases the ion 
trapping capacity, as well as increased the scanning speed.  
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Figure 1.7 Schematic of LTQ Orbitrap Velos ETD mass spectrometer (Adapted from Thermo Scientific) 
Based on Thermo Scientific, 2009. It comprises of an ion guide for collimating ion beam and enhancing ion transmission; a dual-pressure ion trap, which isolates ions according 
to m/z value and fragment ions; an Orbitrap mass analyser coupled with a C-trap and HCD collision cell for high-resolution MS scan and HCD fragmentation; and an ETD unit 
that provides ETD fragmentation. 
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Developed by Makarov in 199681, Orbitrap mass analyser is the modification of ion trap, which 
is made of an electrically isolated barrel-like outer cylindrical electrode and a spindle-shape 
inner electrode (see Figure 1.7). In Orbitrap, ions are ejected tangentially into the interstice 
while an electrostatic voltage is applied to the inner electrode and the outer electrode is at the 
ground potential. As ions enter the trap, they start to oscillate around the inner electrode under 
the electrostatic attraction. Due to properties of quadro-logarithmic potential, ion motion in the 
axial direction is harmonic. To stabilize the ions in a stable spiral radius around the inner 
electrode and to prevent unwanted collisions with the outer electrode, the potential of inner 
electrode is set at around -3200 V for positive ions to provide kinetic energy. The axial 
frequency (w) of ion oscillation can be described as: 
 
q: total charge; m: ion mass; k: force constant of the potential 
This equation shows the axial frequency is dependent on the m/q ratio. Therefore, ions of 
different m/z ratios will oscillate along the inner electrode at a specific frequency. The image 
current induced by the oscillating ions can be detected on the outer electrode and converted to 
frequencies and intensities by Fourier transform algorithm, yielding the mass spectrum. 
LTQ and Orbitrap work in parallel in data dependent acquisition: Orbitrap is performing MS1 
scan while LTQ is isolating and fragmenting ions detected in MS1 spectrum. This combination 
allows for acquirement of high resolution MS spectra with excellent mass accuracy in the 
Orbitrap and rapid MS/MS scan (several Hz) in the ion trap. A pre-defined number of precursor 
ions will be selected according to their abundance and reported back to LTQ for selection and 
fragmentation. MS/MS scan can be acquired in either CID or ETD mode in LTQ. In addition, 
HCD fragmentation is introduced in HCD collision cell to overcome the drawback of low mass 
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resolution and accuracy when performing fragmentation of LTQ. For highly complex samples, 
the high resolution of hybrid LTQ/Orbitrap instrument maximizes the number of ions analysed, 
which is particularly advantageous for bottom-up proteomic analysis. Initial reports showed 
the resolution of Orbitrap spectrum can achieve 60,000 at m/z in 1 second of scan time and the 
increases of resolution are proportional to the allowed scan time and inversely proportional to 
the square root of m/z values. In proteomics, these features make it ideal for analysis of intact 
protein, complex peptide mixtures and their PTMs. Coupled with nanoLC and electrospray, 
LTQ Orbitrap is one of the most commonly used mass spectrometers in large scale proteomics 
analysis. The LTQ Orbitrap Velos mass spectrometer was used in Chapter 3 and 4; LTQ 
Orbitrap Elite mass spectrometer was used in Chapter 5. 
 
1.3.4.2 Triple-quadrupole mass spectrometer 
TSQ Vantage Triple Quadrupole Mass Spectrometer (referred to as QqQ in the thesis), 
introduced by Thermo Scientific, is a triple quadrupole (QqQ) mass spectrometer featuring a 
QqQ mass analyser. QqQ mass analyser primarily used in study of drug metabolism, 
environmental studies and targeted proteomic quantitation96.  
QqQ analyser is made of four cylindrical or hyperbolic rods in parallel97. In a quadrupole, ions 
are separated based on the stability of their trajectories in oscillating electric fields which are 
applied to the rods. Each rods pair is connected electrically. Paul and Steinwegen described the 
principle of the quadrupole98.  
 
φ represents the potential applied to the rods, w is the angular frequency, U is the DC voltage and V is the 
amplitude of RF voltage. 
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Ions travelling between the quadrupole rods are subjected to a RF field superposed on a 
constant field (DC voltage) that is applied to one pair of the rods or the other. The principle of 
ion motion in a quadrupole field can be described by Mathieu equation: 
 
u represents x, y and z coordinates, au and qu are dimensionless trapping parameters, and ζ is a dimensionless 
trapping parameter equal to Ωt/2 (Ω is frequency and time). 
While travelling along the z axis, ions are also exposed to x and y accelerations induced by the 
electric field: 
 
φ the quadrupolar potential: 
 
Thus, we can deduce: 
 
Both U and V are constant for a given quadrupole instrument. Thus, each ion has a specific au 
and qu, resulting in the difference in field influence. At a given ratio of voltages, only the ions 
of a certain m/z value are allowed to travel through the poles and reach the detector. By varying 
the applied DC voltage, selection of ions within a particular m/z window can be achieved. 
In this thesis, QqQ mass spectrometer was used predominantly in Chapter 6 in selected reaction 
monitoring (SRM)99 mode. Figure 1.8 shows the schematic design of the QqQ mass 
spectrometer. Ions are focused into the instrument via the S-Lens, through quadrupoles and 
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reached the channel electron multiplier (CEM) for detection. QqQ analyser is comprised of 
three quadrupoles: Q1 and Q3 act as mass filters and Q2 is the collision cell.  
 
Figure 1.8 Schematic of TSQ Vantage Triple Quadrupole Mass Spectrometer (Thermo Scientific) 
Based on Thermo Scientific, 2009. It comprises of an S-lens, an ion guide for collimating ion beam and enhancing 
ion transmission; a quadrupole mass filter (Q1), which filters ions according to m/z value; a collision cell for 
fragmentation of selected ions; and a linear ion trap that can also function as a mass filter. 
 
The design of QqQ analyser allows the mass analysis to happen in a sequential manner100. QqQ 
analyser can operate in full scan mode, product ion mode, precursor ion mode and neutral loss 
mode etc, as shown in Figure 1.9. In full scan mode, Q1 and Q3 quadrupoles are set to scan the 
full mass range, which is used to detect unknown products in a sample. Product ion scan mode 
selects a particular ion, passes it into Q2 for fragmentation and full mass range of fragment 
ions is scanned in Q3. SRM scan mode has two stages of mass selection. Q1 quadrupole is 
responsible for filtering the precursor ions according to their m/z ratio. Q2 acts as collision cell 
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and Q3 is then set to filter the pre-set fragment ions, allowing only the selected fragment ions 
to reach detector. If Q1 or Q3 is set to scan more than a single mass, this method is referred to 
multiple reaction monitoring (MRM).  
 
Figure 1.9 Scan modes of QqQ mass analyser 
 
 
1.4 Proteomics by mass spectrometry 
Proteomics is an established field focusing on study of proteins hugely aided by the 
development of mass spectrometry. Proteomics aims to understand the molecular mechanism 
of biological processes and diseases from the study of peptide or protein structure, expression, 
protein-protein interaction and post-translational modification etc101.  
There are two complementary strategies in MS-based proteomics: bottom-up and top-down 102. 
The bottom-up approach focuses on MS/MS analysis of tryptic digested peptides for protein 
identification. This approach usually requires pre-separation prior to MS analysis, such as high 
performance liquid chromatography (HPLC). The peptide sequence identified in the bottom-
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up analysis can be searched against protein databases and limited sequence coverage is required 
for unambiguous identification. An alternative approach is top-down, which analyses intact 
proteins without proteolytic digestion and preserves the labile structural characteristics which 
are likely to be destroyed in bottom-up strategy. However, the application of top-down 
approach is limited to certain types of proteins and instruments and is faced with technical 
challenges such as electrospray efficiency, instrument sensitivity and detection limit. 
Proteomic profiling of a biological process or cellular network is typically achieved by bottom-
up approaches. Especially within the last decade, owing to technological advances the scale of 
our understanding has been expanded with great accuracy and depth, from identification and 
structure of proteins to creation of a comprehensive proteomic network. Subsequently, to 
determine the candidate arising from discovery experiment, a targeted quantitation method is 
required. Selected reaction monitoring (SRM, also known as MRM, multiple reaction 
monitoring) has emerged as the method of choice103. This method is well-established for 
quantitative MS/MS analysis, offering high selectivity and high-throughput ability. SRM has 
been applied in small molecules quantitation for several decades104. More recently, researchers 
employed SRM approach in environmental compounds, drug metabolites and it is being 
increasingly applied in peptide quantitation in complex biological samples. 
 
1.4.1 Bottom-up proteomics workflow 
1.4.1.2 Bottom-up proteomics workflow 
Complex samples, such as whole cell lysate and protein complexes, often require pre-
separation prior to LC-MS/MS analysis in bottom-up approach. Coupled with high scanning 
speed of mass spectrometry, this approach is able to recover hundreds to thousands of peptides 
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in a single analysis. The work in this thesis used the bottom-up approach. Figure 1.10 
summarises the typical workflow of a bottom-up proteomic analysis. 
 
Figure 1.10 Typical bottom-up proteomics workflow 
Bottom-up proteomic analysis requires the following: (1) cell labelling or label-free strategies 
for quantitative analysis (if quantitation is required); (2) proteolytic digestion of proteins; (3) 
separation and fractionation; (4) for identification of phosphopeptides, further purification 
using affinity enrichment or chromatography methods; (5) characterisation of peptides and 
proteins using mass spectrometry; (6) database search using software for peptide identification 
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and site specific identification. The development and application of these aspects are discussed 
in detail in the following sections. 
1.4.1.3 Data scan mode 
The extreme complexity of biological samples typically requires mass spectrometers with 
faster scanning speeds, better resolution and broader dynamic range. Traditionally MS/MS data 
are acquired through data-dependent acquisition (DDA) mode, where a full mass spectrum 
dictates which peptide ions are selected for fragmentation. Data-independent acquisition (DIA) 
performed fragmentation on all peptides in a defined m/z window, and this process can be 
repeated to map the desired m/z range. This approach is not biased towards the peptides with 
the strongest signal and has been proved efficient in the identification of low abundance 
precursors, with at least 5-fold increase in precursor selectivity105.  
Another research area that attracts attention is ion mobility mass spectrometry (IMS). IMS is a 
gas phase separation technique that can either be used prior to MS detection or as an integrated 
part of mass spectrometer. Drift tube IMS, travelling wave IMS and differential IMS have been 
applied as an additional dimension of separation/fractionation technique and have shown 
potential in enhancing separation/identification. 
 
1.4.2 Phosphoproteomics by mass spectrometry 
Phosphoproteomics is a branch of proteomics that focuses on identification and quantitation of 
specific and global phosphorylation events. As the most common mechanism of regulation of 
protein function and signal transduction, the interpretation of protein phosphorylation in the 
context of human diseases is an area of intense research106. Phosphorylation has been 
extensively investigated with small-scale protein approaches (e.g. immuno-detection and 
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kinase activity assays) and high throughput mass spectrometry approaches. Developments in 
enrichment strategies, sample labelling methods, and mass spectrometry methods have all 
contributed to the rapid progress of phosphoproteomics in recent years107. 
1.4.2.1 Enrichment and fractionation 
Efficient isolation of phosphopeptides from a complex biological mixture, e.g. whole cell lysate 
or serum, is the initial step in phosphoproteomics analysis. Currently, the immunoaffinity-
based approach is the most commonly used methods for phosphopeptide and phosphoprotein 
enrichment108. Table 1.1 summarises the main methods used in phosphoproteomic studies. 
Incorporation of additional reagents, such as citric acid109 and aliphatic hydroxy acid110 in 
enrichment protocols has been shown to enhance enrichment efficiency, especially for multiply 
phosphorylated peptides. The former has been used in the work presented here. New affinity 
materials (e.g. TiO2, Fe2O3
111 and SiO2
112) that exhibit complementary enrichment 
performance are being used in combination in phosphoproteomic studies.  
Table 1.1 Summary of the classic enrichment methods used in phosphoproteomic studies  
(Adapted from Thingholm et al.108) 
Name Principle Reference 
Immunoprecipitation 
(IP) 
Isolation of phosphoproteins by binding to 
antibodies (e.g. anti-phosphotyrosine 
antibodies) 
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Immobilised Metal ion 
Affinity Chromatography 
(IMAC) 
Purifying phosphoproteins and 
phosphopeptides from complex samples by 
their affinity toward positively charged metal 
ions (Fe3+ or Al3+ ) 
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Titanium dioxide (TiO2) 
chromatography 
Highly selective enrichment of 
phosphopeptides from complex samples by 
their affinity toward TiO2-coated beads 
packed in a micro-column 
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Sequential elution from 
IMAC (SIMAC) 
Method in which mono-and multi-
phosphorylated peptides are enriched from 
highly complex samples and separated prior to 
MS/MS analysis 
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Phosphoramidate 
Chemistry (PAC) 
To link phosphate groups to 
immobilised iodoacetyl groups for purification 
117 
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Fractionation methods, e.g. strong cation exchange chromatography (SCX) and hydrophilic 
interaction chromatography (HILIC), provide an extra dimension of separation prior to MS/MS 
analysis. Alternatively, two-dimensional gel electrophoresis (2-DE) can be used for the 
separation of proteins and phosphoproteins in proteomic analysis. Combinations of enrichment 
and fractionation methods are used widely in current phosphoproteomic strategies to maximize 
phosphoproteome coverage (see Table 1.2). 
 
Table 1.2 Summary of fractionation methods used in phosphoproteomic studies 
 
 
1.4.2.2 Quantitation strategy 
Strategies based on differential stable isotope labelling are frequently used in quantitative 
phosphoproteomic analyses. Mass spectrometric isotope dilution was first introduced by 
Moore et al., a MS-based quantitation strategy to determine the concentration by adding known 
amount of isotopic standards118. This concept has since been applied to quantitation of a large 
number of biological analytes, such as glucose and cholesterol119,120. A quantitation approach 
in complex biological mixtures using isotope-coded affinity tags (ICAT) tag was described by 
Gygi and co-workers in 1999121. The ICAT tag specifically target reduced cysteine residues 
and the tag can result in a mass difference of either 8 Da. Samples carrying light or heavy 
107 
260 
259 
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isotope labels are mixed prior to trypsin digestion, minimising the variance arising from sample 
preparation procedures. Using this strategy, they investigated the protein expression level in 
Saccharomyces cerevisiae under glucose-repressed conditions. ICAT method has been widely 
used and the concept of ICAT strategy has been adapted and modified to a number of isotope 
labelling methods, such as Isotope-coded protein labels (ICPL)122, Isobaric tags for relative and 
absolute quantitation (iTRAQ)123 and tandem mass tags (TMT)124. 
In stable isotope labelling by amino acids in cell culture (SILAC)125 approach, cells are cultured 
in a medium containing differentially isotopically labelled amino acids (usually lysine and 
arginine). Lysates with different labels are mixed prior to digestion and sample preparation. As 
a result, peptides with the same amino acid sequence and different isotopic labels can be 
distinguished by mass spectrometry; relative abundance can be obtained by calculating the ratio 
of differentially labelled peptides. For example, using the SILAC-based method combined with 
SCX and TiO2 enrichment, 6600 unique phosphorylation sites from 2244 proteins were 
successfully identified in EGF-stimulated HeLa cells107. More recently, Olsen et al. showed 
that quantification of 20,443 phosphorylation sites from 6027 proteins was achieved in a study 
of the phosphoproteome of the cell cycle and a specific kinase motif was identified at various 
stages in the cell cycle126. Hinsby et al. applied SILAC in the phosphoproteomics workflow to 
study protein phosphorylation in response to FGF1 stimulation in the human 293T cell line. 
An antibody was used to isolate binding proteins of a specific phosphoprotein and 28 binding 
partners were identified that were involved in stimulation by FGF1127. A novel component of 
FGF signalling, for example insulin receptor substrate 4 (IRS4), was identified and a novel 
tyrosine phosphorylation site (Tyr915) in IRS4 was found to directly interact with several 
proteins in FGF signalling cascade. More recently, the SILAC approach has been not only 
limited to cell culture systems, but also available to in vivo experiments in mice128. 
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Label-free quantitation methods typically require the use of an internal standard. Methods were 
developed using peak height, spectral count or fragment-ion intensities to normalize the peptide 
signal 129,130. These methods are increasingly popular, as they are especially valuable for 
samples that are not suitable for in vitro labelling. Langlais et al. investigated the site-specific 
phosphorylation of Insulin Receptor Substrate-1 with a label-free method and were able to 
relatively quantify isobaric phosphopeptides within one protein131. Old et al. performed global 
profiling using a label-free quantitation method to identify the phosphorylation events involved 
in oncogenic B-Raf signalling. Ninety phosphorylation events were revealed to be sensitive to 
MEK1/2 inhibitor. Multiple phosphorylation sites of an uncharacterised protein were subjected 
to detailed investigation and its phosphorylation was shown to be involved in controlling 
melanoma cell invasion132. 
 
1.4.2.3 Mass spectrometry analysis 
CID and ETD are the most frequently used fragmentation techniques in proteomics133. Some 
reports suggest ETD can identify a larger number of phosphopeptides than CID, especially for 
multiply charged peptides134. An alternative strategy is to combine CID and ETD results or 
alternate CID/ETD in one analysis. Electron capture dissociation (ECD)135 and higher energy 
collision activated dissociation (HCD)136 are also used in large-scale localization of 
phosphorylation. 
Phosphopeptides in complex mixtures often escape standard mass spectrometry detection 
because of their low abundance and inadequate fragmentation patterns. Neutral loss scanning, 
in which the mass range is continuously scanned for ions with a mass shift of 98 Da (H3PO4), 
can be used in sequential fragmentation to partially address these issues137. In ion traps, MS3 
will be triggered if a 98 Da mass shift is detected. A drawback of this approach is tyrosine-
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phosphorylated peptides typically lose HPO3  rather than H3PO4 thus the product ion is the 
unmodified amino acid, which may limit the identification of tyrosine-phosphorylated peptides 
Combinations of multiple fragmentation methods have been employed to exploit their 
complementarity. Frese and co-workers coupled multi-enzyme digestion and alternate CID and 
ETD tandem mass spectrometry for the characterisation of caseins138. They concluded that the 
complementary information provided by CID (peptide sequencing and identification of single-
point modification) and ETD (PTMs) was crucial for complete protein sequencing, where an 
average 32% increase of sequence coverage was observed in alternating CID/ETD approach 
compared to CID or ETD alone. 
 
1.4.2.4 Data analysis 
The three main databases in phosphoproteome research, which store biochemically verified 
and mass spectrometry identified protein phosphorylation data are PhosphoSitePlus 
(www.phosphosite.org), Phospho.ELM (http://phospho.elm.eu.org) and Phosida 
(www.phosida.com). Phosphoproteome data of model organisms and various species are 
available through their websites. 
Annotation of phosphorylation is the first step towards the interpretation of protein function. 
While phosphoproteomics has greatly broadened the knowledge of phosphorylation events in 
various biological processes, the need to characterise the regulatory relationship between 
kinases and phosphorylation substrates has expanded. Software focusing on motif analysis, e.g. 
Scansite (http://scansite.mit.edu), NetWorkin (http://networkin.info) and iGPS 
(http://igps.biocuckoo.org), have been developed to identify the upstream kinases responsible 
for identified phosphorylation sites. Results from bioinformatic mining are powerful in 
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revealing the protein family, pathway or biological function related to a group of 
phosphorylation substrates139.  
Software based on consensus motif to predict upstream kinases are popular in deciphering high-
throughput phosphoproteomic data. Pawson and co-workers showed with Networkin kinase 
prediction was able to assign 60-80 % of substrate from an in vivo study139. Although this 
marked huge progress in phosphoproteome software, it still points out limitation of current 
bioinformatic tools. It should be noted that the prediction does not provide direct evidence of 
specific kinase-substrate information and further validation is required. In addition, the 
knowledge of novel phosphorylation sites is limited in context of their function and consensus 
motif, which offers another direction of future bioinformatic innovation. 
 
1.4.2.5 Future prospects 
Owing to the huge role played by phosphorylation in signal transduction, phosphoproteomics 
is becoming one of the fastest-growing areas in the study of signal transduction pathways. 
Many studies have focused on the temporal dynamics of regulated phosphorylation events in 
cell signalling or various biological processes. In recent years, the large-scale 
phosphoproteomics workflow is able to map phosphorylation events in considerable depth, 
from a few hundreds of phosphorylation sites up to thousands of sites in one single analysis. A 
huge emphasis has also been placed from discovery-driven to site-specific analysis that focuses 
on interpretation of specific biological connections.  
Phosphopeptide identification capacity is still limited by enrichment methods, instrument 
performance and data interpretation methods. For tryptic peptides, singly modified peptides 
constitute the majority of the total phosphopeptides identified by current technologies140. 
Current understanding holds that it is more challenging to identify doubly- and multiply-
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phosphorylated peptides than singly-phosphorylated peptides. Nevertheless, deciphering the 
mechanisms of cell signalling requires knowledge of multiply-phosphorylated peptides as these 
adjacent phosphorylation sites may play important regulatory roles. Therefore, one of the 
crucial challenges in cell signalling research is to map modification sites in multiply-
phosphorylated peptides.  
Although significant progress has been made, low phosphoproteomic coverage, limited 
dynamic range and co-elution of peptide isomers still remain a challenge. The development of 
phosphoproteomics required the advances in sample preparation, multiplexed MS techniques 
and novel data handling software in the future. 
 
1.4.3 Targeted proteomics-selected reaction monitoring 
1.4.3.1 Overview 
Large-scale proteome analysis has been extensively applied in biomarker discovery and the 
development of shotgun approaches greatly increased proteome coverage141. Accurate 
quantitation and validation is a necessary step for further characterisation. Conventional 
methods, e.g. Western blot and enzyme-linked immunosorbent assay (ELISA) provide good 
sensitivity and reproducibility. However, antibody is not always available for such assays. 
SRM has emerged as an alternative approach with high reproducibility and throughput. Also, 
in combination with LC-MS/MS, the detection limit in attomole level can be routinely achieved 
by SRM142,143. 
Unlike full MS scan mode, where data are collected by summing up signal intensity over all 
m/z to a total-ion chromatogram (TIC), SRM data is collected to form an extracted ion 
chromatogram (XIC), where m/z values are extracted from the full mass range to build an 
38 
 
elution profile for a given analyte. In SRM analysis, mass spectrometer only selects a set of 
target ions within the given m/z range and allow them for fragmentation. The relative 
abundance of specified fragment ions is indicative of the abundance of peptides in the sample. 
In some cases, peptides with similar m/z or isobaric peptides may appear in the same mass 
window in SRM selection144. Thus, monitoring a single precursor mass is not sufficient to 
define a unique analyte. Then, targeting a specific precursor as well as multiple fragment ions 
may provide highly specific signal to minimize the incidence of false positive detection.  
SRM assay typically makes use of a QqQ mass analyser. The most widely used instruments 
are QqQ mass spectrometer, quadrupole-time of flight (Q-TOF) mass spectrometer and 
quadrupole-TRAP mass spectrometer. TSQ Vantage Triple Quadrupole Mass Spectrometer 
used in this thesis was described in detail in Section 1.3.4.2. 
 
Figure 1.11 Selected reaction monitoring technique 
As a targeted method, SRM has to be hypothesis-driven; therefore, knowledge of the analyte 
is required from previously acquired discovery data145. Based on information of 
precursor/fragment ions obtained from discovery data, a transition (pair of product ion and 
fragment ion) list can be built to ensure accurate and specific quantitation. This underlying 
mechanism of SRM makes it an ideal validation platform, complimentary to the results 
obtained from the discovery-based method.  
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1.4.3.2 SRM experiment design 
As SRM-based quantitation approach does not allow peptide de novo sequencing. Knowledge 
of the MS/MS behaviour of the peptides is required. The selection of target peptides and 
transitions are crucial for accuracy and precision of the SRM assays, especially for complex 
biological samples.  
The target peptides are usually referred to as signature peptides or proteotypic peptides 
(PTPs)146. The signal intensity of different peptides of the same protein can differ by up to 100-
fold in intensity147. There are several factors and empirical rules affecting the choice of peptides. 
First, peptides with the most intense MS response are promising targets for SRM assay, such 
as the highly detectable peptides derived from previous shotgun experiments or peptides 
predicted by computational tools148. Second, the signature peptides can be uniquely identified 
only in one protein or one isoform. Third, for peptides with post-translational modification, it 
is important to distinguish the unmodified and modified form as in most cases they tend to 
show different responses. 
The selection of signature peptides is then followed by the selection of a set of fragment ions. 
There are a number of public available databases of MS/MS spectra and validated SRM assays 
to provide empirical guides to assay development and transition selection149–151. An alternative 
way to optimize the transition selection is to directly infuse the target peptide and select the 
unique fragments with the most intense signals. Fragments with similar masses should be 
avoided. To study PTM peptides, the fragment losing the modified group, e.g. phosphate group, 
is necessary in order to distinguish them from unmodified peptides. Commonly, 2 to 4 fragment 
ions are selected for each peptide due to the limitation of the number of transitions that can be 
measured per LC-MS/MS analysis. If measuring too many transitions in one run, the cycle time 
will be prolonged, thus there will not be enough data points to build the chromatographic 
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elution profile of the targeted peptides. However, the number of transitions analysed per LC-
MS/MS run can be increased by scheduling SRM transitions152. A retention time window can 
be set to scan for a specific peptide, therefore a higher number of peptides can be measured in 
one LC-MS/MS run. 
To improve the accuracy and precision of SRM assay, pre-fractionation is usually necessary 
depending on the complexity of sample. The most widely used approach is to couple LC with 
SRM tandem mass spectrometry153. Selective enrichment procedures following enzyme 
digestion could be employed for the investigation of peptides with PTM154,155. It is reported the 
combination of enrichment and fractionation is able to enrich the target peptide by up to 3 
orders of magnitude104. However, it is worth mentioning that the introduction of sample 
processing procedures will potentially affect the reproducibility and precision of SRM assay. 
SRM has also been coupled with ion mobility separation156. 
 
1.4.3.3 Absolute quantitation 
SRM can perform relative and absolute quantitation. Relative (differential) quantitation by 
SRM is straightforward and can be used to determine the relative quantities between two 
samples. In some cases, the amount of biomarkers present in a sample or a parallel comparison 
of peptide quantities is needed among multiple samples, thus the relative quantitation 
information is insufficient. Absolute quantitation can be achieved, combined with isotope 
labelling or label-free approach.  
1.4.3.3.1 Isotope-based quantitation 
The widespread and frequently used absolute quantitation approach employs an internal 
standard (IS) with isotope labelling154. First, a calibration curve needs to be established by 
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infusing stable-isotope labelled IS peptides. IS peptides can be synthesised by solid-phase 
peptide synthesis to incorporate heavy labelled amino acids. Then, IS peptides of known 
amount can be spiked into the isotopic labelled endogenous peptides. The amount of IS peptide 
required can be determined in a pilot experiment for the individual peptide. The absolute 
amount of endogenous peptides can then be derived from the relative signal intensity of 
endogenous peptides compared with that of the IS peptides. The introduction of isotopic labels 
as internal standards has enabled absolute peptide quantitation and data replication. Although 
labelling the endogenous peptides and synthesis of IS peptide are cost-intensive, it is 
compensated by better accuracy and more precise quantitation157. 
 
1.4.3.3.2 Label-free quantitation 
Label-free SRM is based on quantitation of a  single or a group of IS peptides as the reference 
standard to measure all the target endogenous peptides158. Although the label-free approach is 
experimentally simple, variations in the signal intensity among LC-MS/MS analyses or within 
a single LC-MS/MS pose a challenge to the accuracy of quantitation assay. To minimize these 
fluctuations, normalization is performed to ensure there is no global shift in the ion intensities.  
The need for absolute quantitation information and reducing the cost of an experiment has 
increased the demand for label-free quantitation strategies. The QconCAT159 strategy employs 
a pool of signature internal standard peptides and enables absolute parallel quantitation of 
multiple samples. A recently developed label-free approach uses internal standard peptides 
with a quantitation tag160. The tag is added via the trypsin cleavage site to all peptides, which 
can then be used to normalize the amount of internal standard peptides. 
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1.4.3.4 Applications of SRM 
The specificity of SRM assay depends on the uniqueness of the peptide sequence and the 
response of the fragment ions of each peptide. Highly sequence-homologous proteins and 
mutant proteins, which cannot be distinguished by traditional affinity-based methods, can be 
unambiguously identified by SRM. Wang et al. demonstrated the applicability of SRM in the 
measurement of peptides with somatic mutations of Ras, with peptides differing by only one 
amino acid161. The capability of site-specific quantitation opens up opportunities for SRM-
based diagnostic applications. 
Large-scale proteomics and genomics screen can generate a list of proteins of potential interest. 
Based on this previous knowledge, SRM-based experiment can then be performed to target 
these proteins for validation or detailed characterisation. Jovanovic and co-workers used SRM 
to quantitatively monitor a set of putative target proteins of microRNA let-7 in Caenorhabditis 
elegans162. These targets were selected from microarray RNAi screen, microRNA target 
prediction algorithms and literature. Around 50% of proteins of interest were successfully 
quantified and biologically relevant let-7 interactors were identified. Wolf-Wolf-Yadlin et al. 
investigated previously identified phosphorylation events in EGF signalling163. They combined 
affinity-based enrichment and SRM to study the dynamics of phosphorylation in a time-course 
manner during EGF simulation. Over 200 hundred phosphorylation profiles were recorded, and 
early and late phosphorylation responses were identified upon stimulation. 
The SRM approach can be applied to identify novel biomarkers for a disease due to its 
multiplexing capabilities of up to 100 analytes164. Anderson and Hunter assessed the precision 
and dynamic range of SRM technique for multiple quantitations in plasma samples99. They 
used multiplexed SRM to reproducibly quantify 47 out of 53 proteins. These quantitation 
results yielded a limit of quantification (LOQ) of 0.1 μg/mL and a dynamic range of 
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approximately 4.5 orders of magnitude. Coupled with affinity enrichment and fractionation, 
Keshishian et al. significantly expanded the detection limit down to 1–10 ng/mL165. With this 
strategy, Cima et al. measured 49 candidate biomarkers for prostate cancer from serum samples 
from more than 100 individuals, from which they proposed a four-protein signature for prostate 
cancer detection166. 
 
 
1.5 High-Field Asymmetric Waveform Ion Mobility Spectrometry 
(FAIMS) 
1.5.1 Ion mobility mass spectrometry 
Ion mobility spectrometry (IMS) is a gas-phase analytical technique used to separate and 
identify ions based on their ion mobility as they travel through an electric field167. Separation 
is not based on m/z ratio as it is in conventional mass spectrometry, but on a combination of 
the mass, charge, size, and shape of an ion. Separation in IMS occurs on a timescale of 
milliseconds, several orders of magnitudes faster than the seconds to hours in chromatographic 
separations. The compact design of some IMS devices has allowed the approach to be used in 
detection of explosives, drugs and chemical weapons. Although it was demonstrated in 1962 
that IMS could be coupled with mass spectrometry168, it was not until 1993 with the 
advancement of instrumentation that IMS-MS has been used in detection of low abundance 
chemicals, separation of complex mixtures and characterization of structural information169. 
Types of IMS techniques in mass spectrometry include drift tube ion mobility spectrometry 
(DTIMS), travelling wave ion mobility spectrometry (TWIMS) and high-field asymmetric ion 
mobility spectrometry (FAIMS)170. Features of these three techniques are shown in Table 1.3.  
44 
 
Table 1.3 Comparison of the three types of IMS 
 
Drift tube ion mobility spectrometry makes use of a long, gas-filled (typically helium) drift 
tube in the presence of a constant electric field. Ions are injected in the opposite direction to 
the buffer gas and migration time through the drift tube is measured to distinguish analyte ions. 
The movement of ions in applied electric fields is analogous to electrophoresis in that their 
movement is delayed by the counter-flow buffer gas. The drift time measurement provides 
information on chemical structure and three-dimensional conformation of an ion, as the 
mobility of an ion is related to rotationally-averaged collision cross section (CCS) in a DTIMS 
cell. The CCS of an ion can be calculated according to Mason–Schamp equation171: 
 
z is the charge state, K0 is the mobility in low field, e is the elementary charge, N is the number density of the drift 
gas, μ is the reduced mass of the ion–neutral drift gas pair, kB is the Boltzmann constant and T is the gas 
temperature. 
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Together with molecular dynamics simulations, DTIMS technique is useful in providing 
structural information, which can be compared with data acquired by techniques such as X-ray 
crystallography and nuclear magnetic resonance (NMR) spectroscopy. Commercially available 
instruments, e.g. Agilent ion mobility Q-TOF mass spectrometer, featuring a drift tube ion 
mobility cell are able to provide extra separation and acquire structural information besides 
routine qualitative and quantitative applications.  
The travelling wave ion mobility spectrometry (TWIMS) device is similar to traditional 
DTIMS but comprised of stacked ring electrodes, to which a radio frequency (RF) is applied172. 
Adjacent rings have opposite RF voltage applied to them, which confines the ions within the 
cell, whilst the application of a direct current (DC) to each pair of adjacent rings provides the 
wave that drives the ions through the mobility cell. By tuning RF and DC, separation can be 
achieved. TWIMS has shown improved duty cycle and better capabilities for multiply charged 
ions compared with traditional DTIMS173. Another advantage of TWIMS is that the ion 
confinement and accumulation ability does not hugely compromise the sensitivity of mass 
spectrometer, therefore allowing the application of low abundance analytes. TWIMS is only 
available in a number of Water SYNAPT family instruments. 
FAIMS is exploited in the course of this study. Fundamental theories and applications of 
FAIMS are described in the following sections. 
 
1.5.2 Fundamentals of FAIMS 
FAIMS separates ions according to differences in ion mobility in high and low electric fields. 
In a FAIMS device, ions are guided by carrier gas into a pair of parallel electrodes to which a 
radiofrequency waveform voltage is applied. The radiofrequency waveform, termed dispersion 
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voltage (DV), is asymmetric and alternating between positive and negative field. An equal 
product of each part for the wave form is maintained but the value of positive field is higher 
than that of negative field. To produce equal part of waveform, the high-field wave is twice the 
magnitude and half the duration of the low-field. Ions, exposed to alternating high and low 
electric fields, travel through electrodes guided by the carrier gas (helium or nitrogen). Ion 
mobility in an electric field can be described as below169: 
 
                                        (1) 
Kh is the ion mobility at high field and K0 is the ion mobility at zero field. f(E/N) describes the ion mobility as a 
function of electric field strength (E) and density of gas (N).  
 
At zero/low field, ion drift velocity is proportional to the applied field and K is constant with 
varying field strength. As field strength increases, the velocity is no longer proportional to the 
applied field and the increase in K is nonlinear170. The dependence of Kh on field strength is 
the basis of FAIMS separation. When exposed to high electric field, the collision energy 
between an ion and a carrier gas molecule is different from that in low electric field. Certain 
ions show increased mobility as field strength increases (type A ions); certain ions show initial 
increase in ion mobility as field strength increases, follow by decreased mobility as field 
strength further increases (type B ions); certain types of ions show decreased mobility with 
increased field strength (type C ions).  
The ion mobility can also be influenced by use of gas mixtures. According to Blanc’s law, the 
mobility of an ion in gas mixtures is correlated to the mobility in individual gas and their 
abundance. Therefore, for a mixture of gas X and gas Y, the mobility of an ion can be calculated 
as: 
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                                                (2) 
KX and KY is the ion mobility in gas X and gas Y. x and y is the relative abundance of gas X and gas Y. 
Furthermore, when the ions interact with the carrier gas which is dense enough, the ions will 
quickly acquire a terminal velocity. The terminal velocity is proportional to the strength of the 
electric field. This proportionality differs at high and low electric field and allows the 
separation of FAIMS. 
                                                     (3) 
Vd represents an ion's terminal velocity, k is the ion’s mobility and E is the electric field strength. 
 
Thus, in each cycle of changing waveform the ions will drift towards one of the electrodes. 
After a couple of cycles, the majority of the ions will end up colliding with one of the electrodes 
and neutralize. Only the ions with ‘balanced’ drift will be allowed to pass on and exit the 
electrode. Figure 1.12 shows the separation trajectory of a FAIMS device. 
 
 
Figure 1.12 Schematic diagram of FAIMS separation 
 
 
48 
 
 
 
 
Figure 1.13 FAIMS separation by tuning CVs 
 
By superposing a small direct current (DC), the compensation voltage (CV) to the electrode, 
the drift induced by the difference in high and low electric field can be compensated or 
eliminated. Accordingly, by applying different CVs, ions of interest can be selectively 
transmitted through the device (see Figure 1.13). The CV value of an ion is compound-specific.  
To analyse a mixture of ions, separation can be achieved by scanning through CVs. As majority 
of the chemical noise and short peptide exhibit type C behaviour, they will be largely filtered 
out during FAIMS cycles. This selective transmission significantly improved signal-to-noise 
ratio and detection limit of FAIMS technique. 
 
1.5.3 Design of FAIMS electrodes  
1.5.3.1 Planar FAIMS 
Separation in planar FAIMS is performed between two parallel planar electrodes (see Figure 
1.14A). The design of planar FAIMS (p-FAIMS) allows decreased residence time and faster 
49 
 
CV scanning speed, and p-FAIMS can switch between FAIMS and non-FAIMS mode by 
setting the electrode potential to ground174. Another advantage is p-FAIMS can achieve higher 
resolving power compared to c-FAIMS because the parallel electrodes can produce a uniform 
electric field without the focusing effect175. It was also observed that the sensitivity of p-FAIMS 
device is limited to the field strength applied174. The reason is, within p-FAIMS electrodes, 
increased field strength causes ions to drift further during each cycle of the waveform and 
neutralize with the electrodes, decreasing signal. 
 
 
 
Figure 1.14 Schematic diagrams of (A) p-FAIMS, (B) c-FAIMS and (C) ultra-FAIMS chip. 
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1.5.3.2 Cylindrical FAIMS 
An electrode design of concentric cylinders was first introduced by Carnahan et al. and 
improved by Guevremont et al176. The prototype design consisted of an inner electrode 
(cylinder) and an outer electrode, which are coaxially aligned with a 5 mm gap. In this model, 
ions are focused in the electrode gap, travelling transversely along the electrode. Asymmetric 
waveform (up to ±3000V) is applied to outer electrode at a frequency of 200 kHz. The 
cylindrical design creates an inhomogeneous ion focusing effect, where ions with high field 
dependence will be efficiently focused and transmitted while ions exhibit low field dependence 
may be poorly focused177. A theoretical analysis of the focusing effect was described by 
Krylov178. In contrast to p-FAIMS, the sensitivity of cylindrical FAIMS increases as the field 
strength increases due to the focusing effect. 
In 2005, c-FAIMS device was marketed by Thermo Fisher Scientific (developed by Ionalytics 
Corporation) with interface to mass spectrometer. Improvements were adopted where ions are 
introduced into the electrodes in a direction orthogonal to the axis of the electrodes and guided 
by carrier gas to the exit through an aperture on the opposite side of the electrode (Figure 1.11). 
In this device, the inner and outer electrode is 13 mm and 18 mm in diameter, with a 2.5 mm 
gap. Asymmetric waveform is applied to the inner electrode. A high flow ESI probe (New 
Objective probe, μL/min to mL/min) is compatible with the Thermo c-FAIMS device. Recently, 
to couple nanoLC with FAIMS, a modified HESI probe (Thermo Scientific) was introduced by 
Swearingen et al. to accommodate a capillary column179. This probe also allows the use of 
sheath gas to assist electrospray. A 33.0% increase in proteome coverage was observed with 
these modifications. The Thermo c-FAIMS device with a modified HESI was used in the work 
presented in Chapter 3 and 4. 
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1.5.3.3 Ultra FAIMS 
A multichannel microchip p-FAIMS device (termed ultra-FAIMS) was described by 
Shvartsburg et al.180 and is manufactured by Owlstone Nanotech. It is constructed with 
interleaved plates with multiple parallel gaps 35 μm in width and 300 μm in length, as shown 
in Figure 1.11. Compared with conventional p-FAIMS with field strength of approximate 20 
kV/cm, ultra-FAIMS device can raise the field strength up to 60 kV/cm or 180 kV/cm. The 
drawback of the ultra-FAIMS device is that extreme high fields will decrease transmission 
efficiency due to increased diffusion, but this loss can be partially offset by the decreased 
residence time. The scan time of ultra-FAIMS device can be 100-10,000 times faster than 
previous devices. Dispersion field and compensation field can be varied simultaneously to 
allow two dimensional FAIMS analysis and identify the optimum conditions for separation of 
a particular (set of) ion. The chip-based FAIMS device can be attached to suitable mass 
spectrometers between the ionisation source and MS inlet. 
 
1.5.3.4 Novel cylindrical electrode design 
Recently, a modified FAIMS device was described which is based on the Thermo c-FAIMS 
device181. There are two main improvements in the modified FAIMS interface: (1) the gap 
between inner and outer electrode was reduced gap from 2.5 mm to 1.5 mm; (2) FAIMS inlet 
was modified to improve ion transmission. 
 
Figure 1.15 Side view comparison of standard and modified FAIMS electrodes 
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The field strength in a ring-shaped region can be described as in the equation below174. The 
reduction in gap by increasing the radius of the inner electrode allows application of higher 
field strength at a fixed Va. The increase in the magnitude of the focusing field could enhance 
dependence of ion on field strength; therefore enhance ion focusing effect through the 
electrodes. Separation at low field strength is closely related to m/z ratio and therefore 
separation at low field strength has no particular advantages in resolving similar analytes. 
Therefore, increasing applied field strength compatible with available instrument becomes a 
useful separation enhancement tool in optimization of the FAIMS device.  
                                  (4) 
Va: potential applied to inner electrode; r: radial distance from the inner electrode; a: outer diameter of the inner 
electrode; b: inner diameter of the inner electrode. 
 
The ion inlet region of the FAIMS device was modified to accommodate two carrier gas inlets, 
creating a symmetric gas flow and reducing ion loss in the entrance region. Comparison 
between standard and modified FAIMS showed little improvement in sensitivity but significant 
improvement in S/N was observed. It has been demonstrated that in analysis of standard 
peptides the modified FAIMS device resulted in up to ten-fold increase in S/N and simulation 
analysis showed the ion transmission efficiency was improved of ~9-fold and residence time 
can be reduced to 13.2 ms (± 3.9 ms), compared with 50-100 ms in standard FAIMS. Evaluation 
of the modified FAIMS for qualitative and quantitative analysis of complex biological samples 
is presented in Chapter 5. 
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1.5.4 FAIMS and proteomics 
The FAIMS technology has introduced new opportunities into proteomics research. FAIMS 
can be used to separate ions, either with direct infusion electrospray or with LC, prior to their 
introduction into mass spectrometer182. In 2001, a commercialized c-FAIMS device was first 
introduced by Ionalytics Corporation, which enabled FAIMS to couple with electrospray 
ionization (ESI). Thermo Fisher Scientific released the c-FAIMS device based on Ionalytics 
that interfaced with their instruments in 2005. Since then, an increasing number of studies have 
been carried out to investigate the potential of FAIMS in proteomics research179,183,184. 
The application of FAIMS in proteomics as a separation technique provides advantages in 
several aspects: (a) reduced background signal and improved signal-to-noise ratio; (b) 
increased limits of detection and dynamic range; (c) enhanced separation and identification of 
isobaric ions.  
Venne et al. combined FAIMS with a quadrupole time-of-flight (Q-TOF) spectrometer in the 
study of Glu-fibrinopeptide B185. A 6~12-fold improvement of S/N ratio and a 20% increase in 
peptide identification were observed. They applied an ‘internal CV-stepping’ FAIMS method: 
each LC-MS/MS scan was collected at a different CV in a single LC-FAIMS-MS/MS run. 
With this method, LC-FAIMS-MS/MS provided a 20% increase in the number of peptide ions 
compared with the conventional LC-MS/MS approach in the analysis of U937 cells.  
FAIMS has shown potential in shotgun proteomic analysis, especially when coupled with LC, 
adding an extra dimension of separation. Canterbury et al. coupled FAIMS with a LTQ linear 
ion trap to analyse a complex tryptic digest of S. cerevisiae proteins186. The use of FAIMS 
resulted in a fivefold increase in dynamic range and an eightfold increase in peak capacity. 
However, a loss of signal of one order of magnitude was reported. They proposed the loss may 
occur in the ion inlet region of FAIMS device as explained above. Saba et al. have 
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demonstrated the ability of FAIMS to enrich multiply charged peptides and increase dynamic 
range while reducing the background signal187. The ‘external CV-stepping’ method was used 
in their study: the CV was kept constant during one LC-FAIMS-MS/MS analysis and multiple 
CVs were scanned individually (in this case ranging from -22 V to -46 V). With this method, 
they reported a 46% increase in the number of peptide assignment in analysing tryptic digest 
of U937 cells.  
In early studies, FAIMS was normally operated with nitrogen alone. Recently, several groups 
have also reported the addition of He to the carrier gas could enhance the peptide detection188,189. 
Shvartsburg et al. investigated the effect of He content (as carrier gas with nitrogen) on the 
separation of 3 mono-phosphorylated peptide isomers189. They found increasing helium 
content from 0 % to 75 % induced a shift in the CV value and a decrease in peak widths, which 
led to improved isomer separation. Shvartsburg et al. have examined 50:50 He:N2 as the carrier 
gas and the result showed that it significantly improved peptide transmission and resolving 
power (2~3 times). The composition of carrier gas can greatly affect the behaviour of ions in 
high and low electric field. They proposed the addition of He enhanced the ion unfolding in 
the gas environment, resulting in broader separation space and narrower peaks.  
FAIMS also provides us a new angle to improve the performance of LC-MS/MS by addressing 
some of its instrumental limitations. In the investigation of PTM, the presence of positional 
isomers and co-eluting peptides of the same mass often lead to ambiguous identification190. 
The separation based on LC alone is limited. Thus, pre-separation is particularly useful for the 
accurate localization of modifications. Bridon et al. have also demonstrated the advantages of 
FAIMS in PTM identification in the study of Drosophila melanogaster Schneider S2 cells, 
where FAIMS expanded the phosphoproteome coverage by 49%. Meanwhile, 78 potential 
phospho-isomers were identified by FAIMS. Creese et al. applied FAIMS to the analysis of a 
phosphopeptide library, which comprised of 4000 phosphopeptides with sequence inversions 
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and structural isomers191. The use of the library enabled evaluation of the performance of 
FAIMS regards the separation ability more accurately. The results showed, combined with 
SCX, LC-FAIMS-MS/MS analyses exhibited a 2-fold increase in the number of 
phosphopeptide assignments compared to SCX-LC-MS/MS. 
 
1.6 Aims and objectives 
The aim of this thesis was to develop and apply methods to gain a greater insight into the key 
phosphorylation events of FGF signalling following inhibitor treatments. To achieve this, LC-
MS/MS and LC-FAIMS-MS/MS were applied to global phosphoproteomics of FGF signalling 
together with targeted quantitation of specific phosphorylation events. 
 
The specific aims of the work presented in the following chapters were: 
 To evaluate the performance of FAIMS in quantitative proteomic analysis and generate a 
method suitable for SILAC-based LC-FAIMS-MS/MS analysis (Chapter 3). 
 To investigate of site-specific phosphorylation in FGFR signalling following chemical 
inhibitions by LC-MS/MS and LC-FAIMS-MS/MS (Chapter 4). 
 To evaluate the performance of standard and modified FAIMS interface in proteomic 
analysis (Chapter 5). 
 To investigate the dynamics of the key phosphorylation events in the FGF signalling by 
SRM (Chapter 6). 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2.1. Buffers and solutions  
2.1.1 General laboratory reagents 
 Acetic acid (J. T. Baker) 
 Acetonitrile, HPLC grade (J. T. Baker) 
 Ammonium bicarbonate (Fisher Scientific) 
 Ethylenediaminetetraacetic acid (EDTA) (Fisher Scientific) 
 Formic acid (Fisher Scientific) 
 Iodoacetamide (Sigma-Aldrich) 
 Methanol, HPLC grade (J. T. Baker) 
 Potassium chloride (Sigma-Aldrich) 
 Potassium dihydrogen phosphate (Sanofi) 
 Trifluoroacetic acid (TFA) (Sigma-Aldrich) 
 Water, HPLC grade (J. T. Baker) 
 
2.1.2 Cell culture 
 Phosphate buffered saline (PBS): PBS pH 7.2 tablets (Oxoid) made up according to 
manufacturers’ instructions 
 RPMI 1640 medium (Life technologies) 
 RPMI 1640 medium for SILAC (Life technologies) 
 SILAC labels: L-arginine and L-lysine (R0K0) (Sigma-Aldrich) 
 SILAC labels: 13C6 L-arginine and 4,4,5,5-D4 L-lysine (R6K4) (Goss Scientific) 
 SILAC labels: 13C6 15N4 L-arginine and 13C6 15N2 L-lysine (R10K8) (Goss Scientific) 
 0.1 mg/mL streptomycin and 100 I.U./ml penicillin (Sigma-Aldrich) 
 0.5 mg/mL proline (Sigma-Aldrich) 
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 10 % Fetal bovine serum, FBS (Biosera) 
 10 % dialyzed FBS (Labtech International) 
 20 ng/mL FGF1 (BioLegend) 
 10 mg/mL heparin (Sigma-Aldrich) 
 1μM dasatinib (Sellek Chemicals) 
 Cell lysis buffer: 0.05 M tris-HCl (Thermo Fisher Scientific), 0.15 M NaCl (Thermo Fisher 
Scientific), 1 % Triton X-100 (Sigma-Aldrich) (v/v), complete protease inhibitor cocktail 
tablets (Roche Applied Science): 1 tablet per 10 mL (contains EDTA; final concentration 
0.001 M) 
 Complete Mini, Protease Inhibitor Cocktail Tablets (Roche Diagnostics) 
 
2.1.3 Sample preparation 
 C18 Zip-Tip (Millipore) 
 Coomassie protein assay kit (Fisher Scientific) 
 Trypsin Gold-Mass spectrometry grade (Promega) 
 TitansphereTM Phos-TiO2 kit (GL Sciences) 
 NuPAGE 4-12% pre-cast Bis-Tris gels (Life technologies) 
 
2.1.4 Fractionations 
Strong cation exchange (SCX) chromatography: 
 100×2.1 mm polysulfoethyl aspartamide column (5 μm particle size, 20 nm pore size) 
 Mobile phase A (5 mM KH2PO4, 20 % (v/v) acetonitrile, pH 3.0) 
 Mobile phase B (5 mM potassium dihydrogen phosphate, 20 % (v/v) acetonitrile, 250 
mM potassium chloride, pH 3 with phosphoric acid) 
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Phosphoenrichment : 
 Buffer A (0.5% TFA, 80 % acetonitrile) 
 Buffer B (25% lactic acid and 75% Buffer A) 
 5 % ammonia hydroxide (Sigma-Aldrich) 
 5% pyrrolidine (Sigma-Aldrich) 
 
2.1.5 Mass spectrometry 
 LTQ Velos ESI Positive Ion Calibration Solution (Life technologies) 
 Protein Mixture Digest (Dionex) 
 MS Qual/Quant QC Mix (Sigma-Aldrich) 
 Substance P (Sigma-Aldrich) 
 
2.2 Methods  
2.2.1 Cell culture 
2.2.1.1 Cell culture 
SUM52PE breast cancer cell lines were kindly provided by Dr. Simon Cook, Babraham 
Institute. SUM52PE cells were grown in RPMI1640 media supplemented with 10% foetal 
bovine serum (FBS), 0.2 U/ml penicillin, 0.1 mg/ml streptomycin and 2 mM L-glutamine. Cells 
were cultured at 37ºC with 5% CO2. 
 
2.2.1.2 Cell labelling 
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For SILAC labelling, SUM52PE cells were grown in amino acid deficient media (RPMI1640) 
supplemented with 0.1 mg/mL L-Lysine and L-Arginine, “medium” 13C6 L-Lysine and 13C6 
15N2 L-Arginine or “heavy” 13C6 L-Lysine and 13C6 15N4 L-Arginine, 10% dialyzed FBS, 0.1 
mg/mL streptomycin, 0.2 U/mL penicillin and 2 mM L-Glutamine. Cells were cultured for at 
least five doublings in order for the cells to fully attain complete labelling192.  
 
2.2.1.3 Cell treatment: SILAC 
Prior to treatment, cells grown to 80-90% confluence were serum-starved for 4 hours. After 
serum starvation, “light” cells were treated with 20 ng/mL FGF1 and 10 mg/mL heparin for 30 
min; “medium” cells were treated with 20 μM SU5402 for 30 min followed by treatment of 10 
mg/mL heparin and 20 ng/mL FGF1 for 30 min; cells cultured in “heavy” media were treated 
with 1 μM dasatinib for 30 min followed by a 30-minute treatment of 20 ng/mL FGF1 and 10 
mg/mL heparin. 
 
2.2.1.4 Cell treatment: SRM 
Prior to treatment, SUM52PE cells were serum-starved for 4 hours. Cells were treated with 20 
ng/mL of FGF1 and 10 ng/µL of heparin for 0 s, 20 s, 40 s, 1 min, 3 min, 5 min, 10 min, 20 
min, 30 min and 60 min individually.  
 
2.2.1.5 Cell lysis 
Prior to cell lysis, cells cultured in 100 mM dish were washed twice with cold PBS and 
incubated at 4 °C for at least 30 min in 800 μL lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 1% Triton TX-100, 1 tablet of protease inhibitor cocktail and 1 tablet of phosphatase 
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inhibitor cocktail per 10 mL of buffer). Protein concentration was determined using the 
Coomassie Protein Assay Kit according to manufacturers’ instructions. Lysates were adjusted 
to the desired concentration prior to further experiments. 
 
2.2.1.6 Trypsin digestion 
Samples were suspended in 50 mM ammonium bicarbonate. For SILAC samples, equal amount 
of “light”, “medium” and “heavy” lysates were pooled prior to trypsin digestion. Reduction 
was performed at 56 °C in the presence of 8 mM dithiothreitol (DTT) for 45 min. Sample was 
then alkylated in 25 mM iodoacetamide at room temperature in the dark for 45 min. After 
reduction and alkylation, proteins were digested by trypsin at an enzyme: protein ratio of 1:100 
at 37 °C overnight. The digestion was terminated by the addition of 0.5% (v/v) formic acid. 
 
2.2.2 Fractionations 
2.2.2.1 Peptide desalting using Sep-Pak Cartridges 
Sep-Pak Cartridges were wet with 4 mL of acetonitrile. Cartridges were then conditioned with 
1.5 mL of 50% acetonitrile/0.5% acetic acid and 4 mL of 0.1% TFA. Sample was loaded 
through the cartridges twice. Wash with 4 mL of 0.1% TFA. Cartridges were conditioned with 
1 mL of 0.5% acetic acid. Peptides were eluted by use of 2 mL of 50% acetonitrile. Elution 
was dried by vacuum centrifugation. 
 
2.2.2.2 Peptide desalting using Macro-trap 
Sample was resuspended in 20 µL of 1% TFA. Trap was wet with 200 µL of 50% acetonitrile 
and washed with 100 µL of 0.2% TFA. Sample was loaded twice. Trap was washed with 300 
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µL of 0.1% TFA. Sample was eluted with 300 µL of 70% acetonitrile. Elution was dried by 
vacuum centrifugation. 
 
2.2.2.3 Peptide desalting using Ziptip 
Sample was resuspended in 20 µL of 1% TFA. Tip was wet with 10 µL 100% acetonitrile 
(repeat twice) and conditioned with 10 µL of 0.1% TFA (repeat three times). Sample was 
loaded by aspirating and dispensing the solvent 7-8 times. Tip was washed with 10 µL of 0.1% 
TFA (repeat three times). Peptides was eluted by aspirating and dispensing in 10 µL of 70% 
acetonitrile. Elution was dried by vacuum centrifugation. 
 
2.2.2.4 Strong cation exchange (SCX) chromatography 
Peptides were resuspended in 100 μL of mobile phase A and loaded onto a 100×2.1 mm 
polysulfoethyl aspartamide column at a flow rate of 200 μL/min. Separation gradient started 
from 0 % mobile phase B and increased to 50 % mobile phase B in 30 min, increased from 50% 
to 100 % mobile phase B in 5 minutes and returned to 100 % mobile phase A to equilibrate. 
Fractions with 750 μL were collected throughout the run. 
 
2.2.2.5 Phosphoenrichment 
Phosphoenrichment was performed using Phos-TiO2 Phosphopeptide Enrichment Kit 
according to manufacturers’ instructions. Spin tips were conditioned sequentially with 20 μL 
of Buffer A and 20 μL of Buffer B by centrifugation (3000 ×g, 2 min). Samples were re-
suspended in 50 μL of Buffer B and loaded onto the tip for centrifugation (1000 ×g, 10 min). 
Repeat this step and centrifuge again to maximize the binding. Column was washed with 20 
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μL of Buffer B and 20 μL of Buffer A sequentially and subjected to centrifugation (3000 ×g, 2 
min). Phosphopeptides were eluted with 5 % ammonium hydroxide and 5% pyrrolidine 
solution upon centrifugation individually (1000 ×g, 5 min). Elution was dried by vacuum 
centrifugation. 
 
2.2.3 LC-MS/MS analysis 
2.2.3.1 Orbitrap Velos mass spectrometer (Chapter 3 and 4) 
Experiments were performed on an Orbitrap Velos ETD mass spectrometer, equipped with a 
Dionex Ultimate 3000 Nano-LC system. Samples were loaded onto a 15 cm C18 Acclaim 
PepMap100 column in mobile phase A (0.1% formic acid) and separated by a gradient from 
3.2% to 44% mobile phase B (acetonitrile in 0.1 % formic acid) in 30 min, followed by a 10-
minute wash of 90% mobile phase B and a 15 min re-equilibration of 3.2% mobile phase B. 
Peptides were eluted via a TriVersa Nanomate chip-based electrospray device into the mass 
spectrometer. For both CID and ETD analyses, the mass spectrometer performed a ‘top 7’ 
method comprising a full FT-MS scan (m/z 380–1600) at a resolution of 30,000 in the Orbitrap 
with a 1×106 automatic gain control (AGC) target and a 1 s maximum fill time. The seven most 
abundant precursor ions was isolated for MS/MS scans in ion trap. For CID, MS/MS analysis 
of the seven most abundant precursor ions above 1000 was performed with a normalized 
collision energy of 35% (AGC target 5×104 charges, maximum fill time 100 ms). For ETD, 
MS/MS analyses of the seven most abundant precursor ions above a threshold of 5000 was 
performed with 100 ms activation time (AGC target 5×104 charges, maximum fill time 100 ms, 
reagent AGC target 1×105). The precursor isolation window was 2 m/z. Only multiply charged 
precursors were selected for fragmentation. Dynamic exclusion was applied for 60 s. 
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2.2.3.2 Orbitrap Elite mass spectrometer (Chapter 5) 
The mass spectrometer performed a ‘top 7’ method comprising a full FT-MS scan (m/z 380–
1600) at a resolution of 30,000 (m/z 400) in the Orbitrap with an AGC target of 1×106 charges 
and a maximum fill time of 1 s. The seven most abundant precursor ions detected was isolated 
for MS/MS scans in ion trap. For CID, MS/MS analyses of the seven most abundant precursor 
ions above a cut-off of 1000 with a 35% normalized collision energy was performed (AGC 
target: 5×104 charges and maximum fill time 100 ms). Width of the precursor isolation window 
was 2 m/z. Only multiply charged precursors were subjected to fragmentation. Dynamic 
exclusion was applied for 60 s. 
 
2.2.4 LC-FAIMS-MS/MS analysis 
2.2.4.1 Standard FAIMS analysis 
The standard FAIMS device was used in Chapter 3, 4 and 5. The standard FAIMS device with 
a 2.5mm electrode gap width was operated under the following conditions: carrier gas flow 
rate 2.9 L/min and carrier gas composition 50/50 He:N2, dispersion voltage (DV) -5 kV, and 
the inner and outer electrodes temperatures 70 °C/90 °C. Liquid chromatography method was 
as described above. To couple nanospray, the HESI-II source was modified to accommodate 
the 360 μm O.D. fused silica capillary, with 2 arbitrary units sheath gas to assist electrospray, 
similar to that described by Swearingen et al179. The ‘external CV stepping’ method was used 
in which the CV is kept constant throughout the LC-MS/MS analysis. Therefore, each analysis 
is performed at a fixed and separate CV. Liquid chromatography method and MS/MS methods 
were as described above. 
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2.2.4.2 Modified FAIMS analysis 
The modified FAIMS device was used in Chapter 5. The modified FAIMS device with a 1.5 
mm electrode gap width (Thermo Fisher Scientific) was operated under the following 
conditions: carrier gas (He) flow rate 2.0 L/min, dispersion voltage -5 kV, and the inner and 
outer electrodes temperatures 70 °C/90 °C. To couple nanospray, an in-house nanospray source 
was modified to accommodate the 360 μm O.D. fused silica capillary. The ‘external CV 
stepping’ method was used in which the CV is kept constant throughout the LC-MS/MS 
analysis. Therefore, each analysis is performed at a fixed and separate CV. Liquid 
chromatography method and MS/MS methods were as described above. 
 
2.2.5 LC-SRM-MS/MS analysis 
2.2.5.1 Synthesis of internal standard peptides 
The phosphopeptides selected for SRM analysis were synthesised by GenicBio Limited, 
Shanghai, China. The phosphopeptides were synthesised without isotope labels by solid phase 
peptide synthesis. The quantity of each phosphopeptide is 1 mg and the purity of all 
phosphopeptides is above 95%. Synthetic peptides were resuspended in 50% ACN, 0.1% 
formic acid to a concentration of 2 pmol/μL. A pool of phosphopeptides was generated by 
mixing phosphopeptides at the concentration of 2 pmol/μL and stored at -20 °C until further 
use. 
 
2.2.5.2 Selection of transitions 
Synthesized phosphopeptides were directly infused into Orbitrap Velos mass spectrometer to 
assess the purity of each phosphopeptide and optimize the SRM parameters. Specifically, each 
peptide was prepared at a concentration of 2 pmol/μL in 30% ACN, 0.1% FA. 
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To assess the quality of each peptide, the total ion MS profile of each peptide was acquired 
within the mass range m/z 380–1800 and the MS/MS profile of each peptide was acquired. 
Fragment ions with the highest intensity were selected, along with the neutral loss fragment 
ions for Ser and Thr-containing peptides. To allow comparable quantitation, the same 
transitions were selected corresponding to endogenous (heavy-labelled) peptides and internal 
standard (unlabelled) peptides (see Appendix 2). 
 
2.5.5.3 Scheduling of SRM peptides 
Scheduling retention time of the phosphopeptides was performed using a Dionex 3000 UHPLC 
coupled to a TSQ Vantage triple stage quadrupole mass spectrometer. Synthetic 
phosphopeptides pool (2 picomole/uL) were prepared for LC-SRM-MS/MS analysis. An LC 
gradient of 3.2-44% ACN over 20 min was delivered, followed by a 5-minute wash of 90% 
mobile phase B and a 10 min re-equilibration of 3.2% mobile phase B. The SRM transitions 
were scheduled around their expected elution times. Due to the large number of transitions in 
this assay (450 transitions for endogenous labelled) and IS peptides), 3 identical methods with 
different transition sets were created. 
 
2.5.5.4 Establishment of calibration curve 
For absolute quantitation, a calibration curve is required to determine the absolute expression 
level of a peptide. Calibration curves were prepared for each phosphopeptide using synthetic 
version. A 6-point calibration curve was produced using the following concentrations: 100 
attomole, 500 attomole, 1 femtomole, 10 femtomole, 50femtomole and 250 femtomole. Three 
runs were performed individually in order to accommodate large number of transitions. Three 
technical replicates were performed in different days. 
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2.5.5.5 LC-SRM-MS/MS 
Peptide mixtures were separated at a flow rate of 352 nL/min in Dionex UHPLC system 
equipped with 1:300 splitter cartridge to provide nano flow. Samples were loaded onto a 150 
mm Acclaim PepMap100 C18 column in mobile phase A (0.1% formic acid) and separated by 
a 20-minute gradient from 3.2% to 44% in mobile phase B (acetonitrile, 0.1 % formic acid), 
and followed by a 10-minute wash of 90% mobile phase B and re-equilibration (10 min) with 
3.2% mobile phase B. Peptides were eluted via a TriVersa Nanomate chip-based electrospray 
device into the mass spectrometer and a spray voltage of 1.7 kV was used. 
All peptides were analysed by TSQ Vantage Triple Quadrupole mass spectrometer. The TSQ 
Vantage was operated with an ion source temperature of 275 °C, a unit/unit resolution of 0.7 
Da in Q1 and Q3, and a scan width of 0.002 m/z for all SRM transitions. 
 
2.2.6 Data analysis 
2.2.6.1 SILAC data analysis (Chapter 3 and 4) 
Mass spectra were collected using Xcalibur 2.2 and processed by the MaxQuant (version 
1.4.1.3).193 Data were searched against SwissProt human database containing common 
contaminants and reverse sequence (175242 protein entries) with Mascot (Matrix Science). 
The search parameters were: minimum peptide length 6, cleavage enzyme trypsin, missed 
cleavages 2, peptide tolerance 20 ppm and mass tolerance 0.5 Da. Carbamidomethyl (C) was 
set as a fixed modification. Oxidation (M), acetylation (N-term) and phosphorylation (STY) 
were set as variable modifications. The appropriate SILAC labels were selected and the 
maximum labelled amino acids was set to 3. FDR for peptide, protein and site identification 
was set to 0.01. FDR was calculated as Global FDR at spectral level. Within the Maxquant 
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output, phosphorylation sites with a Localization Score above 0.75 were considered localized 
accurately and the accurately localized phosphorylation sites were selected for further analysis.  
 
2.2.6.2 Peptide identifications (Chapter 5) 
Data were searched by the Proteome Discoverer 2.1 using the SEQUEST and Mascot 
algorithms. The following parameters were used: no spectral grouping; fully tryptic, 2 missed 
cleavages allowed; precursor ion m/z tolerance ±10 ppm; fragment ion m/z tolerance ±0.8 Da; 
Carbamidomethyl (Cys) was set as a fixed modification; N-terminal acetylation, oxidation 
(Met) and phosphorylation (Ser, Thr, and Tyr) were set as variable modifications. Data were 
filtered to 1 % peptide FDR. For data search of 6 standard proteins, a database containing the 
6 proteins and containing common contaminants and reverse sequences were used. For data 
search of SUM52PE lysates, the SwissProt human database containing common contaminants 
and reverse sequences were used. 
 
2.2.6.3 SRM data analysis (Chapter 6) 
SRM data were acquired using Xcalibur 3.0 and loaded into Skyline 3.1194 for data analysis. In 
Skyline, peak detection was manually inspected to ensure retention time of relative transitions 
were similar and correct peaks were detected. The SRM peak area of synthetic peptides was 
used to generate calibration curves. The SRM peak area of endogenous peptides was used to 
generate correlation profiles.  
A logarithm transform approach was adopted to combine inter-day calibration data. The mean 
of triplicate measurements was calculated for further analysis. Next, transform all data and the 
value of concentration by taking the log base 2 value. Then, calculate the slope and intercept 
of each peptide in each assay. Next, calculate the mean of slope and intercept of each peptide 
in inter-day assays. Calculate the R-squared value and the mean of R-squared value of each 
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peptide. The calibration of data with a less than 0.9 R-squared value will be excluded from 
further analysis. Convert the data to linear scale and construct calibration curve.  
 
2.2.6.4 Motif-X analysis 
The sequence window with the centred phosphorylation sites were submitted for Motif-X 
analysis. Search parameters were: width 13, occurrences 20, significance 0.000001 and 
background IPI Human Proteome. 
 
2.2.7 Workflow of SILAC experiment 
The schematic diagram of sample preparation process is shown in Figure 2.1. Equal amounts 
of light, medium and heavy labelled peptides were mixed, digested and then desalted using 
Sep-pak cartridges. Peptides were re-suspended for SCX fractionation. In SCX, 53 fractions 
were collected and these fractions were combined into 12. The combined fractions were 
desalted using Macro-trap cartridges. Phosphoenrichment were performed for the 12 fractions. 
Following phosphoenrichment, each of the 12 fractions was subsequently split into two. One 
half of each of the fractions was destined for LC-MS/MS analyses. Ziptip desalting was 
performed prior to mass spectrometry analyses. For the LC-FAIMS-MS/MS analyses, the 
remaining twelve half-fractions were pooled and divided equally into 12 aliquots. Each of these 
12 aliquots was then analysed at a separate CV. Each of the 24 samples (12 x half-fractions for 
LC-MS/MS and 12 x aliquots for LC-FAIMS MS/MS) was split into four to allow 2 x CID 
MS/MS analyses and 2 x ETD MS/MS analyses.  
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Figure 2.1 Schematic diagram of the sample preparation procedure 
 
2.2.8 Workflow of SRM experiment 
In this SRM assay, an absolute quantitation strategy was employed (see Figure 2.2). To obtain 
absolute quantitation information, internal standard peptides were synthesised corresponding 
to the peptides of interest. Each IS peptide is identical to native peptides except from their 
isotopic labels with a difference of 6-10 Da in molecular weight. A known amount (20 fmol) 
of an IS peptide was spiked to SUM52 cell digests, desalted by Ziptip and analysed by LC-
SRM-MS/MS. The quantity of native peptide was calculated using peak ratios in Skyline. 
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Figure 2.2 Strategy for absolute SRM quantitation assay 
 
 
  
20 fmol 
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PHOSPHOPROTEOMIC ANALYSIS BY  
LC-FAIMS-MS/MS 
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3.1 Introduction 
The aim of the work presented in this chapter was to establish a method that can be used in 
SILAC-based LC-FAIMS-MS/MS analysis. In this thesis, SILAC was used for quantitative 
analysis of FGF signalling.  In SILAC, cells cultured in different media are labelled by light, 
medium and heavy isotopic labels. It has been shown, by Shvartsburg et al, that different 
peptides are transmitted at various compensation voltages (CVs) ranges in FAIMS device195. 
It was unclear whether peptides with different isotope labels would be transmitted over 
different CV ranges, leading to discrepancies in quantitative results. In order to couple SILAC 
with FAIMS, it was first necessary to evaluate the transmission behaviour of stable isotopic 
labels in FAIMS device. Secondly, in order to ensure maximum proteome coverage, a pilot 
experiment was set up to determine the appropriate workflow for SILAC FAIMS using 293T 
cells and explore the optimum CV range for phosphoproteomics analysis of SU5402 whole cell 
lysate.  
 
3.2 Results 
3.2.1 Quantitation analysis by LC-FAIMS-MS/MS 
MS Qual/Quant QC Mix (Sigma-Aldrich) is an “injection-ready” standard and is typically used 
to monitor quantitation performance. MS Qual/Quant QC Mix contains a set of 14 peptides 
with light and heavy isotopic labels from 6 pre-digested proteins. These peptides span a 25-
fold range of concentration, which makes it ideal for quantitation assessment. A volume of 2 
μL of resuspended solution was subjected to LC-FAIMS-MS/MS analyses. Four separate 
analyses were performed at CVs of -25.0 V, -30.0 V, -35.0V and -40.0V. Results are shown in 
Table 3.1. The values shown in the table were the average of the four CV steps. 
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Table 3.1 Quantitation results of Qual/Quant Mix by LC-MS/MS and LC-FAIMS-MS/MS 
Ratio of light/heavy peptides by LC-MS/MS analysis was shown in grey ; ratio of light/heavy peptides by LC-
FAIMS-MS/MS analysis was shown in yellow ; SD indicates the standard deciation among FAIMS analysis  
 
 
The results show that when peptides were selected at different CVs (-25 V, -30 V, -35 V and -
40 V), FAIMS was not altering the transmission efficiency of peptides with isotope labels, as 
indicated by the standard deviation between LC-MS/MS and LC-FAIMS-MS/MS analyses. 
Comparison of the ratio of light/heavy peptide between LC-MS/MS and LC-FAIMS-MS/MS 
analyses demonstrated LC-FAIMS-MS/MS was capable of performing quantitative analysis. 
A few peptides failed to be identified in FAIMS or both of the methods, which is possibly due 
to their poor capacity to bind columns, low abundance in the mixture or inadequate CV steps. 
Figure 3.1 shows the MS/MS spectrum of 2+ peptide ALIVLAHSER obtained via LC-MS/MS 
and LC-FAIMS-MS/MS at CV of -25.0 V and -30.0 V. 
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Figure 3.1 MS/MS spectrum of 2+ peptide ALIVLAHSER 
A: LC-FAIMS-MS/MS, CV -25 V; B: LC-FAIMS-MS/MS, CV -30 V; C: LC-MS/MS  
 
3.2.2 Phosphoproteomic analysis of 293T cells by LC-MS/MS and LC-
FAIMS-MS/MS 
3.2.2.1 Workflow 
The whole cell lysate of 293T cells was digested, as described in Chapter 2.2.1. For LC-MS/MS 
analysis, peptides were separated by SCX, following by phosphoenrichment. Previous 
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experiments conducted within the laboratory suggested that the optimum CV range for 
proteomic analysis ranged from -20 V to -50 V. Therefore, a CV range of -20 V to -50V was 
selected. For LC-FAIMS-MS/MS, 13 separate analyses were performed and for each the CV 
remained constant throughout (CV -20 V, -22.5 V, -25 V…-50 V), as described in Chapter 
2.2.4.1.  
 
Figure 3.2 Workflow of phosphoproteomics analysis of 293T cells 
293T cells lysates were halved after trypsin digestion. For LC-MS/MS analysis, peptides were fractionated by 
SCX, enriched and submitted for 12 LC-MS/MS runs. For LC-FAIMS-MS/MS analysis, peptides were enriched 
and analysed at 12 individual CVs. 
 
 
3.2.2.2 Results 
Table 3.2 Number of peptides and proteins identiﬁed 
MS SCX-LC-MS/MS LC-FAIMS-MS/MS Overlap 
Phosphopeptide 2034 340 155 
Protein 939 184 96 
 
Table 3.2 shows the number of non-redundant phosphopeptides identiﬁed from the two 
analyses. A total of 2034 non-redundant phosphopeptides were identiﬁed by LC-MS/MS 
(duplicate), compared to 340 by FAIMS analysis (one replicate). LC-MS/MS outperformed 
FAIMS in terms of the number of identifications. Due to instrument failure, only one set of 
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FAIMS analysis was performed, which has limited the identification number to some extent. It 
is also possible that the phosphoenrichment before FAIMS was not efficient. Moreover, these 
data may indicate further optimization of FAIMS is necessary. It should be noted that although 
limited information was obtained, 54.4% of the identification by FAIMS was missed by LC-
MS/MS approach, which implied FAIMS has the potential to augment proteome research.  
 
 
 
 
 
 
 
Figure 3.3 (A) Number of phosphopeptides identified in LC-MS/MS per SCX fraction and (B) number of 
phosphopeptides identified in LC-FAIMS-MS/MS per CV step. 
 
 
Figure 3.3 shows the number of phosphopeptides identified per SCX fraction and CV step. In 
LC-MS/MS analyses, 57.2% phosphopeptides were identified from the fraction 3 to 6. In the 
latter fractions, non-phosphopeptides started to appear while the number of phosphopeptides 
has started to decrease, which is in agreement with previous studies196. In the FAIMS analyses, 
the identification of phosphopeptides is more evenly distributed across the CV range and the 
majority (92.3%) of phosphopeptide are identified from CV ranging from -25.0 V to -42.5 V. 
These data provided the basis for further optimization of CV range. 
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3.2.3 Phosphoproteomic analysis of SUM52 cells by LC-MS/MS and LC-
FAIMS-MS/MS 
3.2.3.1 Workflow 
In order to further explore the complementarity of LC-MS/MS and LC-FAIMS-MS/MS in 
phosphoproteomics, a workflow that directly compared the performance of the two techniques 
was developed. The whole cell lysate of SUM52 was digested by trypsin, separated by SCX, 
followed by phosphoenrichment and then split for two analyses. 
 
Figure 3.4 Workflow of phosphoproteomics analysis of SUM52 
SUM52PE cells were digested, fractionated and enriched prior to MS analyses. For LC-MS/MS, peptides were 
submitted for 12 LC-MS/MS runs. For LC-FAIMS-MS/MS analysis, peptides were analysed at 12 individual CVs. 
 
 
 
3.2.3.2 Results 
Table 3.3 Number of peptides and proteins identiﬁed 
MS LC FAIMS 
Phosphopeptide 321 331 
Peptide 468 515 
Protein 350 449 
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Number of peptides identified is shown in table 3.3. The two approaches have identified a 
similar number of phosphopeptides and peptides. The composition of phosphorylation status 
differs greatly, as shown in Figure 3.5. In the FAIMS analyses, 102 multi-phosphorylated 
peptides were identified (an increase of 65% over those identified by LC-MS/MS analyses). 
Accordingly, LC-MS/MS has resulted in identification of 195 singly-phosphorylated peptides, 
an increase of 22% over FAIMS.  
 
 
 
 
 
 
 
 
Figure 3.5 Phosphorylation status by LC-MS/MS and LC-FAIMS-MS/MS analyses 
 
The overlap in identifications between the workflows is 12 %. In total 73 peptides were 
identified by both analyses, of which 90% are phosphopeptides. Of the peptides identified only 
by FAIMS, 18.6% and 21.1% are doubly-phosphorylated and multiply-phosphorylated 
respectively. In the LC-MS/MS analyses, a relative smaller proportion of doubly-
phosphorylated and multiply-phosphorylated peptides are identified (9.6% and 9.2% 
individually). These data suggest FAIMS has potential in improving proteome coverage, 
especially for identification of multiply-phosphorylated peptides. This aspect is further 
explored in Chapter 4. 
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Figure 3.6 Overlap between LC-MS/MS and LC-FAIMS-MS/MS analyses 
The table below shows the difference in phosphorylation status 
 
Nevertheless, in this experiment the overall proteome coverage was low and limited 
information was obtained. This is partly due to the FAIMS workflow needing to be further 
optimised. It is possible that following SCX, the efficiency of enrichment is limited, which 
could affect the number of phosphopeptides. Therefore, a replicate experiment was performed 
with more TiO2-enrichment tips. As shown in Table 3.4, LC analysis identified 736 
phosphopeptides compared to 660 identified by FAIMS. 
Table 3.4 Number of peptides and proteins identiﬁed in LC-MS/MS and LC-FAIMS-MS/MS analyses 
Number of LC FAIMS 
Phosphopeptide 736 660 
Peptide 1271 979 
Protein 499 349 
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3.2.4 Optimization of phosphoenrichment 
The TitansphereTM Phos-TiO2 Kit is based on lactic acid assisted phosphoenrichment using a 
TiO2 micro column. Zhao and co-workers developed a two-step separation procedure for 
sequentially enriching mono- and multi-phosphorylated peptides using citric acid109 and 
improvement of multi-phosphorylated peptides identification was observed. In order to 
evaluate this method and to further apply it to large-scale phosphoproteomic analysis, an 
experiment comparing the performance of lactic acid and citric acid was performed. 
Whole cell lysate of SUM52PE was digested overnight by trypsin. After desalting with Sep-
Pak, phosphopeptides were enriched with TitansphereTM Phos-TiO2 kit using lactic acid and 
citric acid according to Zhao et al. Enriched peptides were desalted using reversed phase C18 
Zip-Tip prior to LC-MS/MS analyses. 
 
Figure 3.7 Phosphopeptides identified by two enrichment methods (one repeat) 
Citric acid-assisted enrichment resulted in a slight increase in the number of phosphopeptides 
but a very different group of phosphopeptides was identified (see Figure 3.7). Citric acid 
resulted in a 20.0% increase in the identifications of multiply-phosphorylated peptides 
compared to lactic acid-assisted enrichment. The two-step method is helpful for the enrichment 
and purification of phosphopeptide, especially multi-phosphorylated peptides. In this thesis, in 
order to achieve maximum proteome coverage, phosphoenrichment was performed by lactic 
acid and two-step citric acid jointly in Chapter 4. 
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Table 3.5 Peptides identified in phosphoenrichment by lactic acid and citric acid 
Number of Lactic acid Citric acid 
Peptide 340 
 
363 
Phosphopeptide 248 274 
Multi-phosphor (%) 25.9 46.2 
 
 
3.3 Conclusion 
The performance of LC-FAIMS-MS/MS for quantitative proteomic analysis was evaluated. 
The use of calibration standards with isotopic labels showed FAIMS did not alter quantitation 
results compared with the LC-MS/MS method. The method for quantitative LC-FAIMS-
MS/MS analysis was established using 293T cells and SUM52 cells. A CV range from -22.5 
V to -50 V was selected for further experiments. 
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CHAPTER 4 
 
FAIMS AND PHOSPHOPROTEOMICS OF  
FGF SIGNALLING 
 
 
 
The content of this chapter has been published in Journal of Proteome Research: Zhao H, 
Cunningham DL, Creese AJ, Heath JK, Cooper HJ.  FAIMS and Phosphoproteomics of 
Fibroblast Growth Factor Signaling: Enhanced Identification of Multiply Phosphorylated 
Peptides. 2015, 14(12), 5077-87 
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4.1 Introduction 
By current technologies, singly-phosphorylated peptides constitute the majority of the total 
phosphopeptides identified140. The identification of doubly- and multiply-phosphorylated 
peptides is more challenging due to their low stoichiometry, poor binding ability to 
chromatographic columns. Nevertheless, deciphering mechanisms of FGFR signalling requires 
the knowledge of multiply-phosphorylated peptides as the adjacent phosphorylation sites may 
play important regulatory roles. Therefore, one of the major challenges in phosphoproteomics 
research is to map sites of modification in multiply-phosphorylated peptides.  
 
Figure 4.1 Schematic diagram of sample preparation workflow 
 
In this chapter, LC-MS/MS and LC-FAIMS-MS/MS was applied for the investigation of site-
specific phosphorylation in FGFR signalling. Previously, quantitative LC-MS/MS was used to 
identify SFKs-mediated phosphorylation events in FGFR signalling. To further map the key 
phosphorylation events involved in FGF signalling and SFKs, we used the SILAC approach 
combined with inhibition of FGFR and SFK. SU5402, a specific FGFR tyrosine kinase 
inhibitor, and dasatinib, a SFKs inhibitor, were used. Figure 4.1 describes the sample 
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preparation workflow. SILAC-labelled SUM52 cells were treated with either SU5402 or 
dasatinib before FGF1 stimulation. Following cell lysis, equal amounts of cell lysates were 
pooled and digested by trypsin. Next, peptides were fractionated and enriched, and each of the 
resulting twelve fractions was then divided into two for separate LC-MS/MS and LC-FAIMS-
MS/MS analysis. Each LC-FAIMS-MS/MS analysis was performed at a separate and constant 
compensation voltage (-22.5 V, -25.0 V, -27.5 V…-50.0 V, in 2.5 V steps).  
 
4.2 Results 
4.2.1 Phosphopeptide identification by LC-MS/MS and LC-FAIMS-MS/MS 
In LC-MS/MS analyses, a total of 3197 non-redundant peptides were identified, of which 2741 
were phosphopeptides (85.7%), as shown in Table 4.1. From these phosphopeptides, 2642 
phosphosites were identified, of which 1853 phosphosites were accurately localized. Within 
the well-localised phosphosites, 1542 serine (83.2%), 207 threonine (11.1%) and 104 tyrosine 
(5.6%) residues were identified. 
Table 4.1 Summary of LC-MS/MS and LC-FAIMS-MS/MS analyses 
 
In LC-FAIMS-MS/MS analyses, a total of 1774 non-redundant peptides were identified, of 
which 1529 were phosphopeptides (86.2%). Within these phosphopeptides, a total of 1930 
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phosphosites were identified and 1261 phosphosites were well localized. The distribution of 
phosphorylated residues is: 897 (71.1%) serine, 264 (20.9%) threonine and 100 (7.9%) tyrosine. 
A notable increase in the relative proportion of identified pThr and pTyr phosphorylation sites 
was observed in the LC-FAIMS-MS/MS dataset.  
 
Figure 4.2 Well-localized phosphosites identified via LC−MS/MS and LC−FAIMS−MS/MS 
In total, 2538 well-localised phosphorylation sites were identified and the well-localised 
phosphorylation sites were selected for the following analysis. The two workflows showed 
good complementarity and the overlapping population comprised 44.0% of the identifications 
by LC-FAIMS-MS/MS (see Figure 4.2). In order to explore properties of the phosphopeptides 
identified in LC-MS/MS and LC-FAIMS-MS/MS, the CV distribution, charge state, length and 
phosphorylation status of these phosphopeptides was examined in the following sections. 
 
4.2.2 CV Distribution  
The number of phosphopeptides identified per SCX fraction is shown in Figure 4.3A. In LC-
MS/MS analyses, the majority of the peptides identified were derived from the first four SCX 
fractions (64.7%). In contrast, in the LC-FAIMS-MS/MS analyses (Figure 4.3B), 
phosphopeptide identification did not show any bias towards a particular (range of) CVs. 
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Figure 4.3 Unique peptides identified in (A) LC-MS/MS and (B) LC-FAIMS-MS/MS analyses 
 
4.2.3 Charge state distribution 
The distribution of charge states of the identified phosphopeptides is shown in Figure 4.4. 
Doubly-charged ions (57.7%) constituted the majority of identifications from the LC-MS/MS 
dataset, with 3+ ions contributing 36.6% of the identifications. For the LC-FAIMS-MS/MS 
dataset, 26.9% of the total identifications arose from 2+ precursor ions, compared with 63.8% 
from 3+ ions.  
 
Figure 4.4 Pie chart showing doubly, multiply-charged peptides in LC-MS/MS and LC-FAIMS-MS/MS 
analyses 
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Further examination revealed that the majority of the 2+ peptides were identified from the first 
four fractions, see Figure 4.5. The distribution of triply charged peptides showed a bimodal 
distribution. 
 
Figure 4.5 Distribution of 2+ and 3+ ions identified in (A) LC-MS/MS and (B) LC-FAIMS-MS/MS 
 
Examination of the LC-MS/MS dataset showed, again, that the majority of ions are identified 
in the first four fractions (Figure 4.5A). In the LC-FAIMS-MS/MS dataset, 2+ and 3+ ions 
were identified at distinctly different CV ranges (Figure 4.5B). Doubly-charged ions were 
mainly observed in CV -22.5 V to -30 V (72.8%); however, 3+ ions were identified throughout 
all CVs.  
 
4.2.4 Phosphopeptide length  
 The length of the phosphopeptides identified in the FAIMS dataset ranged from 7 to 40 amino 
acids and 98.6% were between 7 to 33 amino acids. The distribution of phosphopeptides 
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according to peptide length (7 to 33 amino acids) and CV is shown in Figure 4.6A. The heat 
map identified two areas with high incidence of phosphopeptide identification. One is in the 
CV range -22.5 V to -27.5 V and length 12-18 amino acids. The other area is in the CV range 
-32.5 V to -47.5 V and length 15-21 amino acids. The two regions overlap with the charge state 
distribution discussed above: the top-left area is mostly comprised of 2+ phosphopeptides and 
the middle one is exclusively comprised of 3+ ions. For phosphopeptides identified in LC-
MS/MS analyses, 64.7% peptides were identified from the first 4 fractions and 72.5% the 
peptides were between 11 and 23 amino acid residues (Figure 4.6B). 
 
 
Figure 4.6 Distribution of identified phosphopeptides in (A) LC-MS/MS and (B) LC-FAIMS-MS/MS 
according to fraction and peptide length (number of amino acid residues). Numbers in each cell represent the 
number of phosphopeptides identified under the given condition.  
A 
B 
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4.2.5 Phosphorylation status 
The distribution of singly-, doubly- and multiply-phosphorylated peptides is shown in Figure 
4.7A. The majority of the phosphopeptide assignments were singly-phosphorylated in both 
workflows (80.7% in LC-MS/MS dataset and 70.5% in LC-FAIMS-MS/MS dataset).  A total 
of 29.5% of the phosphopeptides identified in the LC-FAIMS-MS/MS analyses were doubly- 
or multiply-phosphorylated, compared with 19.3% in the LC-MS/MS analyses. 
 
 
Figure 4.7 (A) Distribution of singly-, doubly- and multiply-phosphorylated peptides. (B) Comparison of 
singly-, doubly- and multiply-phosphorylated peptides in LC-MS/MS and LC-FAIMS-MS/MS 
 
The distribution of charge states for the doubly- and multiply-phosphorylated peptides 
identified is shown in Figure 4.8. The multiply-phosphorylated peptides are mainly associated 
with 3+ ions in the FAIMS dataset compared to non-FAIMS. The enhanced identification of 
multiply phosphorylated peptides is likely due to the separation of charge states by FAIMS. 
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Figure 4.8 Distribution of charge states of doubly- and multiply- phosphorylated peptides in (A) LC-
MS/MS analyses and (B) LC-FAIMS-MS/MS analyses 
 
In Figure 4.9, the overlap in identification of doubly-phosphorylated peptide from the two 
workflows was 21.2%. For multiply-phosphorylated peptides, only 7 of the 188 
phosphopeptides were identified by both methods, less than 4% of the total multiply-
phosphorylated peptide identifications, emphasizing the complementarity of the two methods, 
particularly in multiply-phosphorylated peptides. 
 
Figure 4.9 Identification of doubly- and multiply-phosphorylated peptides from LC-MS/MS and LC-
FAIMS-MS/MS: (A) doubly-phosphorylated peptides and (B) multiply-phosphorylated peptides 
 
 
4.2.6 Novel phosphorylation sites 
To further probe the two datasets, PhosphoSitePlus (http://www.phosphosite.org)197 was used 
to identify novel phosphorylation sites from the known sites. In the LC-MS/MS dataset, 75 
(4.3%) of the identified phosphosites were novel phosphorylation sites, including 33 pSer sites, 
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9 pThr sites and 33 pTyr sites. Only three of these sites were also identified in the LC-FAIMS-
MS/MS dataset. In contrast, 227 novel phosphosites (19.9%) identified by LC-FAIMS-MS/MS 
have not been previously reported, comprising of 168 pSer, 42 pThr and 17 pTyr sites. 
Remarkably, 187 of the novel phosphorylation sites were assigned from multiply-
phosphorylated peptides. Details of the novel phosphosites can be found in Appendix 1. 
In order to explore the sequence features of the novel sites, Motif-X198 was used to identify 
motifs from the novel phosphosites identified in the LC-FAIMS-MS/MS dataset. From 227 
novel phosphorylation sites, 3 potential motifs were identified (P<0.0003): SxxT, SxxxT and 
TxxxxS (see Figure 4.10). SxxxT is a highly conserved motif, recognised by MAPKK 
supergene family in animals199. As promotion and attenuation of FGF signalling requires the 
involvement of the MAPKK cascade, this observation indicates that substrates of MAPKK 
with uncharacterised phosphorylation sites may possess interesting properties for further 
investigation. No consensus motif was identified from the novel phosphosites identified in the 
LC-MS/MS dataset. 
 
Figure 4.10 Motif analysis of the novel phosphorylation sites in the LC-FAIMS-MS/MS analyses 
Motif-X centred on the phosphorylated serine residue. The size of the adjacent amino acid indicates the frequency 
of the appearance of a particular amino acid. 
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To determine if the enhancement in identification of novel phosphorylation sites is associated 
with charge state, the charge state distribution was profiled. In the LC-FAIMS-MS/MS 
analyses, phosphopeptides with charge states ≥ 3+ represented 91.2% of the novel sites 
identified compared to 55.3% in LC-MS/MS analyses.  
Further analysis by DAVID Functional Classification200 based on KEGG database revealed a 
number of highly involved proteins (see Appendix 2). A cluster of G protein-coupled receptors 
(GPCRs) was enriched in the novel proteins identified in the LC-FAIMS-MS/MS workflow. 
An example of this is Trem-like transcript 2 (TLT-2) protein, a cell surface receptor protein 
that may play a role in immune response201. A quadruply-phosphorylated peptide 
MAPAFLLLLLLWPQGCVSGPpSADpSVpYpTK of TLT-2 including the signal peptide 
region (1-18) was identified at CV of -27.5V. Tandem mass spectrum of the 3+ peptide was 
shown in Figure 4.11. The signal peptide region is not phosphorylated, but the N-terminus of 
Ig-like V-set domain (19-268) is highly phosphorylated and this is the first time that 
phosphorylation sites have been reported within this region.  
 
Figure 4.11 CID mass spectrum of [M+3H]3+ ions of MAPAFLLLLLLWPQGCVSGPpSADpSVpYpTK at 
CV of -27.5 V, a multiply-phosphorylated peptide containing previously unobserved phosphosites 
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4.2.7 FGFR and Src mediated phosphorylation events 
4.2.7.1 Initial assessment 
To analyse the quantitative response of the phosphosites, an initial assessment was necessary. 
In the LC-MS/MS dataset, SILAC information on 75.6% of the identified phosphosites were 
obtained compared to 69.8% in LC-FAIMS-MS/MS dataset. SILAC ratios were normalised 
(by Maxquant) to avoid unimodal global distribution. The fold change cut-off was applied 
based on a previous experiment. In that experiment, samples labelled with light, medium and 
heavy isotopic labels were mixed in equal portions and subjected to LC-MS/MS analysis. The 
mean SILAC ratios and SD was calculated. For a probability cut-off of p=0.05, the mean ratio 
± 2SD was between 0.58 and 1.73. For a more stringent cut-off (p=0.0027), the mean ratio ± 
3SD was between 0.44 and 2.23. Therefore, |log2 (FC)|=1 was defined as the boundary of 
differentially regulated phosphosites to give greater than 95% confidence. 
The consistency of quantitation results of the two approaches is shown in Figure 4.12. The 
quantitation results of the corresponding peptides between the two approaches are in good 
agreement with 68.6% of the fold-change ratios in the 95% confidence interval. 
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Figure 4.12. Histogram showing the quantitation consistency between LC-MS/MS and LC-FAIMS-MS/MS 
assays. The frequency was calculated using the ratio of the fold-change of the corresponding peptides of LC-
MS/MS against LC-FAIMS-MS/MS assays. (A) Quantitation of SU5402/FGF1; (B) Quantitation of 
dasatinib/FGF1. 
 
 
The labelling efficiency of SILAC approach was determined by submitting the light, medium 
and heavy isotope labelled peptides for individual LC-MS/MS analysis. A manual analysis was 
performed to ensure the medium and heavy cells were corrected labelled over 98.5%. 
 
4.2.7.2 SU5402 and dasatinib sensitive phosphosites 
In order to map the phosphosites regulated by SU5402 and dasatinib, a large-scale quantitative 
analysis was performed. The comparative analysis of phosphosites responded to SU5402 in 
LC-MS/MS dataset only, LC-FAIMS-MS/MS dataset only and in both is shown in Figure 4.13. 
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Figure 4.13 (A) Log2 plot of the ratio of the peptide abundance for SU5402/FGF1 treatments for each 
phosphopeptide identified; (B) Log2 plot of the ratio of the peptide abundance ratio for dasatinib/FGF1 
treatments for each phosphopeptide identified. Peptides identified by FAIMS only are shown in green and 
those identified by LC-MS/MS only are shown in red. Peptides identified by both are shown in blue. Dashed lines 
indicate the cut-off (log2 = ±1). 
 
A high occurrence of global down-regulation in phosphorylation levels was observed in the 
FGF pathway and downstream processes. A total of 256 phosphosites responded to SU5402 
(log2 ≤ -1 or log2 ≥ 1) were detected by both methods (Figure 4.13, shown in blue). LC-MS/MS 
identified 175 phosphosites (shown in red) and LC-FAIMS-MS/MS identified 153 
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phosphosites (shown in green) sensitive to SU5402 treatment. There were 186 phosphosites 
down-regulated due to SU5402 treatment, of which 70 were uniquely identified via the FAIMS 
workflow. Seventy four phosphosites were up-regulated in response to SU5402, with 29 unique 
to FAIMS workflow (see Table 4.2). 
There are 87 phosphosites sensitive to dasatinib were detected by both methods. LC-MS/MS 
and LC-FAIMS-MS/MS identified 24 and 60 phosphosites sensitive to dasatinib respectively. 
A total of 40 phosphosites were down-regulated due to dasatinib treatment, of which 27 were 
uniquely identified via the FAIMS workflow. Forty-seven phosphosites were found to be up-
regulated in response to dasatinib, with 32 unique to the FAIMS workflow. 
Table 4.2 Summary of quantitation analysis 
 
The LC-MS/MS and LC-FAIMS-MS/MS dataset was further explored to interrogate the 
coordination between SU5402 and dasatinib treatments. A log2-log2 plot was used to visualise 
the underlying interaction (see Figure 4.14).  There are 53 phosphosites sensitive to both 
SU5402 and dasatinib treatment. LC-FAIMS-MS/MS alone detected 38 phosphosites sensitive 
to both treatments, 2 of which were found by both methods. 
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Figure 4.14 (A) Log2-log2 plots to visualise SU5402 and dasatinib sensitive phosphosites.  
The ratio of phosphosites abundance of SU5402/FGF1treatment is plotted against the ratio of dasatinib/FGF1 treatments. Phosphosites identified by LC-MS/MS analyses 
only are shown in red. Phosphosites derived from singly- and multiply-phosphorylated peptides identified by FAIMS only are shown in blue and green respectively. Those 
identified by both methods are shown in grey. Dashed lines indicate the cut-off (log2 = ±1). 
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4.2.7.3 SU5402 and dasatinib sensitive proteins 
The DAVID Functional Classification tool was used to identify the protein groups in response 
to SU5402 and dasatinib. The regulated peptides were submitted to DAVID and two groups of 
protein were enriched in the KEGG database annotation. One is the kinases involved in the cell 
cycle regulation and translation. For instance, ribosomal protein S6 kinase beta-2 (S6K2) with 
decreased phosphorylation upon SU5402 and dasatinib inhibition was identified in FAIMS 
analysis. S6K2 has been previously identified as a downstream effector of FGF signalling202. 
The other group contains a cluster of cell membrane receptors participating in signal 
transduction, such as LILRB1 and MRG.  
Although some of the identified proteins were already known to be associated with FGF 
signalling, many of the individual proteins or phosphosites identified are novel to this pathway. 
As an example, breast cancer anti-estrogen resistance protein 3 (BCAR3) acts as an adapter 
protein for tyrosine kinase-based signalling in breast cancer cells203. The FAIMS results 
revealed a previously unidentified phosphorylation site within this protein (Thr 368). It has 
been shown BCAR3 enhances cell mobility through interaction with p130 and Src. It has been 
demonstrated this binding capacity could be greatly reduced when Src activity is affected204. 
The phosphorylation level of T368 site was up-regulated upon SU5402 and dasatinib treatment. 
Whether or not the up-regulation of T368 is associated with the activity of BCAR3 is yet 
unknown: this result may provide an entry point to decipher mechanisms of estrogen regulation.  
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4.2.7.4 Enrichment in multiply-phosphorylated peptides 
 
Table 4.3 Phosphopeptides containing novel phosphosites sensitive to SU5402 or dasatinib 
 
Modified sequence
Novel
site
Amino
acid
No of
phosphosites
Charge
Localization
probability
(ac)ATPAAVNPPEMAS(ph)DIPGSVTLPVAPM(ox)AAT(ph)GQVR 29 T 2 4 0.957
(ac)EETMKLAT(ph)M(ox)EDT(ph)VEYCLFLIPDESR 12 T 2 3 0.758
(ac)M(ox)S(ph)S(ph)NSDTGDLQES(ph)LK 3 S 3 3 0.899
(ac)MAS(ph)LS(ph)AAAIT(ph)VPPSVPSR 3 S 3 3 1.000
AS(ph)SPHQAGLGLS(ph)LTPS(ph)PES(ph)PPLPDVSAFS(ph)RGRGGGEGR 2 S 5 4 0.826
AS(ph)SPHQAGLGLS(ph)LTPS(ph)PES(ph)PPLPDVSAFS(ph)RGRGGGEGR 29 S 5 4 0.787
ASLY(ph)VGDLHPEVT(ph)EAM(ox)LY(ph)EK 13 T 3 3 1.000
AT(ph)PLS(ph)STVTLS(ph)M(ox)S(ph)ADVPLVVEY(ph)K 22 Y 5 3 0.987
AT(ph)PLS(ph)STVTLS(ph)M(ox)S(ph)ADVPLVVEY(ph)K 11 S 5 3 0.781
AT(ph)PLS(ph)STVTLS(ph)M(ox)S(ph)ADVPLVVEY(ph)K 13 S 5 3 0.781
DQTAALPLAAEET(ph)ANLPPSPPPSPAS(ph)EQTVT(ph)VEEAS(ph)K 36 S 4 3 0.996
DQTAALPLAAEET(ph)ANLPPSPPPSPAS(ph)EQTVT(ph)VEEAS(ph)K 31 T 4 3 0.831
DS(ph)GQVIPLIVES(ph)CIR 2 S 2 2 1.000
DS(ph)GQVIPLIVES(ph)CIR 12 S 2 2 1.000
DSEDS(ph)LY(ph)NDYVDVFY(ph)NTK 7 Y 3 3 0.989
DSEDS(ph)LY(ph)NDYVDVFY(ph)NTK 5 S 3 3 0.942
EVM(ox)LENY(ph)GNVVS(ph)LGILLR 12 S 2 3 1.000
EVM(ox)LENY(ph)GNVVS(ph)LGILLR 7 Y 2 3 1.000
FPGGSCM(ox)AALTVT(ph)LM(ox)VLSS(ph)PLALAGDTR 13 T 2 3 0.953
GS(ph)FIITLVKIPRMILM(ox)Y(ph)IHS(ph)QLK 2 S 3 3 0.868
GS(ph)T(ph)VHT(ph)AY(ph)LVLSSLAMFT(ph)CLCGM(ox)AGNSMVIWLLGFR 18 T 5 4 0.924
GS(ph)T(ph)VHT(ph)AY(ph)LVLSSLAMFT(ph)CLCGM(ox)AGNSMVIWLLGFR 8 Y 5 4 0.814
LES(ph)Y(ph)LDLM(ox)PNPSLAQVK 3 S 2 3 1.000
LLEPGTHQFAS(ph)VPVR 11 S 3 3 1.000
LLS(ph)HPFLS(ph)THLGSS(ph)M(ox)AR 3 S 2 3 0.957
LPAPLIS(ph)KQQFLS(ph)NS(ph)S(ph)R 7 S 4 3 1.000
LPAPLIS(ph)KQQFLS(ph)NS(ph)S(ph)R 13 S 4 3 1.000
LPVAT(ph)IFTT(ph)HAT(ph)LLGR 5 T 2 3 1.000
M(ox)DIGTLIWDGGPVPNT(ph)HINKCKNY(ph)Y(ph)EVLGVTK 25 Y 2 4 0.915
M(ox)GRTPT(ph)AVQVKS(ph)FTK 12 S 4 3 0.990
M(ox)T(ph)CT(ph)AFGNPKPIVT(ph)WLK 14 T 4 2 1.000
MAPAFLLLLLLWPQGCVSGPS(ph)ADS(ph)VY(ph)T(ph)K 27 T 3 3 0.999
MAPAFLLLLLLWPQGCVSGPS(ph)ADS(ph)VY(ph)T(ph)K 26 Y 3 3 0.999
MAPAFLLLLLLWPQGCVSGPS(ph)ADS(ph)VY(ph)T(ph)K 24 S 3 3 0.998
MAPAFLLLLLLWPQGCVSGPS(ph)ADS(ph)VY(ph)T(ph)K 21 S 3 3 0.839
PLAPPPQPPASPTHS(ph)PS(ph)FPIPDR 17 S 2 3 1.000
PLAPPPQPPASPTHS(ph)PS(ph)FPIPDR 15 S 2 3 0.998
QGQY(ph)S(ph)PM(ox)AIEEQVAVIY(ph)AGVR 17 Y 2 3 1.000
QLEPT(ph)VQSLEMKSKT(ph)AR 15 T 2 3 0.908
QLEPT(ph)VQSLEMKSKT(ph)AR 5 T 2 3 0.908
THNYSM(ox)AIT(ph)Y(ph)Y(ph)EAALK 10 Y 3 3 0.979
TLLTPHT(ph)GVT(ph)S(ph)QVLGVAAAVM(ox)TPLPGGHAAGR 7 T 2 5 0.788
TVTGT(ph)T(ph)M(ox)T(ph)LIPSEMPTPPK 8 T 2 3 0.866
VT(ph)VNYYDEEGS(ph)IPIDQAGLFLT(ph)AIEIS(ph)LDVDADR 2 T 3 4 0.841
VT(ph)VNYYDEEGS(ph)IPIDQAGLFLT(ph)AIEIS(ph)LDVDADR 27 S 2 4 1.000
VT(ph)VNYYDEEGS(ph)IPIDQAGLFLT(ph)AIEIS(ph)LDVDADR 11 S 2 4 0.967
VVLAAASHFFNLM(ox)FT(ph)T(ph)NM(ox)LES(ph)K 16 T 2 3 0.996
VVLAAASHFFNLM(ox)FT(ph)T(ph)NM(ox)LES(ph)K 21 S 2 3 0.990
Y(ph)IWGGFAY(ph)LQDM(ox)VEQGIT(ph)R 18 T 2 3 1.000
Y(ph)IWGGFAY(ph)LQDM(ox)VEQGIT(ph)R 1 Y 2 3 1.000
Y(ph)IWGGFAY(ph)LQDM(ox)VEQGIT(ph)R 8 Y 2 3 1.000
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As described above, an enrichment of multiply-phosphorylated peptides was observed in the 
peptides identified by LC-FAIMS-MS/MS: a total of 67 (55.8%) phosphosites sensitive to 
SU5402 were from multiply-phosphorylated peptides, compared with 6 from the LC-MS/MS 
dataset. Similarly, 46 out of 70 phosphosites sensitive to dasatinib originated from multiply 
phosphorylated-peptides in the LC-FAIMS-MS/MS dataset. Furthermore, among the 67 
phosphosites sensitive to SU5402 treatment, 31 were novel phosphosites. The results therefore 
provide a useful starting point for follow-up functional investigations. A list of novel 
phosphorylation sites identified from multiply-phosphorylated peptides sensitive to SU5402 or 
dasatinib treatment is presented in Table 4.3. 
 
4.2.7.5 Kinases involved in FGFR-and Src-regulated phosphorylation events 
Based on the kinase-substrate specificity assay, the analysis of regulated phosphosites further 
reveals how kinases mechanistically affect the changes in a cell. Analysis of amino acid 
frequency in the phosphorylation sites in FAIMS and non-FAIMS dataset was performed by 
WebLogo205 (see Figure 4.15A). The majority of the sequence motif is pSer-derived in both 
datasets. A higher frequency of serine residues in proximity to the site of phosphorylation in 
the FAIMS dataset was observed compared to the non-FAIMS because of the multiply 
phosphorylated peptides. 
To identify kinases with putative roles in FGF signalling, bioinformatics tools were used to 
characterise the phosphorylation motifs identified by FAIMS analysis, non-FAIMS analysis 
and both methods. Phosphorylation sites sensitive to SU5402 were searched using the kinase 
prediction tool iGPS 1.0106 and the number of phosphorylation sites predicted in each method 
were displayed representatively in the heatmap shown in Figure 4.15. In total, 355 kinases were 
predicted and the kinases with over 22 substrate matches were shown. Kinases with various 
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biological functions were identified. Notably, one family that exhibits active kinase activity in 
response to SU5402 is MAPK family kinase (including Erks, p38 and JNKs). 
A closer inspection of the phosphorylation sites in response to SU5402 treatment was analysed 
by Cytoscape 3.0206. The predicted kinases/shared substrates was visualised by nodes/edges 
relationship. A cluster with a high degree of consensus substrates have been classified. In this 
cluster, MAP kinases, PLKs and KSRs are fundamental participators Ras-raf-ERK/MAPK 
pathway207 and these findings indicate the ERK pathway plays an important role in mediating 
FGF signalling. It is noteworthy that the kinase prediction is based on consensus 
phosphorylation motif. Therefore, the prediction does not take into consideration 
interdependence between multiple phosphorylation sites, which make it difficult to correlate 
the function of these sites to the activity of signalling. Pie charts (representing nodes) were 
used to display the number of substrates identified in FAIMS analysis, non-FAIMS analysis 
and both methods, displayed in Figure 4.16. 
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Figure 4.15 (A) Motif analysis of phosphorylation sites in FAIMS and non-FAIMS dataset by WebLogo. (B) Heat map showing proteins and kinases that predicted 
to phosphorylate substrates in FAIMS and non-FAIMS dataset. Motif analysis centred on the phosphorylated S/T/Y residue. The size of the adjacent amino acid indicates 
the frequency of the appearance of a particular amino acid. Kinase prediction was performed using iGPS3.0. Kinase predicted with over 22 substrates were shown in the 
heatmap.  
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Figure 4.16 A group of kinase predicted to phosphorylate substrates identified by FAIMS, non-FAIMS and both methods. These kinases 
were identified by Cytoscape 3.0 as a subgroup with shared substrates. Size of pie charts indicate the number of substrate predicted by certain 
kinase.
105 
 
4.3 Discussion 
4.3.1 Complementarity  
The scale of the analyses was not designed to comprehensively map FGF signalling and its 
downstream pathways, but to generate a complementary set of phosphosites that provide novel 
insights into the field of phosphoproteomic research. The stochastic nature of LC-MS/MS 
sampling can result in complementary peptide identifications in technical repeats. Nevertheless, 
the application of FAIMS identified a distinct set of phosphosites, which is evidenced by a 
37.0% increase in the phosphoproteome coverage. Notably, a similar increase in 
phosphoproteome coverage was observed following multiple replicates (n=2) of LC-MS/MS 
analyses; however, the properties of the phosphopeptides identified by FAIMS are intrinsically 
different to those identified by LC-MS/MS in regards to charge state, length and 
phosphorylation status. 
Fewer phosphosites were identified from the FAIMS dataset than the non-FAIMS dataset. This 
is likely due to low transmission efficiency of FAIMS (typically about 10-20%). In addition, 
samples analysed by FAIMS were homogenous while samples analysed by the non-FAIMS 
approach were fractionated by SCX. This difference will contribute to the difference in 
performance of electrospray ionisation efficiency, LC separation and MS/MS identification. 
Note that an increase in the relative proportion of pThr and pTyr sites was observed in the LC-
FAIMS-MS/MS dataset. It has been estimated, in eukaryotic cells, the composition of pSer, 
pThr and pTyr sites is expected to be approximately 86.4%, 11.8% and 1.8%107. The successful 
identification of tyrosine phosphorylation is particularly challenging as it is a substoichiometric 
modification often occurring on low-abundance proteins208. Moreover, knowledge of tyrosine 
phosphorylation is necessary in deciphering the mechanisms of signal transduction processes 
and regulation of kinase activity.  
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4.3.2 CV distribution 
In an acidic solution, most tryptic peptides carry ≥2+ charges, however many tryptic 
phosphopeptides carry 1+ or even negative charges due to the addition of phosphate groups209. 
Therefore in SCX chromatography, peptides are eluted according to their net charge states: 
multiply-phosphorylated peptides are eluted first due to their negative charge, followed by 
singly-phosphorylated peptides, missed cleavage phosphopeptides and finally non-
phosphopeptides. An enrichment of phosphopeptides was therefore observed in the first few 
fractions. In the FAIMS analyses, samples from all SCX fractions were pooled to ensure 
homogeneity, whilst allowing a direct comparison in sample preparation. Thus, the distribution 
of phosphopeptides in FAIMS analyses is solely based on pre-set CV values. 
The extent of proteome coverage is in proportion to the degree of peptide fractionation and 
resolving power of mass spectrometer. The uneven distribution of phosphopeptides across the 
12 LC-MS/MS fractions potentially lowers the efficiency of peptide fractionation, as evidenced 
by the under-representation of phosphopeptides in the latter eight SCX fractions (35.3% of the 
total identifications).  
 
4.3.3 Charge state distribution 
In MS analysis, one of the difficulties of phosphopeptide detection is low protonation 
efficiency in the presence of acidic groups (e.g. phosphate group). Doubly-charged species are 
normally the predominant ions following electrospray of tryptic peptides. By coupling FAIMS 
to LC-MS/MS, an enrichment of 3+ and 4+ ions was observed. These findings suggest that the 
charge-based selection afforded by the FAIMS device influences the phosphopeptides 
identified. 
107 
 
In LC-MS/MS analyses, the distributions of peptide charges agree with the pH-dependent 
elution from SCX cartridges, where phosphopeptides are eluted first as a result of their negative 
charge, followed by non-phosphopeptides then acidic peptides.  
 
4.3.4 Phosphorylation status 
In MS analyses, it is more challenging to detect multiply-phosphorylated peptides due to low 
ionization efficiency in electrospray process and poor binding to chromatographic columns. 
The enhancement in identification multiply-phosphorylated peptides is significant in view of 
their low abundance relative to singly- and non-phosphorylated peptides. This finding may be 
the result of the improved S/N ratio afforded by FAIMS or charge state differentiation via 
FAIMS as discussed above. The identification of singly- and multiply-phosphorylated peptides 
did not show any correlation with the distribution of CV. 
Successful identification of multiply-phosphorylated peptides and localization of the 
phosphorylation sites also has a profound impact on data interpretation, enabling evaluation of 
the coordination among adjacent phosphorylation sites or investigation of the dynamics 
between singly- and multiply-phosphorylated peptide forms. 
 
4.3.5 Novel phosphorylation status 
The results show that coupling FAIMS to LC-MS/MS in phosphoproteomic analyses not only 
improves the proteome coverage but also identifies a large set of uncharacterized 
phosphorylation sites, suggesting that FAIMS has specifically accessed a group of 
phosphosites not readily accessible by LC-MS/MS. Remarkably, a large number of the novel 
phosphosites were assigned from multiply-phosphorylated peptides. Again, this finding 
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highlights the advantages of FAIMS in identification of multiply-phosphorylated peptides. A 
relationship between the overrepresentation of higher charge state (>3+) and enhanced 
identification of multiply-phosphorylated peptides is also established, indicating charge-based 
selection of FAIMS may be responsible for the increase in the number of novel sites.  
The peptide MAPAFLLLLLLWPQGCVSGPpSADpSVpYpTK was found to be down-
regulated in response to SU5402 but not to dasatinib. Whether these phosphorylation sites in 
the N-terminus are involved in cleavage of signal peptides or signal recognition is yet unknown. 
An in-depth analysis is required to establish the cross-talk between these phosphorylation 
events and perturbation of FGF signalling. 
 
4.3.6 FGFR and Src mediated phosphorylation events 
Overall, the results show that chemical inhibition induced significant changes in ~ 17% of the 
measured phosphosites. The scale of this experiment was not intended to reveal the whole map 
of FGF signalling, but to provide a unique resource of phosphosites for further study and an 
example of the utility of FAIMS in phosphoproteomic research. 
Activation of FGF signalling can induce diverse cellular response and Erk pathways is one of 
the four downstream targets of FGF signalling.210 Activated FGFRs can initiate the downstream 
cellular response by phosphorylation of specific residues in MAPK family kinases to induce 
cell differentiation. Previous findings also demonstrated that the activation of Erk1/2 could 
reduce the FGF-stimulated receptor tyrosine phosphorylation as feedback control.211 Based on 
the kinase prediction, our data shows that MAPK pathway exhibits the most prominent 
perturbation following the inhibition of FGFR activity. 
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It has been shown, both theoretically and experimentally, that multisite phosphorylation can 
generate a switch-like temporal profile of response212 and, when executed in a specific order, 
dictates the timing of output responses213,214. The ability to efficiently define multisite 
phosphorylation events is of particular biological significance as they represent a significant 
regulatory mechanism in a variety of settings. However, judged by existing phosphosite 
databases, the extent and identity of multisite phosphorylation events is poorly defined 
compared to single site events. Current bioinformatic software, e.g. iGPS and NetWorkin, 
mainly focuses on interpretation of single sites, rather than interaction of multi-phosphorylation 
sites. Kinases with a variety of biological functions were identified and FAIMS provides a 
small and complementary fraction. This is likely because in the FAIMS dataset, 55.8% of 
regulated phosphosites were identified from multiply-phosphorylated peptides. 
Phosphorylation of tyrosine residues is a well-defined mechanism of eliciting protein/protein 
interaction via sequence specific recognition, such as pTyr binding motifs-SH2 domain215. 
Recognition of pTyr binding motifs can be modified by concurrent phosphorylation of adjacent 
Ser/Thr that occlude the SH2 binding pocket216. This results in the formation/dissolution of 
protein complexes, which is controlled by the combined action of Tyr and Ser/Thr directed 
kinases. It is notable that multiply-phosphorylated peptides identified in the FAIMS dataset 
reveal a significant fraction (58.4%) in which a phosphorylated Tyr is located within ±4 
residues of a phospho Ser/Thr. This indicates that the multisite phosphorylation is a prevalent 
regulatory event which can be preferentially resolved by the application of FAIMS. Besides, 
this points to the work that can be carried out in the following step, which focuses on the 
dynamics of key phosphorylation events within FGF signalling. The site-specific analysis of 
key phosphorylation sites, especially the interdependence among multisite phosphorylation, 
will be of great significance to determine the downstream network of FGF perturbation. 
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4.4 Conclusion  
The LC-MS/MS and LC-FAIMS-MS/MS analyses have combined SILAC labelling with SCX 
pre-fractionation and phosphoenrichment. This approach allows us to investigate the regulated 
phosphorylation events involved in FGF signalling. The two techniques showed 
complementarity. The application of FAIMS improved the phosphoproteome coverage by 37.0% 
over that identified with the conventional LC-MS/MS workflow. An enhancement in the 
identification of multiply phosphorylated peptides and a preference for peptides with high 
charge states (3+ and above) was observed in the LC-FAIMS-MS/MS dataset. It is also 
observed that ~20% of the phosphosites identified via FAIMS have not been reported 
previously. Remarkably, 82.3% of these novel sites are identified from multiply 
phosphorylated peptides. These properties make FAIMS a valuable addition to 
phosphoproteomic studies, enhancing the coverage of the phosphoproteome and increasing the 
confidence of site localisation. 
The LC-FAIMS-MS/MS analyses also revealed a substantial number of phosphosites regulated 
upon inhibitor treatments, especially sites from multiply-phosphorylated peptides. Hence, I 
propose the LC-FAIMS-MS/MS workflow is a suitable complementary approach in 
phosphoproteomic analysis. Together, these observations open new possibilities for in-depth 
characterisation of interesting candidates for their roles in FGF signalling and trafficking. 
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CHAPTER 5 
 
EVALUATION OF A MODIFIED FAIMS INTERFACE 
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5.1 Introduction 
FAIMS, coupled with LC-MS/MS, has been applied in proteomics studies, and offers 
advantages including reduced chemical noise and increased signal-to-noise ratio, as described 
in the introduction. FAIMS can be applied as a complementary tool to augment proteomic 
analysis.  
Recently, a novel FAIMS interface (termed modified FAIMS) was introduced with a reduced 
electrode gap width (as shown in Figure 1.15) and modified ion inlet design181. The standard 
FAIMS electrode consists of an outer electrode with an inner radius of 9 mm and an inner 
electrode with a radius of 6.5 mm, forming a 2.5 mm gap. The modified FAIMS electrode is 
comprised of the standard outer electrode with an enlarged inner electrode (radius of 7.5 mm). 
The gap between electrodes is reduced from 2.5 mm to 1.5 mm. The reduction in gap allows 
the application of higher field strength at a fixed DV. The increase in the field magnitude 
enhances the ion focusing effect through the electrodes. The modification in the ion inlet 
creates a symmetric gas flow, decreasing the disruption of ion flow and increasing the gas flow 
to the electrodes. These modifications were reported to enhance the performance of FAIMS 
(coupled to a triple quadrupole mass spectrometer) by increasing peak capacity without 
decreasing signal output as shown for bromochlorate anions and six tryptic peptides from 
bovine serum albumin and enolase181. The aim of the work presented in this chapter was to 
characterise the performance of the standard and modified FAIMS device on an Orbitrap mass 
spectrometer for proteomic analysis, from a standard peptide to a complex protein digest. The 
modified FAIMS device was developed by Thermo Fisher and supplied to the University of 
Birmingham for evaluation. 
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5.2 Results 
5.2.1 Direct infusion of substance P 
The operating parameters of the modified FAIMS device were optimised to maintain similar 
transmission efficiency to that obtained with the standard FAIMS device by tuning the flow 
rate and composition of carrier gas and spray voltage etc. The instrumental parameters used in 
the following experiments are shown in Table 5.1. 
Table 5.1 Comparison of conditions for the standard FAIMS device and the modified FAIMS device 
 
Substance P was directly infused for FAIMS-MS analysis and a CV scanning experiment was 
performed to identify the optimum CV range for the 2+ ion of substance P, as shown in Figure 
5.1. The CV scanning analysis is performed by collecting MS1 scans at CV ranging from 0 to 
-60 V, with a 0.3 V minimum CV interval. The optimum CV of 2+ ions of substance P (DV = 
-5 kV) was -32.09 V for the standard FAIMS device and -39.88 V for the modified FAIMS 
device, with a shift of 7.79 V. Peak capacity is calculated as the CV peak width at the optimum 
CV between the lowest and highest CV at half-maximum height. Peak capacity was changed 
from 7.67 V to 3.68 V, with a 2-fold increase in the modified FAIMS analysis. 
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Figure 5.1 Optimum CV of 2+ ions of substance P 
 
 
5.2.2 Direct infusion of a tryptic digest of six standard proteins 
A tryptic digest of six standard proteins (cytochrome c, lysozyme, alcohol dehydrogenase, 
bovine serum albumin, transferrin and beta-galactosidase) was directly infused for FAIMS 
analysis. Two representative peptides were selected for CV scanning analysis, as shown in 
Figure 5.2. For 3+ ions of the peptide GTDKcAcSNHEPYFGYSGAFK (transferrin), the 
optimum CV shifted from -36.08 V to -47.12 V, an 11.04 V difference. Peak capacity was 
changed from 10.43 V to 3.98 V, resulting in a 2.62-fold increase in the modified FAIMS 
analysis. A 68% decrease in the ion signal is observed in the modified FAIMS analysis. 
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Figure 5.2 Optimum CV of the peptide (A) GTDKcAcSNHEPYFGYSGAFK and (B) 
FDEFFSAGcAPGSPR 
 
Figure 5.2B shows the CV scanning analysis of 2+ ions of the peptide FDEFFSAGcAPGSPR 
(transferrin). The optimum CV of this peptide shifted from -28.11 V to -38.53 V from the 
standard to the modified FAIMS analysis, resulting in a 10.42 V difference. Peak capacity is 
changed from 7.66 V to 3.38 V, resulting in a 2.26-fold increase in the modified FAIMS 
analysis. Similarly, a decrease of 72% in the ion signal in the modified FAIMS analysis was 
observed. 
Overall, direct infusion analysis of these two peptides and substance P revealed the optimum 
CV values for transmission shifted on average by approximately 9.75 V when using the 
modified FAIMS device. An average increase of 2.32-fold in peak capacity was observed with 
the modified FAIMS device.  
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5.2.3 LC-FAIMS-MS/MS analysis of a tryptic digest of six standard proteins 
An LC-FAIMS-MS/MS analysis was performed on the tryptic digest of six standard proteins. 
Based on the direct infusion experiments described above, a different CV range was selected 
for analyses with the standard and the modified FAIMS device: standard FAIMS CV range = 
-20 V to -45 V; modified FAIMS CV range = -30 V to -60 V. The ‘external CV stepping’ 
method was used in which the CV is kept constant throughout the LC-MS/MS analysis, as 
described in Chapter 2.2.4.0. The data were searched using the Sequest algorithm in Proteome 
Discoverer 1.4. 
 
Figure 5.3 Number of peptides identified across CVs: 
CV range of the standard FAIMS analysis -25V to -45V; CV range of the modified FAIMS analysis -30V to -
60V 
 
 
Figure 5.3 shows the number of peptides identified in each analysis. For the standard FAIMS 
analysis, approximately ~70 to ~110 peptides were identified in each analysis with the most 
identified at CV = -35 V. For the modified FAIMS analysis, the majority of the peptides were 
identified at CVs -35 V and -40 V; at CVs of -50 V to -60 V, no peptides were identified (see 
discussion below). 
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Figure 5.4 Sequence coverage, protein score, number of peptide and PSM in FAIMS analyses 
 
The protein sequence coverage, protein score, number of peptide and peptide spectrum matches 
(PSM, the number of spectrum matches for the protein) obtained following LC-FAIMS-
MS/MS analyses is shown in Figure 5.4. The two devices provided similar results in terms of 
sequence coverage and the number of peptides identified; however, increased scores and PSMs 
were observed when using the modified FAIMS device. 
 
5.2.4 LC-FAIMS-MS/MS analysis of SUM52 cell lysate 
5.2.4.1 Number of identified peptides 
In order to explore the performance of the modified FAIMS device for complex mixtures, 
SUM52 cells were lysed, and digested for LC-FAIMS-MS/MS analysis, see Chapter 2.2.2.6. 
The CV range for standard and modified FAIMS was further optimised: for the standard 
FAIMS device the CV range was -20 V to -45 V; for the modified FAIMS device the CV range 
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was -30 V to -55 V. Experiments were performed in duplicate. The first replicate analyses were 
performed on the Orbitrap Velos and the second were performed on the Orbitrap Elite.  A 
higher number of identifications were observed for both FAIMS devices for the analyses 
performed on the Orbitrap Elite. As shown in Figure 5.5, non-redundant peptide identifications 
obtained via the two FAIMS devices were complementary, of which 69.4% of the total peptide 
identifications were identified by both devices.  
 
Figure 5.5 Number of peptides identified in the FAIMS analysis (performed by Orbitrap Elite) 
(A): replicate 1; (B) replicate 2 
 
 
5.2.4.2 Distribution of peptides according to CV 
In order to visualise the number of peptides across the different CV ranges, Figure 5.6 was 
plotted. For the standard FAIMS analyses, peptides were uniformly identified across the CV 
range. In the modified FAIMS analyses, fewer than 100 peptides were identified from CV steps 
-50 V to -55 V. 
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Figure 5.6 Distribution of peptides identified across CV steps in the FAIMS analyses 
(A): replicate 1; (B) replicate 2 
 
In the standard FAIMS analyses, e.g. replicate 1, there are 396 peptides identified in each CV 
analysis on average, compared with 290 identified in modified FAIMS analyses (excluding CV 
of -52.5 and -55). In replicate 2, 1399 peptides are identified in each CV analysis on average 
in the standard FAIMS dataset, compared with 1112 identified in the modified FAIMS analyses. 
Figure 5.5 shows that use of the modified FAIMS device resulted in more identifications than 
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the standard FAIMS device. This contradiction indicates there might be a lower level of 
redundant identifications in the modified FAIMS analysis. To that end, the distribution of 
unique peptides was plotted, see Figure 5.7. In the following, redundant peptides refers to the 
peptides identified in multiple CV analyses. 
 
5.2.4.3 Redundancy  
5.2.4.3.1 Intra-assay redundancy 
The intra-assay redundancy was calculated by extracting the matched ions between biological 
replicate analyses (see Figure 5.7). The number of matched ions is the number of identified 
ions matched to a specific peptide in a single analysis, therefore indicating the level of 
redundancy within an assay. The distribution of the number of matched ions between the two 
analyses shows a small but significant difference of P<0.0001. 
 
Figure 5.7 Box plot of the number of matched ions in the FAIMS analyses 
The box spans from the Q1 (quartile 1) to Q3 (quartile 3) and median (quartile 2) is shown in the middle. Whiskers 
above and below the box show the maximum and minimum values. *** indicates a significant difference of 
P<0.001. (A): replicate 1; (B) replicate 2 
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5.2.4.3.2 Inter-assay redundancy 
Figure 5.8 and Figure 5.9 show the number of unique and redundant peptides identified in each 
FAIMS analysis. As predicted, a higher level of redundant peptides was identified in standard 
FAIMS analyses. In replicate 1, for example, the average number of unique peptides in each 
CV is 98 in the standard FAIMS analyses, while in the modified FAIMS the average number 
is 153. The increase in unique peptide identification of the modified FAIMS analyses is 1.56-
fold over the standard FAIMS. 
 
 
Figure 5.8 Distribution of peptides in the (A) standard and (B) modified FAIMS analysis in replicate 1 
Performed by Orbitrap Velos 
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Figure 5.9 Distribution of peptides in the (A) standard and (B) modified FAIMS analysis in replicate 2 
Performed by Orbitrap Elite 
 
Figure 5.10 and Figure 5.11 below show the redundancy level in both analyses. The redundancy 
rate is calculated by dividing the number of redundant peptides against the number of all 
peptides identified in each CV analysis. In replicate 1, the average redundancy rate of the 
standard FAIMS analyses is 78.1%, while the redundancy rate of the modified FAIMS analyses 
is 49.7%. In replicate 2, the average redundancy rate of the standard FAIMS analyses is 83.1% 
and the redundancy rate of the modified FAIMS analyses is 59.0%. 
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Figure 5.10 Replicate 1: redundancy rate of the (A) standard and (B) modified FAIMS analysis 
The dashed line indicates the average redundancy level. Performed by Orbitrap Velos. 
 
 
Figure 5.11 Replicate 2: redundancy rate of the (A) standard and (B) modified FAIMS analysis 
The dashed line indicates the average redundancy level. Performed by Orbitrap Velos 
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To further understand the redundancy level, the number of times that a peptide is identified 
across the whole analysis was investigated, as shown in Figure 5.12. In replicate 1, in the 
standard FAIMS analyses, peptides identified twice and three times constitute 42.5% of the 
total identifications. While in the modified FAIMS analyses, peptides identified once alone 
constitute 49.9% of the total identifications. In replicate 2, in the standard FAIMS analyses, 
peptides identified twice and three times constitute 50.7% of the total identifications. While in 
the modified FAIMS analyses, peptides identified once alone constitute 61.8% of the total 
identifications. 
 
 
Figure 5.12 Number of times a peptide is identified in the (A) standard and (B) modified FAIMS analysis 
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5.2.4.4 Charge state  
As shown in Chapter 4, the charge-based selection is a feature of FAIMS separation. To explore 
differences in the charge-based selection in the modified FAIMS device, Figure 5.13 was 
plotted. In each case 2+ ions constitute the majority of the identifications. In experiment 1, the 
percentage of 2+ ions is dramatically increased from 58% in the standard FAIMS analyses to 
83% in the modified FAIMS analyses. A similar trend was observed in experiment 2, in which 
48% of the identifications came from 2+ ions when using the standard FAIMS device compared 
with 62% with the modified FAIMS device.  
To further understand whether this difference relates to the differences in redundancy level, the 
charge state distribution of uniquely identified ions (ions that have been identified in one CV 
only) was analysed. A similar trend was observed, where the average proportion of 2+ ions 
were increased from 52% to 65% from the standard to the modified FAIMS dataset. 
 
 
Figure 5.13 Charge state distribution in the standard and modified FAIMS analysis 
(A): replicate 1; (B) replicate 2 
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5.3 Discussion 
Although FAIMS has proven beneficial for proteomics in recent years, the wide-spread 
application has been hindered by poor ion transmission, especially for ions with weak field 
dependence or ions having extreme low CV. The recently developed modified FAIMS interface 
was reported to have potential to increase ion transmission efficiency217. In the present study, 
direct infusion experiments and LC-FAIMS-MS/MS analyses were employed to evaluate the 
performance of the standard and the modified FAIMS device in proteomic applications. 
 
5.3.1 Instrumental and operational parameters 
The analytical response of FAIMS is controlled by a fine balance of multiple instrumental and 
operational parameters. In cylindrical FAIMS, such as that used here, a reduced electrode gap 
can increase field strength (E) without altering the DV, and enhance the ion focusing effect218. 
For example, by reducing the gap from 2.5 mm to 1.5 mm, the maximum field strength can 
increase from -23.6 kV/cm to -42.1 kV/cm. This enhancement significantly improves the peak 
capacity, hence increases separation efficiency. It should be noted that the increase in 
separation efficiency is at the expense of sensitivity, as shown in Figure 5.2.  
The trade-off between sensitivity and resolution has been observed by others and can be 
partially offset by tuning the gap width, waveform frequency, carrier gas compositions and 
electrode temperatures218–220. By reducing the gap width to 0.5-1 mm, FAIMS becomes more 
suitable for large multi-charged ions analysis, especially intact protein separation and 
identification218. Barnett and co-workers investigated the effect of temperature and other 
variables on field strength and ion separation efficiency220. By inverting the electrode 
temperatures (the inner/outer electrode temperature was 70℃/90℃), sensitivity was increased 
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but peak capacity was reduced. Based on this finding, Swearingen et al. tested the performance 
of a modified FAIMS device with the addition of a gas-phase fractionation within the mass 
analyser using an unfractionated yeast digest217. Their findings were published after our 
experiments finished in this chapter. Their device used the electrodes with 1.25 mm gap and 
no ion inlet modification was made. By reducing the electrode gap, better separation was 
achieved at the expense of a decreased sensitivity, which is in agreement with the results in this 
chapter. They found the modified FAIMS, operating at DV of -4 kV, improved protein 
discovery by 86%. Further, by inverting the electrode temperatures, the decrease in sensitivity 
of modified FAIMS could be partially offset. 
Shvartburgs et al. found increasing He fractions in carrier gas composition significantly 
improved resolution189. Peak capacity is defined as the ratio of separation space to the peak 
width at half maximum. The molecular polarizability of He is much lower than that of N2 and 
there is greater unfolding in He-rich environments than N2-rich environments, leading to a 
higher separation space in He and, thus, improved peak capacity221. Barnett and Ouellette 
demonstrated that using FAIMS with a reduced electrode gap eliminates the He requirement 
222. In the present study, therefore, supplemental He is not required as carrier gas. The benefits 
of this are reduced costs and risk of He interfering with mass analyser performance of mass 
analysers, without sacrificing resolution181. 
 
5.3.2 Direct infusion 
Adjustments in electrode gap width were previously reported to alter the gas flow velocities 
and CV values222.The results obtained from direct infusion ESI of substance P and tryptic digest 
of standard proteins also showed the optimum CV range for peptide ion transmission by the 
modified FAIMS device shifted by approximately 9.75 V. Moreover, the shift of CV of 
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different ions follows a similar pattern. In the standard FAIMS device, the DV of -5 kV creates 
a field strength equivalent to -23.6 kV/cm. In the modified FAIMS device, the DV is identical 
to that in the standard device but due to decrease in the gap width, the field strength is increased 
to -43.1 kV/cm. As the field strength is different in the two devices, the voltage required to 
compensate ion shift would be different accordingly. 
 
5.3.3 LC-FAIMS-MS/MS analysis of a tryptic digest of six standard proteins 
As the sample is a simple protein mixture, the sequence coverage is expected to be limited by 
sample purity and instrumental limits. As expected, the two devices achieved similar results 
for sequence coverage; however, a higher number of PSMs and higher protein scores were 
observed in the modified FAIMS analyses. The number of PSMs indicates the number of 
MS/MS spectra matched for any peptide assigned to a particular protein. The results of the 
modified FAIMS showed more spectrum were unambiguously matched to the identified 
peptides. When using the Sequest algorithm, the protein score relates to the number of possible 
peptide matches. Thus, better protein scores were observed in the modified FAIMS analyses. 
In the broader CV ranges (from -50 V to 60 V), no peptides were successfully identified. This 
result is probably due to the CV range from -30 V to -45 V being adequate for transmission of 
peptides from this simple mixture. 
 
5.3.4 LC-FAIMS-MS/MS analysis of SUM 52 cell lysate 
In bottom-up proteomics, protein mixtures are usually enzymatically digested into small 
peptides and subjected to fractionation and MS analyses. In this manner, identifications yield 
a series of redundant results within a single LC-MS/MS analysis, as well as across multiple 
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analyses223. Tremendous efforts have been given to enhance the throughput of MS analysis, 
from prolonged fractionations, multiple replicates and multi-stage MS/MS fragmentations224. 
Yet little consideration has been given to reducing the redundancy in identifications225. 
In the modified FAIMS analyses, the overall reduction in redundant identifications arises 
through reduced redundancy levels both within an assay and between assays. For intra-assay 
redundancy, statistical tests showed the distribution of the number of matched ions was 
significantly lower in the modified FAIMS than that of the standard analyses. For inter-assay 
redundancy, the modified FAIMS analyses have shown a lower redundancy rate in peptide 
identifications across multiple CV analyses, as demonstrated in Figure 5.11 and 5.12. This 
finding can be explained by the reduction in FAIMS peak width in the modified device, as 
shown in Figure 5.1 and 5.2. That is, the narrower the peak, the less likely a peptide will be 
observed in multiple CV steps. Therefore, the difference in the inter-assay redundancy seems 
to have accounted for the overall lower level redundancy.  
Typically, FAIMS analyses of complex mixtures are performed at separate CVs, therefore 
samples need to be split into a number of fractions for each CV analysis. The splitting of 
samples will result in reduced sample amounts and long instrument hours. Therefore, there is 
a balance between the number of CV steps and the amount of sample for each analysis. The 
reduced peak widths observed with the modified FAIMS allows the analyses to be performed 
with fewer CV steps, potentially increasing the sample amount in each analysis. 
 
5.3.4 Charge state 
Comparison of the charge state distribution of the peptide identifications from the standard and 
modified FAIMS analyses revealed a higher proportion of 2+ peptide ion identification from 
the modified FAIMS dataset. Chapter 4 shows that charge-based selection is an important 
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feature of FAIMS separation and, typically, 2+ ions are better transmitted in the non-FAIMS 
analyses and 3+ ions are the dominant group in the standard FAIMS analyses. The preference 
for lower charge state ions of the modified FAIMS device resembles that of the non-FAIMS 
analyses. The extent of charging reflects the compactness of a conformation, where higher 
charge state typically indicates unfolded structure226. The difference in peptide/proteins charge 
state is also sequence specific. The change in charge state preference in the modified FAIMS 
device indicates, for a particular range of CV, the change in the preferred structure, which is 
the possible reason for the difference in the preferred CV range in the modified FAIMS device. 
The difference in charge state is also likely to contribute to the unique identifications in the 
modified FAIMS dataset. 
 
5.4 Conclusion 
In this chapter, the performance of a novel FAIMS interface developed by Thermo and supplied 
to the University of Birmingham was evaluated and compared with the commercial Thermo 
ScientificTM FAIMS device. The direct infusion ESI analysis showed that the modified FAIMS 
device resulted in a nearly 3-fold increase in the peak capacity and a CV shift of approximately 
10 V. Based on this, a different CV range was selected for LC-FAIMS-MS/MS analysis. In 
analysis of tryptic digest of standard proteins, the two devices showed similar results in 
sequence coverage but a higher number of PSMs was observed in the modified FAIMS dataset.  
In order to further explore the potential of the modified FAIMS in proteomic experiments, a 
whole cell lysate sample was analysed. An increase in the proteome coverage of 69.4% was 
observed in the modified FAIMS dataset. The increase in proteome coverage can be attributed 
to the reduced redundancy in identifications between CV steps in the modified FAIMS analysis, 
in turn the result of improved resolution.  
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CHAPTER  6 
 
INVESTIGATION OF DYNAMICS OF THE KEY 
PHOSPHORYLATION EVENTS IN FGF SIGNALLING 
BY SELECTED REACTION MONITORING 
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6.1 Introduction 
In a proteomic workflow, the discovery of key proteins is typically initiated by a large-scale 
shotgun experiment for de novo identification of potential biomarkers. A large number of 
studies have used this methodology for discovery of potential biomarkers involved in a 
biological process or a disease. The selected reaction monitoring (SRM)-based approach can 
then be applied for determination and efficient quantitative validation of targeted analytes. 
The FGF signalling cascade is the result of protein-protein interactions regulated by specific 
phosphorylation events. One of the downstream signalling protein family is Src, a non-receptor 
tyrosine kinase, which has been shown to be recruited by receptor-mediated phosphorylation 
to the FGF signalling complex to regulate signalling dynamics227. Deregulation of FGF 
signalling, such as overexpression and inhibition, has been associated with many human 
diseases, including cancer10. It has been indicated that the intervention of FGFR activity can 
be accentuated for therapeutic use56. From a clinical view, it is necessary to understand the 
downstream effect of this inhibition if patients are to receive treatment with FGFR or Src family 
kinases inhibitors. 
Previously, in order to understand the global impact on intracellular phosphorylation events 
following inhibition of FGFR or Src family kinases, a SILAC experiment was carried out using 
the triple negative breast cancer cell lines: SUM52 and MFM233 (unpublished, Debbie 
Cunningham et al.,). Results showed that the FGFR dependent phosphorylation events 
represented a wide variety of biological functions and processes. Therefore, the understanding 
of the key phosphorylation dynamics is a useful indicator of protein activity and related kinase 
function. 
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The aim of the work presented in this chapter was to (1) study the dynamics of key 
phosphorylation events following activation of FGF signalling, and (2) explore the molecular 
mechanisms of the FGF signalling cascade in SUM52 cells.  
To directly study the downstream dynamics of FGF signalling, we focused on proteins with 
kinase function. In total, 75 phosphopeptides from kinase were selected for the SRM assay, 
including 62 singly-phosphorylated peptides and 13 doubly-phosphorylated peptides. These 
candidates were selected from kinases that contained phosphosites that were sensitive to 
treatment with the FGFR inhibitor, SU5402, in the SILAC experiment described previously 
(shown in Table 6.1 and Appendix 2). The phosphorylation profile of these peptides following 
FGF1 stimulation was studied in a time-resolved way (0 s, 20 s, 40 s, 1 min, 3 min, 5 min, 10 
min, 20 min, 30 min and 60 min). An absolute quantitation strategy was employed (see Chapter 
2.2.8). To explore the dynamics of the specific phosphorylation events, peptides with 
differentially phosphorylated versions were investigated individually. 
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Table 6.1 Overview of selected phosphopeptides for SRM assay 
 
Peptide sequence Protein Peptide sequence Protein 
ALGERVSIL Serine/threonine-protein kinase D1 RLSSTSLASGHSVR Serine/threonine-protein kinase D2 
ATDSFSGRFEDVYQLQEDVLGEGAHAR MAP kinase-interacting serine/threonine-protein kinase 2 RLSSTSLASGHSVR Serine/threonine-protein kinase D2 
AVLSPGSVFSPGR Inositol-trisphosphate 3-kinase B RLSSTSLASGHSVR Serine/threonine-protein kinase D2 
DALDLSDINSEPPRGSFPSFEPR 
Membrane-associated tyrosine/ threonine-specific cdc2-
inhibitory kinase 
RNSFTPLSSSNTIR 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 
DINNIDYYKK Fibroblast growth factor receptor 2 RNSFTPLSSSNTIR 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 
DINNIDYYKK Fibroblast growth factor receptor 2 RPHFPQFSYSASGRE RAC-gamma serine/threonine-protein kinase 
DINNIDYYKK Fibroblast growth factor receptor 2 RPHFPQFSYSASGRE RAC-alpha serine/threonine-protein kinase 
EHIEIIAPSPQR Eukaryotic translation initiation factor 2-alpha kinase 3 RPHFPQFSYSASGRE RAC-alpha serine/threonine-protein kinase 
EKFSFEPK Ribosomal protein S6 kinase  RPHFPQFSYSASGTA RAC-gamma serine/threonine-protein kinase 
EYGSPLKAYTPVVVTQWYR Cyclin-dependent kinase 11B RPPGMEYSYDINR Fibroblast growth factor receptor 2 
GAILTTM(ox)LVSR Calcium/calmodulin-dependent protein kinase type II subunit  RPPGMEYSYDINR Fibroblast growth factor receptor 2 
GAQASSGSPALPR Abelson tyrosine-protein kinase 2 RRSIQDLTVTGTEPGQVSSR Mitogen-activated protein kinase kinase kinase 7 
GFSFVATGLM(ox)EDDGKPR Ribosomal protein S6 kinase RSDSASSEPVGIYQGFEK Protein kinase C delta type 
GLCTSPAEHQYFMTEYVATR Mitogen-activated protein kinase 7 RSDSASSEPVGIYQGFEK Protein kinase C delta type 
GRNSATSADEQPHIGNYR serine/threonine-protein kinase MARK2 RVSLSEIGFGK Cyclin-dependent kinase 16 
HFM(ox)HQIITGMLYLHSHGILHR Serine/threonine-protein kinase PLK4 RYSDHAGPAIPSVVAYPK MAP/microtubule affinity-regulating kinase 3 
IADPEHDHTGFLTEYVATR Mitogen-activated protein kinase 3 SGEQITSSPVSPK Inositol hexakisphosphate/diphosphoinositol-pentakisphosphate kinase 2 
IADPEHDHTGFLTEYVATR Mitogen-activated protein kinase 3 SGGGDLTLGLEPSEEEAPR Receptor tyrosine-protein kinase erbB 2 
IADPEHDHTGFLTEYVATR Mitogen-activated protein kinase 3 SHNDFVAILDLPEGEHQYK 5'-AMP-activated protein kinase subunit beta 2 
IADPEHDHTGFLTEYVATR Mitogen-activated protein kinase 3 STVASMMHR Calcium/calmodulin-dependent protein kinase type II subunit delta 
KLPSTTL Ribosomal protein S6 kinase  SVVGTPAYLAPEVLR Serine/threonine-protein kinase D1, D3 
KLPSTTL Ribosomal protein S6 kinase SGSPSDNSGAEEMEVSLAKPK RAC-alpha serine/threonine-protein kinase 
LGSYSGPTSVSR Pantothenate kinase 2, mitochondrial STSWHTALR Triple functional domain protein 
LQPFHSTELEDDAIYSVHVPAGLYR ARF GTPase-activating protein GIT1 TPKDSPGIPPSAGAHQLFR Ribosomal protein S6 kinase 
LSEEAECPNPSTPSK Serine/threonine-protein kinase 10 TTSFAESCKPVQQPSAFGSM(ox)K Glycogen synthase kinase-3 beta 
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NFSAAKSLLNKK Calcium/calmodulin-dependent protein kinase type II subunit TTSFAESCKPVQQPSAFGSMK Glycogen synthase kinase beta 3 
NFSAAKSLLNKK Calcium/calmodulin-dependent protein kinase type II subunit 
gamma 
TTSQCKSEPPLLR Uridine kinase;Uridine-cytidine kinase-like 1 
NFSAAKSLLNKK Calcium/calmodulin-dependent protein kinase type II subunit 
gamma 
THFPQFSYSASIRE RAC-beta serine/threonine-protein kinase 
NLQSPTQFQTPR Serine/threonine-protein kinase ULK1 TPKDSPGIPPSAGAHQLFR Ribosomal protein S6 kinase  
NYSVGSRPLKPLSPLR 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 TPKDSPGIPPSANAHQLFR Ribosomal protein S6 kinase  
NYSVGSRPLKPLSPLR 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 TPKDSPGIPPSAGAHQLFR Ribosomal protein S6 kinase 
NYSVGSRPLKPLSPLR 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 TPKDSPGIPPSANAHQLFR Ribosomal protein S6 kinase  
RESVVNLENFRK Death-associated protein kinase 2 TPKDSPGIPPSAGAHQLFR Ribosomal protein S6 kinase  
RISLSDMPR Protein kinase C-binding protein 1 VADPDHDHTGFLTEYVATR Mitogen-activated protein kinase 1 
RLNSSPRAPVSPLK Ribosomal protein S6 kinase beta 2 VADPDHDHTGFLTEYVATR Mitogen-activated protein kinase 1 
RLNSSPRAPVSPLK Ribosomal protein S6 kinase beta 2 VADPDHDHTGFLTEYVATR Mitogen-activated protein kinase 1 
RLNSSPRAPVSPLK Ribosomal protein S6 kinase beta 2 VADPDHDHTGFLTEYVATR Mitogen-activated protein kinase 1 
  VTSGGVSESPSGFSK Serine/threonine-protein kinase Chk1 
Table 5.1 (continued) 
 
Phosphorylation sites are shown in red.  
Differentially phosphorylated versions of the same peptide are shown in grey.
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6.2 Results 
The dynamics of specific phosphorylation events in FGF signalling were investigated by SRM 
in SUM52 cells, as described in Section 2.2.5. The data was collected in a time-dependent 
profile during FGF1 stimulation (0 s, 20 s, 40 s, 1 min, 3 min, 5 min, 10 min, 20 min, 30 min 
and 60 min). Three technical replicates and two biological replicates were performed. 
Phosphopeptides with a peak area count of over 5000 were selected for further analysis. With 
these criteria, 38 of 75 phosphopeptides were quantified reproducibly. 
 
6.2.1 Initial assessment of SRM assay 
To investigate the reproducibility of the quantitation results, precision was assessed using the 
data from technical replicates (intra-assay precision) and biological replicates (inter-assay 
precision). In this assay, data from ten time-points following FGF stimulation were collected. 
Three transitions were selected per phosphopeptide based on the description in Chapter 1.4.3.2. 
The transitions were monitored in a time-constrained way (termed scheduled), where a small 
elution time window was specified for transitions of a given peptides (performed by Dr Andrew 
Creese). In one LC-MS/MS assay, 50 phosphopeptides (25 pairs of IS peptides and endogenous 
peptides, 150 transitions) were scheduled. Therefore, 3 independent analytical runs were 
performed for a total of 75 targeted phosphopeptides. Three technical replicates and two 
biological replicates were performed. Therefore, a total of 6 sets were taken forward for 
replicate analyses. 
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6.2.1.1 Technical reproducibility  
To assess technical reproducibility, relative standard deviation (% RSD, also known as 
coefficient of variation) was used to evaluate the variances among three technical replicates 
(Figure 6.1). RSD was calculated as the standard deviation of peptide measurements over the 
three replicates divided by the average peptide intensity.  
In Figure 6.2, each box displays the distribution of RSD of phosphopeptides detected within 
each dataset. The red line indicates the 10% cut off of RSD. The medians of RSD of 6 sets of 
analysis are all below 10%, ranging from 8.01% to 9.87%.  
 
Figure 6.1 Boxplots of RSDs derived from the 3 technical replicates spectra for 2 independent datasets.  Box 
plot shows the RSD for three technical replicates averaged independently for all biological replicates. The number 
of data point of the 6 datasets are 130,117,119,150,180 and 100 individually. The box spans from the Q1 (quartile 
1) to Q3 (quartile 3) and median (quartile 2) is shown in the middle. Whiskers above the box show the maximum 
values.  
 
 
For peptide quantitation, a typical SRM assay requires the RSD of technical replicates lower 
than 10% to 20%, depending on the concentration of peptides228. Our results demonstrated 
good precision among technical replicates, confirming the robustness of the SRM assay.  
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6.2.1.2 Biological reproducibility 
To assess reproducibility in absolute quantitation between independently prepared biological 
samples, a histogram analysis was performed. For each identified phosphopeptide, the mean of 
their relative abundance across a time series profile was calculated. Next, the ratios of the mean 
of relative abundance (endogenous peptide/ IS peptide) between the two biological replicates 
were calculated, as displayed in Figure 6.2. The distribution shows an approximately normal 
distribution around the ratio of 1. The variance of 28 phosphopeptides (60.9%) is within ± 20%, 
suggesting the overall absolute quantitation results are within the acceptable level of precision.  
 
 
Figure 6.2 Histogram showing the reproducibility of 2 independent biological datasets  
X-axis represents the ratio of the values from 2 biological replicates. The dashed lines indicate the ± 20% 
deviation of the ratio 1. 
 
6.2.2 Overview of SRM-based quantitation of key phosphorylation events in 
FGF signalling 
In order to examine the patterns of phosphopeptide responses following FGF1 stimulation, 
hierarchical clustering was performed on the phosphopeptides identified reproducibly in the 
assay. The clustering of phosphopeptides was based on their relative phosphorylation profile 
and allowed classification of the phosphopeptides from a complex dataset. As shown in Figure 
6.3, phosphopeptides were grouped into 4 clusters. The clustering revealed that the 
phosphopeptides showed different response towards FGF1 stimulation. Different response 
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patterns were identified: early, mid and late responses. Phosphopeptides with early response 
type were either down-regulated at early time points (from 20 s to 1 min) after FGF1 treatment 
or underwent up-regulation followed by rapid down-regulation. Phosphopeptides with mid 
response pattern were up-regulated from 1min to 10 min following FGF1 treatment. Late 
response phosphopeptides were up-regulated from 30 min to 60 min of FGF1 stimulation.  
 
     
Figure 6.3 Hierarchical clustering of relative phosphorylation profile of key phosphorylation events during 
FGF1 stimulation. The expression of each phosphopeptide was normalized to a percentage of the highest 
expression in a time profile (horizontally). The colours in the map display the relative expression of 
phosphopeptides during FGF1 stimulation. Phosphopeptides with similar expression profiles were grouped 
together and were connected by clustering tree. Clustering distance was calculated based on Euclidean distance 
with average linkage by Perseus 1.5.1.6.  
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6.2.3 Phosphopeptides response to FGF1 treatment 
6.2.3.1 Early response phosphopeptides 
In total, 12 phosphopeptides were characterised as early response phosphopeptides (0 s to 1 
min following FGF1 stimulation), see Table 6.2. There are 10 singly phosphorylated peptides 
and 2 doubly phosphorylated peptides. Phosphorylation levels of the early response 
phosphopeptides were down-regulated immediately (except peptide RLSpSTSLASGHSVR 
which shows the highest expression at 20 s) following the addition of FGF1. 
Table 6.2 Early response phosphopeptides 
 
     
 
 
Figure 6.4 Hierarchical clustering of relative phosphorylation profile of early response phosphopeptides. 
The expression of each phosphopeptide was normalized to a percentage of the highest expression in a time profile 
(horizontally). The colours in the map display the relative expression of phosphopeptides during FGF1 stimulation. 
Phosphopeptide sequences were shown on the left of clustering image.  
141 
 
6.2.3.2 Mid response phosphopeptides 
In total, 10 phosphopeptides were characterised as mid response phosphopeptides (1 min to 20 
min following FGF1 stimulation), shown in Table 6.3. There are 9 singly phosphorylated 
peptides and 1 doubly phosphorylated peptide. The kinases corresponding to these 
phosphopeptides include participators of the MAPK pathway, CoA biosynthesis, carbohydrate 
metabolic process, proliferation and apoptosis. Phosphorylation levels of the mid response 
phosphopeptides were up-regulated from 1 min to around 20 min following the addition of 
FGF1. 
Table 6.3 Mid response phosphopeptides 
 
   
 
 
Figure 6.5 Hierarchical clustering of relative phosphorylation profile of mid response phosphopeptides. 
The expression of each phosphopeptide was normalized to a percentage of the highest expression in a time profile 
(horizontally). The colours in the map display the relative expression of phosphopeptides during FGF1 stimulation. 
Phosphopeptides sequences were shown on the left of clustering image. 
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6.2.3.3. Late response phosphopeptides 
In total, 12 phosphopeptides were characterised as late response phosphopeptides (30 min to 
60 min following FGF1 stimulation), shown in Table 6.4. There are 10 singly phosphorylated 
peptides and 2 doubly phosphorylated peptides. The kinases corresponding to these 
phosphopeptides include participators of transcription, translation, MAPK pathway, calcium 
metabolic process, proliferation and apoptosis. Phosphorylation levels of the late response 
phosphopeptides were up-regulated from 30 min to 60 min following the addition of FGF1. 
Table 6.4 Late response phosphopeptides 
 
       
 
 
 
Figure 6.6 Hierarchical clustering of relative phosphorylation profile of late response phosphopeptides. The 
expression of each phosphopeptide was normalized to a percentage of the highest expression in a time profile 
(horizontally). The colours in the map display the relative expression of phosphopeptides during FGF1 stimulation. 
Phosphopeptide sequences were shown on the left of clustering image. 
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6.2.4 Establishment of calibration curve 
For absolute quantitation, a calibration curve is required to determine the absolute amount of a 
peptide. Calibration curves were prepared for each phosphopeptide using synthetic peptides. A 
6-point calibration curve was produced: 100 attomole, 500 attomole, 1 femtomole, 10 
femtomole, 50 femtomole and 250 femtomole. Triplicate measurements were performed for 
each phosphopeptide and three inter-day analyses were performed at the beginning, middle and 
end of the sample analysis.  
When evaluating the reproducibility of the calibration curve assay, the mean of three 
measurements were used for further analysis; however, the inter-assay variance was observed 
for experiments performed over a four-week period. Using the mean of three inter-day results 
could potentially bias the calibration curve as the value of peak area over 6 concentrations can 
differ by up to 1,000 fold.  Therefore, a logarithm transform approach was adopted to combine 
the inter-day results, as shown in Figure 6.7. 
 
Figure 6.7 Schematic diagram of the logarithm transform approach 
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Figure 6.8 Calibration curve of phosphopeptides 
(A) DINNIDpYYKK of Fibroblast growth factor receptor 2; (B) TPKDSPGIPPSAGAHQLFR of Ribosomal 
protein S6 kinase alpha-3; (C) TPKDpSPGIPPSANAHQLFR of Ribosomal protein S6 kinase alpha-1 
A 
B 
C 
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Figure 6.8 shows a number of calibration curves constructed using the approach described 
above. The calibration curve with a less than 0.9 R-squared value will be excluded from further 
analysis. Therefore, 65 phosphopeptides are allowed for absolute quantitation. A representative 
Skyline output is shown in Figure 6.9. 
 
Figure 6.9 Representative Skyline output of 2+ peptide pSVVGTPAYLAPEVLR following FGF1 treatment 
(A) Time profile of endogenous peptides; (B) Time profile of IS peptides. Three transitions shown in the figure 
are neutral loss ion (precursor-98, blue), b3 (purple) and y10 (dark red). 
 
6.2.5 Response of multi-site phosphopeptides 
6.2.5.1 Fibroblast growth factor receptor 2 
Figure 6.10 shows the temporal phosphorylation profile of two isobaric phosphopeptides 
(Tyr656 and Tyr657) following the addition of FGF1 and the absolute abundance of 
phosphopeptides present at each time point is quantified. For DINNIDpYYKK, the 
phosphorylation level showed a time-dependent increase following the addition of FGF1, and 
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at 60 min the maximum phosphorylation level was reached. For DINNIDYpYKK, FGF1 
induced a quick reduction in phosphorylation level and the phosphorylation level tended to be 
stable after 1 min of FGF1 stimulation. 
 
 
 
Figure 6.10 Phosphorylation profile of 2 isobaric phosphopeptides of FGFR2 
(A): Clustering presentation of phosphopeptides from FGFR2. (B) Phosphorylation profile of peptide 
DINNIDpYYKK (Tyr656) following addition of FGF1. (C) Phosphorylation profile of peptide DINNIDYpYKK 
(Tyr657) following addition of FGF1. Early response profile was shown on the right of the figure. Results from 
two biological replicates are shown in green and red. 
 
 
A 
B 
C 
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6.2.5.2 Ribosomal protein S6 kinase alpha-1 
Figure 6.11 shows the temporal phosphorylation profile of three isobaric phosphopeptides 
(Ser363, Ser369 and both) following addition of FGF1 and the absolute abundance of 
phosphopeptides present at each time point is quantified. For all three peptides, up-regulated 
phosphorylation levels were observed from 20 s after the addition of FGF1 and the 
phosphorylation level reached a maximum around 40 s to 1 min. After 10 min stimulation, the 
response was slowly tuned back to initiation level. The phosphorylation of Ser359 of RSK1 
and Ser369 of RSK3 (homologous to Ser363 of RSK1) exhibited a similar profile, displayed 
in Figure 6.12 and 6.13. 
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Figure 6.11 Phosphorylation profile of a group phosphopeptides of RSK1 
(A) Clustering presentation of phosphopeptides from RSK1. (B) Phosphorylation profile of peptide 
TPKDpSPGIPPSAGAHQLFR (Ser363) following addition of FGF1. (C) Phosphorylation profile of peptide 
TPKDSPGIPPpSAGAHQLFR (Ser369) following addition of FGF1. (D) Phosphorylation profile of peptide 
TPKDpSPGIPPpSAGAHQLFR (Ser363 and Ser369) following addition of FGF1. Early response profile was 
shown on the right of the figure. Results from two biological replicates are shown in green and red. 
A 
B 
C 
D 
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Figure 6.12 Phosphorylation profile of peptide pTPKDSPGIPPSAGAHQLFR (Ser359) of RSK1 
Early response profile was shown on the right of the figure. Results from two biological replicates are shown in 
green and red. 
 
Figure 6.13 Phosphorylation profile of peptide TPKDpSPGIPPSANAHQLFR (Ser369) of RSK3 
Early response profile was shown on the right of the figure. Results from two biological replicates are shown in 
green and red. 
 
 
6.2.5.3 Extracellular signal-regulated kinase 1 
Figure 6.14 shows the temporal phosphorylation profile of three isobaric phosphopeptides 
(Thr202, Tyr204 and both) following addition of FGF1 and the absolute abundance of 
phosphopeptides present at each time point is quantified. The expression level of singly 
phosphorylated peptide (Thr202) was up-regulated after the addition of FGF1 and continued 
to increase after 20 min of stimulation. For the Tyr204 phosphopeptide, a similar response was 
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revealed and a rapid increase in phosphorylation was observed at 1 min of FGF1 stimulation. 
For the doubly-phosphorylated peptide (Thr202 and Tyr204), the phosphorylation level was 
increased at 40 s and 20 min of stimulation and decreased after 20 min. From the analysis of 
the three isobaric peptides, it is likely that upon FGF1 stimulation, Thr202 and Tyr204 are both 
activated. Dephosphorylation of these two sites is initiated after 20 min, therefore a decrease 
was observed. 
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Figure 6.14 Phosphorylation profile of a group of isobaric phosphopeptides of ERK1 
(A): Clustering presentation of phosphopeptides from ERK1. (B) Phosphorylation profile of peptide 
IADPEHDHTGFLpTEYVATR (Thr202) following addition of FGF1. (C) Phosphorylation profile of peptide 
IADPEHDHTGFLTEpYVATR (Tyr204) following addition of FGF1. (D) Phosphorylation profile of peptide 
IADPEHDHTGFLpTEpYVATR (Thr202 and Tyr204) following addition of FGF1.Early response profile was 
shown on the right of the figure. Results from two biological replicates are shown in green and red. 
 
 
 
6.2.5.4 Extracellular signal-regulated kinase 2 
Figure 6.15 shows the temporal phosphorylation profile of three phosphopeptides (Thr185, 
Tyr187 and both) following addition of FGF1 and the absolute abundance of phosphopeptides 
present at each time point is quantified. The response of the three phosphopeptides is different 
in response to FGF1. Singly-phosphorylated peptide Thr185 showed an increase following 
addition of FGF1 and the phosphorylation level kept increasing until 60 min of treatment. For 
peptide with Tyr187 phosphorylation, no obvious response was observed. In contrast, the 
phosphorylation level of the doubly phosphorylated peptide showed a reduction immediately 
after treatment. 
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Figure 6.15 Phosphorylation profile of a group of phosphopeptides of MAPK2 
(A): Clustering presentation of phosphopeptides from ERK2. (B) Phosphorylation profile of peptide 
VADPDHDHTGFLpTEYVATR (Tyr185) following addition of FGF1. (C) Phosphorylation profile of peptide 
VADPDHDHTGFLTEpYVATR (Thr187) following addition of FGF1. (D) Phosphorylation profile of peptide 
VADPDHDHTGFLpTEpYVATR (Thr185 and Tyr187) following addition of FGF1. Early response profile was 
shown on the right of the figure. Results from two biological replicates are shown in green and red. 
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6.2.6 Trouble shooting 
A total of 75 phosphosites were submitted for SRM quantitation, 38 of which were 
reproducibly quantified. The other 37 phosphopeptides were not successfully quantified due to 
a number of reasons, as summarised in Table 6.5. In order to ensure reproducible quantitation, 
a peak area cut-off of 5000 was selected to exclude low-abundance ions. A total of 21 
phosphopeptides were removed from further analyses as a result of low MS response. Five 
phosphopeptides showed sufficient MS signal but fell partially outside of the retention time 
window, therefore the data could not be used for quantitation. Peptides EHIEIIAPpSPQR, 
EKFpSFEPK and pSGGGDLTLGLEPSEEEAPR were successfully identified in only one set 
of biological replicates.  Six phosphopeptides did not show good correlation between the two 
biological replicates, therefore they were excluded from further analysis. 
Table 6.5 Summary of identification results 
 
 
 
 
Peptide sequence Identification results Peptide sequence Identification results
ATDSFSGRFEDVYQLQEDVLGEGAHAR Low signal RLNSSPRAPVSPLK Low signal
DINNIDYYKK Low signal RLSSTSLASGHSVR Low signal
EHIEIIAPSPQR One repeat RNSFTPLSSSNTIR Low signal
EKFSFEPK One repeat RPHFPQFSYSASGRE Outside of RT window
EYGSPLKAYTPVVVTQWYR Low signal RPHFPQFSYSASGRE Poor reproducibility
GAILTTM(ox)LVSR Low signal RPPGMEYSYDINR Outside of RT window
GAQASSGSPALPR Low signal RSDSASSEPVGIYQGFEK Low signal
GFSFVATGLM(ox)EDDGKPR Outside of RT window RVSLSEIGFGK Low signal
GLCTSPAEHQYFMTEYVATR Low signal SGGGDLTLGLEPSEEEAPR One repeat
GRNSATSADEQPHIGNYR Low signal SGSPSDNSGAEEMEVSLAKPK Low signal
HFM(ox)HQIITGMLYLHSHGILHR Outside of RT window SHNDFVAILDLPEGEHQYK Outside of RT window
KLPSTTL Poor reproducibility STVASMMHR Low signal
LQPFHSTELEDDAIYSVHVPAGLYR Low signal THFPQFSYSASIRE No calibration data
NFSAAKSLLNKK Poor reproducibility TPKDSPGIPPSANAHQLFR Low signal
NFSAAKSLLNKK Poor reproducibility TTSFAESCKPVQQPSAFGSM(ox)KNo calibration data
NFSAAKSLLNKK Poor reproducibility TTSFAESCKPVQQPSAFGSMK Poor reproducibility
NLQSPTQFQTPR Low signal VADPDHDHTGFLTEYVATR Low signal
NYSVGSRPLKPLSPLR Low signal VTSGGVSESPSGFSK Low signal
NYSVGSRPLKPLSPLR Low signal
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6.3 Discussion 
6.3.1 Initial assessment of SRM assay 
To measure the biological reproducibility of the SRM assay, a histogram was used to assess 
the overall performance between the two datasets. Approximately 39.8% of peptides showed a 
variance above 20%. This results is due, firstly, to the variance in instrumental performance. 
The samples from the two biological replicates were analysed on different days, therefore a 
certain level of instrumental error was expected. Secondly, for each phosphopeptide, the ratio 
of absolute measurements used in the evaluation of biological reproducibility is the average 
expression across the time expression profile, where different phosphorylation levels are 
expected within a time-dependent profile. Although high variances were observed between 
biological replicates, in some cases, a similar response pattern was found in the two replicates. 
To further optimize the reproducibility, inclusion of an internal standard (i.e. a peptide of a 
known amount) was thought to be advisable. 
 
6.3.2 Phosphopeptides response to FGF1 treatment 
In the initial stage of FGF activation, a number of conserved tyrosine residues in the 
intracellular domain of the FGFR will undergo phosphorylation. The activated FGFR kinases, 
in turn, phosphorylate downstream signalling protein for signal transduction. The trafficking 
of FGF signalling is mediated by the diverse downstream responses. Dissecting their 
expression patterns and subjecting them to pathway analysis may yield deeper insights into the 
mechanisms of FGF activation and trafficking. 
The SRM assay identified differences in the phosphorylation response after the activation of 
FGF signalling. The clustering of phosphopeptide expression patterns allowed the peptides that 
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play different roles in FGF signalling to be distinguished. Previously published data 
demonstrated that immediate phosphorylation of the receptor and tyrosine phosphorylation of 
FGFR was observed to occur within 30 seconds of FGF stimulation in vitro18. FGF1 induced 
intra-cellular signalling is time-dependent and the induction can be sustained until 24 hours 
after FGF1 stimulation. In order to study the immediate and transient activation of FGF 
signalling, in this assay, the expression profile of key phosphorylation events within one hour 
of FGF1 stimulation was monitored. 
 
6.3.3 Calibration curve 
The calibration curve was generated from three independent calibration analyses performed on 
different days. Certain types of data, e.g. gene expression data or protein expression data, are 
heavily skewed in linear scale229. It is arbitrary simply to take the average for data analysis. 
When interpreting SRM data, the value of peak area over 6 concentrations can differ by up to 
1,000 fold. Thus, using the mean of three inter-day results could potentially bias the calibration 
curve. To reduce the data skewness in linear scale, a log-transform approach was used to 
calculate the calibration curve, as described by Irizarry et al230. After log2 transformation, 
parameters of linear regression were calculated. To identify the linearity of calibration data, an 
empirical R-squared value of 0.9 was selected as the cut-off. 
 
6.3.4 Response of multi-site phosphopeptides 
6.3.4.1 Fibroblast growth factor receptor 2 
FGFR2 is a key protein in FGF signalling and predominantly expressed in epithelium cells16. 
FGFR2 isoforms, both FGFR2IIIb and FGFR2IIIc have been shown to interact with FGF1 to 
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initiate the signalling231. The crystal structure revealed that the interaction between FGFR2 and 
FGF1 was formed by linking the two ligands into the dimeric receptors chains232. The direct 
result of this interaction is the conformation change in the cytoplasmic domain of the receptor, 
which will lead to the autophosphorylation of two tyrosine site Y656 and Y657.  
A mechanism of FGFR1 activation has been described by Furdui et al21. They hypothesised a 
two-step activation mechanism by using rapid chemical quench method and time-resolved ESI-
TOF-MS. In the first step, the autophosphorylation of Y653 (homologous to Y656 of FGFR2) 
in the activation loop will result in approximately 50 to 100 fold increase in kinase activity, 
whereas the catalyse activity is further enhanced by 500 to 1000 fold after the auto-
phosphorylation of Y654 (homologous to Y657 of FGFR2). The auto-phosphorylation of 
FGFR1 is not a homogenous process, but a sequential, strictly ordered reaction. Next, Y463 in 
juxtamembrane region, Y586 and Y588 in kinase insert, and Y769 in C-terminal region are 
also phosphorylated to enhance the signal propagation or serve as recruitment sites for 
downstream signalling proteins. 
The results here provide temporal evidence in support of this hypothesis. In the first step, FGF1 
stimulation enhances kinase activity by phosphorylating of Y656 of FGFR2, which was 
evidenced by the increased phosphorylation level of DINNIDpYYKK (Figure 6.9B). The 
subsequent phosphorylation of Y657 will further promote catalytic activity of FGFR2, 
resulting in a decreased phosphorylation level of the singly phosphorylated peptide and an 
increased level of the doubly phosphorylated peptide. Unfortunately, the doubly 
phosphorylated version was too low abundance to establish a temporal phosphorylation profile. 
The results presented here support the theory that the catalytic activity of FGFR during signal 
initiation stage is activated and mediated by a sequential tyrosine autophosphorylation process. 
Moreover, this process is likely to be a conserved mechanism of FGFR family members. 
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6.3.4.2 Ribosomal protein S6 kinase alpha-1 
Ribosomal protein S6 kinase (RSK) represents an important family of serine-threonine kinases 
that acts downstream of the Ras-MAPK cascade233. RSKs comprise two distinct kinase domain 
(N- and C-terminal kinase domain) and this family has four isoforms (RSK1-4) in humans. 
Phosphorylation of RSKs occurs at multiple Ser and Thr sites through sequential reactions by 
various kinases, e.g. Erk1/2 in response to growth factors234. RSKs have been extensively 
implicated in mitotic phosphorylation events and the regulation of cell cycle235. There is 
increasing evidence pointing to RSKs as the potential therapeutic targets for a number of 
cancers, including breast cancer236,237.  
 
Figure 6.16 A schematic model for RSK activation (Adapted from Anjum and Blenis234) 
 
RSKs can be activated via canonical MAPK cascade upon treatment with growth factors and 
other extracellular signals. As shown in Figure 6.16, activation of cell surface receptor leads to 
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auto-phosphorylation of receptor and creates recruitment sites for scaffolding proteins such as 
growth factor receptor-bound protein-2 (GRB2). Upon activation of GRB2, downstream 
signalling protein, such as SOS, Ras and Raf, are recruited subsequently, leading to the 
activation of MEK1/2. Next, ERK1/2 directly phosphorylates and activates RSKs (e.g. Ser363 
and Ser380 of RSK1). Alternatively, RSK is modulated by 3'-phosphoinositide-dependent 
kinase-1 (PDK) by phosphorylation of Ser221 of RSK1. 
Ser363 of RSK1 (TPKDpSPGIPPSAGAHQLFR, homologous to other members of RSK 
family) is located within sequences that are conserved in the most AGC kinases and is 
phosphorylated by ERK1/2238. It has been demonstrated that the phosphorylation of Ser363 
and Ser380 is critical for activation of the N-terminal kinase domain. Together with Ser359 
(pTPKDSPGIPPSAGAHQLFR), these two sites has been termed the ‘turn-motif’, which is 
primarily involved in modulating structure of the kinase in order to influence kinase activity. 
Our findings showed FGF1 stimulation induced immediate response and increase of Ser359, 
Ser363 and the doubly-phosphorylated version. It was previously reported the phosphorylation 
of doubly-phosphorylated version was involved in stabilizing the kinase core239. Whether the 
phosphorylation of Ser359 is required for activation is unclear so far, but the low level of the 
Ser359 peptide may indicate it is not a specific target of ERK1/2.  
In addition, absolute quantitation results revealed that the phosphorylation level of Ser369 of 
RSK3 was much higher than the homologous site of RSK1 (see Figure 6.13), which suggests 
the basal level of RSK3-associate phosphorylation is more abundant than other members of 
RSK family. There is evidence demonstrating, upon mitogen stimulation, RSK3 is able to 
maintain interaction with ERK1/2 longer than RSK1 and RSK2 in 293T cells240. Therefore, it 
is likely that the high level of RSK3 phosphorylation is associated with the preference of 
ERK1/2 to bind with RSK3 than other members of RSK family. 
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6.3.4.3 Extracellular signal-regulated kinase 1 
Extracellular signal-regulated kinase, also known as mitogen-activated protein kinase 3 
(MAPK3), is one of the central regulators in cellular response to extracellular stimuli, such as 
oxidative stress, DNA damage and infection etc241. The ERK1/ERK2 pathway is known to be 
the best-characterized MAPK cascade. ERK1 was found to be phosphorylated on Tyr and Thr 
residues in response to a wide variety of stimuli, such as growth factor, Ca2+, 
neurotransmitters242. Thr202 and Tyr204 of ERK1 were shown to be further phosphorylated 
by MEK1/2 to fully active kinase activity and Thr202 and Tyr204 are the only substrates of 
MEK1/2 known so far243. Crystal structure revealed the mono-phosphorylated form at Tyr204 
and dual-phosphorylated form possess distinct conformations, which contribute to the huge 
difference in kinase activity244. Some proteins have been identified to regulate ERK1 activity 
in multiple levels. Upstream of ERK1, the phosphorylation status of Ser298 outside of 
activation loop of MEK could regulate ERK1 activity in positive or negative manner. Dual 
Specificity Phosphatases (DUSPs) interact directly with ERK1 to dephosphorylate both sites 
of Thr202 and Tyr204 to regulate its kinase activity245. Downstream of ERK1, negative 
regulation also occurs through feedback of a variety of substrates and its subcellular 
localization. 
Currently, antibody in the market is only able to target Thr202 and Tyr204 at the same time. 
However, our results showed a different effect on three isobaric phosphopeptides upon FGF1 
treatment. An increase in the singly phosphorylated form while a decrease in the doubly 
phosphorylated form was observed after 20 min stimulation. This is likely to be a negative 
feedback in response to the activated MAPK pathway. It is unclear which mechanism is 
responsible for this negative regulation. However, it is obvious that the addition of ligand is 
able to induce an immediate response of ERK1 through phosphorylation of Thr202 and Tyr204, 
and a negative feedback is initiated around 20 min after the stimulation. 
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6.3.4.4 Extracellular signal-regulated kinase 2 
ERK2 (also known as mitogen-activated protein kinase 1, MAPK1) is a member of MAP 
kinase family. Together with ERK1, they participate in MAP kinase signal transduction 
pathway and regulate a variety of biological processes. The Thr185 and Tyr187 of ERK2 are 
homologous to Thr202 and Tyr204 of ERK1, as shown in Figure 6.17. Similar to ERK1, 
activity of ERK2 is regulated through the dual-phosphorylation mechanism of Thr185 and 
Tyr187246. Thr185 and Tyr187 have been reported to be phosphorylated by a number of 
upstream kinases, e.g. PLC-γ247, MEK1 and MEK2248. All known cellular stimuli of the 
ERK1/2 pathway are able to induce the parallel activation of ERK1 and ERK2. On the other 
hand, a number of downstream substrates can regulate ERK2 kinase activity, e.g. DUSP5, a 
mitogen-activated protein kinase dephosphorylates ERK2 at Thr185 and Tyr187 to prevent it 
from leaving nucleus, therefore deactivating the kinase249. 
 
Figure 6.17 Alignment of amino acid sequence in active site of ERK1 and ERK2 
The dual phosphorylation sites are shown in red. Numbers indicate the site of amino acid in ERK1 or ERK2. The 
unconserved amino acid between ERK1/2 is shown in green. 
 
ERK1 and ERK2 are 82% identical in amino acid sequence and they share the same substrates 
specificity under most circumstances250. Also, they are co-expressed ubiquitously but with a 
remarkably variable relative abundance251. Recent evidence suggests ERK1 and ERK2 are not 
always interchangeable and some differences between their regulation and function have been 
elucidated under specific conditions. Fischer et al,. showed ERK2 was indispensable in 
multiple stages of T-cell development in mice, while ERK1-deficient mice was still viable 
through the development252. Also, ERK2 but not ERK1 is necessary for Ras-induced epithelial-
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to-mesenchymal transformation (EMT)253. Moreover, a number of research points that 
quantitative differences in ERK1 and ERK2 dynamics could have a significant role in their 
regulation. Pages et al,. have shown an elevated level of ERK1 protein was capable of 
compensating the lack of ERK2 during the proliferation and differentiation of positive 
thymocytes254. It indicates ERK1 and ERK2 might compete with each other for upstream MEK 
activation. Last, alternatively spliced isoforms of ERK1 and ERK2 have been reported to 
determine signalling specificity255,256.   
Thr185 (ERK1) and Thr 202 (ERK2) showed a similar phosphorylation profile in response to 
FGF1. Their phosphorylation was gradually increased until 60 min of stimulation. Tyr187 
(ERK1) showed in increase while Tyr204 (ERK2) showed a decrease following addition of 
FGF1. For doubly phosphorylated peptides, ERK2 peptide showed a sharp decrease while 
ERK1 peptide exhibited a peak of phosphorylation aound 20 min of stimulation. ERK2 showed 
higher absolute abundance than ERK1 in general. Our data suggests, in SUM52 cells, the 
activation of FGF signalling does not induce equivalent activation of ERK1 and ERK2, as their 
dual-phosphorylation response are different. It may suggest there is regulation either in the 
specificity of ERK isoform or in the quantitative difference. 
 
6.3.5 Trouble shooting 
The SRM assay reproducibly quantified 38 of 75 phosphopeptides. The method used in this 
assay presents a substantial room for optimization. A total of 28.0% of phosphopeptides were 
not successfully quantified due to a low MS signal. The MS response in SRM analysis is 
determined by the abundance of target peptide in the sample, the compatibility with LC 
separation and the intensity of the specified transitions257. The phosphopeptides selected for 
these assay are all from related kinases, which are usually low-abundant proteins compared 
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with the majority of cellular proteins. Selective prefractionation techniques are available to 
enrich phosphopeptides, however, additional sample handling places more risk in interfering 
with the quantitation results. 
The scheduled SRM approach decreases the number of concurrent transitions monitored 
simultaneously. In this assay, most of the peptides are scheduled in a 6-minute window (from 
13 min to 19 min) and 50 peptides (25 IS peptide and 25 endogenous peptides) are monitored 
within one run. The congestion of scheduled transitions potentially decrease the dwell time for 
each transition, therefore decrease the signal258. A certain number of peptide was not 
successfully quantified because the specified retention time window did not cover the whole 
peak of transitions. A more relaxed schedule method or a method with fewer transitions can be 
established in the future. Compromise choices will need to be made between the amount of 
sample, the number of instrument hours and the signal in order to obtain data for analysis. 
Combined with western blot, the establishment of the phosphorylation site analysis can also be 
applied as a standard platform for further quantitation investigations. 
 
6.4 Conclusion 
In this chapter, a quantitative and time-resolved phosphorylation site analysis was performed 
to study the phosphorylation responses following FGF1 stimulation. A total of 38 
phosphopeptides were reproducibly quantified. The clustering of relative phosphorylation 
profile showed distinct associations towards FGF1 stimulation. The phosphorylation response 
was classified as early, mid and late response type. With a special focus on peptide of 
differentially phosphorylated versions, results showed a sequential phosphorylation pattern 
was observed for phosphorylation sites in the activation loop of FGFR2 and ERK1. A similar 
phosphorylation response was observed for isobaric phosphorylated peptides of RSK1. As 
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shown in this study, evidence for the previously proposed mechanisms of FGF signal 
transduction was provided. Following the proteome-scale studies, this assay provided a more 
detailed insight into the central regulators involved in the signal transduction process. 
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CHAPTER 7 
 
CONCLUSIONS AND FUTURE WORK
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FGF signalling is a highly complex growth factor signalling pathway, reflecting a wide range 
of biological processes regulated through phosphorylation and dephosphorylation events. The 
deregulation of FGF signalling is closely linked to many human diseases, including cancer. 
The aim of the work presented in this thesis was to investigate the key phosphorylation events 
and dynamics of FGF signalling using mass spectrometry tools, including the development of 
those tools. To address this aim, the method of LC-FAIMS-MS/MS analyses was established 
(Chapter 3), the phosphorylation response to signalling inhibitors was investigated by LC-
MS/MS and LC-FAIMS-MS/MS (Chapter 4); the performance of a novel FAIMS interface 
was evaluated for further proteomic analyses (Chapter 5); a targeted quantitation assay was 
performed to profile the dynamics of the key phosphorylation events in FGF signalling 
(Chapter 6). 
 
7.1 Optimization of phosphoproteomic analysis by LC-FAIMS-
MS/MS 
In order to establish the method for quantitative analysis, the performance of LC-FAIMS-
MS/MS was evaluated. The use of calibration standards with isotopic labels showed FAIMS 
did not alter quantitation results compared with the LC-MS/MS method. The method for 
quantitative LC-FAIMS-MS/MS analysis was optimized using 293T cells and SUM52 cells. A 
CV range from -22.5 V to -50 V (with 2.5 V intervals) was selected for future experiments. 
 
7.2 FAIMS and phosphoproteomics of FGF signalling 
In Chapter 4, the LC-MS/MS and LC-FAIMS-MS/MS analyses have combined SILAC 
labelling with SCX pre-fractionation and phosphoenrichment. This approach allowed the 
investigation of the regulated phosphorylation events involved in FGF signalling. The two 
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techniques showed complementarity. An enhancement in the identification of multiply 
phosphorylated peptides and a preference for peptides with high charge states (3+ and above) 
was observed in the LC-FAIMS-MS/MS dataset. It was also observed that ~20% of the 
phosphosites identified via FAIMS have not been reported previously.  
The LC-FAIMS-MS/MS analyses also revealed a substantial number of phosphosites regulated 
upon inhibitor treatments, especially sites from multiply-phosphorylated peptides. An 
attractive application of FAIMS is the targeted analysis of peptides, thus enabling the direct 
quantitation of peptide candidates in the future. Together, these observations open new 
possibilities for in-depth characterisation of interesting candidates for their roles in FGF 
signalling and trafficking. 
 
7.3 Evaluation of modified FAIMS interface 
In Chapter 5, the performance of a novel FAIMS interface was evaluated and compared with 
the commercial standard FAIMS device, from direct infusion of peptide standards and peptide 
mixtures to LC-FAIMS-MS/MS analysis of peptide mixture and whole cell lysates. The 
modified FAIMS interface showed a CV shift of approximately 10 V and nearly 3-fold increase 
in peak capacity. In the analyses of whole cell lysate, an increase in the proteome coverage of 
69.4% was observed in the modified FAIMS dataset. The increase in proteome coverage can 
be attributed to the reduced redundancy in identifications between CV steps when using the 
modified FAIMS, in turn result in improved resolution. 
The elimination of He in the modified FAIMS device is advantageous in terms of cost reduction 
and laboratory automation. Therefore, these results demonstrate the modified FAIMS interface 
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as a powerful tool for proteomic study that provides high resolution and low redundancy 
identifications.  
 
7.4 Investigation of dynamics of the key phosphorylation events in 
FGF signalling by selected reaction monitoring 
A number of phosphoproteomic studies have attempted to understand FGF signalling on a wide 
scale. Chapter 6 was aimed at exploring the site-specific response during the activation FGF 
signalling using a targeted mass spectrometry approach. A quantitative and time-resolved SRM 
assay of 38 phosphorylation sites was successfully performed. The hierarchy clustering of their 
relative phosphorylation profiles showed distinct associations towards FGF1 stimulation. The 
phosphorylation response was classified as early, mid and late response type.  
Following the proteome-scale studies, this assay provided a more detailed insight into the 
central regulators involved in the signal transduction process. For future study, the SRM 
workflow could be optimized to obtain the desired data. The detailed specific phosphorylation 
profile of individual phosphorylation site need to be investigated, ideally compared with 
biochemistry evidence, to fully understand the potential mechanisms of the activation FGF 
signalling. 
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Peptide sequence Position
Ratio
SU5402/
FGF1
Ratio
dasatinib/
FGF1
Amino acid
No of
phosphosi
tes
Charge
Localizati
on prob
Sensitive to
treatments
(ac)AEQVLPQALY(ph)LSNM(ox)R 10 0 0 Y 1 3 0.764266
(ac)ATPAAVNPPEMAS(ph)DIPGSVTLPVAPM(ox)AAT(ph)GQVR 29 2.4473 0.69875 T 2 4 0.957397 +
(ac)EETMKLAT(ph)M(ox)EDT(ph)VEYCLFLIPDESR 12 2.3208 0.94942 T 2 3 0.758026 +
(ac)GQHNLTVLTEFILM(ox)ELT(ph)R 17 0.65406 0.54629 T 1 3 0.999583
(ac)M(ox)DLNNMNQSLTLELNT(ph)MKQAMK 16 0 0 T 1 3 0.99976
(ac)M(ox)S(ph)S(ph)NSDTGDLQES(ph)LK 3 2.2934 1.4706 S 3 3 0.899368 +
(ac)M(ox)TTAHFYCQYCT(ph)ASLLGK 12 9.2525 2.6136 T 1 3 0.832268 +
(ac)MAS(ph)LS(ph)AAAIT(ph)VPPSVPSR 3 0.36143 0.43905 S 3 3 0.999828 +
(ac)PNVPAPLAQSQQLS(ph)S(ph)HTPVS(ph)R 20 0 0 S 3 3 0.999446
(ac)RALAVLS(ph)VTLVMACT(ph)EAFFPFIS(ph)R 23 0 0 S 3 3 0.999818
(ac)RALAVLS(ph)VTLVMACT(ph)EAFFPFIS(ph)R 15 0 0 T 3 3 0.947686
(ac)RALAVLS(ph)VTLVMACT(ph)EAFFPFIS(ph)R 7 0 0 S 3 3 0.754244
(ac)RPGLAPEPLSAPPGS(ph)PPPS(ph)AAPTSATSNSSNGGGPSK 15 0 0 S 2 3 0.899589
(ac)USEVDVLVFVVDS(ph)ADRLR 13 0.96865 1.0219 S 1 3 0.99902
(ac)VALAGLLM(ox)T(ph)LPHFISEPYR 9 0.20042 0.91782 T 1 3 0.984761 +
(ac)VSLPPPQS(ph)DVTLPGPTR 8 1.0517 0.8099 S 1 3 0.825843
AADVWSLGVM(ox)LY(ph)TM(ox)LVGR 12 0.58929 0.69977 Y 1 3 0.840918
AMQEKAQDY(ph)QAEQDALR 9 1.6691 1.031 Y 1 3 1 +
AS(ph)SPHQAGLGLS(ph)LTPS(ph)PES(ph)PPLPDVSAFS(ph)RGRGGGEGR 2 0.2513 0.25375 S 5 4 0.825627 +
AS(ph)SPHQAGLGLS(ph)LTPS(ph)PES(ph)PPLPDVSAFS(ph)RGRGGGEGR 29 0.2513 0.25375 S 5 4 0.786732 +
ASLY(ph)VGDLHPEVT(ph)EAM(ox)LY(ph)EK 13 0.43994 0.24746 T 3 3 0.999923 +
AT(ph)LM(ox)GGQVYFCY(ph)DGSPYR 2 0.65888 0.86031 T 2 3 0.999993
AT(ph)PLS(ph)STVTLS(ph)M(ox)S(ph)ADVPLVVEY(ph)K 22 0.17484 0.19655 Y 5 3 0.986773 +
AT(ph)PLS(ph)STVTLS(ph)M(ox)S(ph)ADVPLVVEY(ph)K 11 0.17484 0.19655 S 5 3 0.781149 +
AT(ph)PLS(ph)STVTLS(ph)M(ox)S(ph)ADVPLVVEY(ph)K 13 0.17484 0.19655 S 5 3 0.781149 +
AY(ph)PGY(ph)YFT(ph)GDGAYR 8 0.69665 0.79007 T 3 2 0.978978
DGKLVPM(ox)T(ph)VFHK 8 0 0 T 1 3 1
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DS(ph)GQVIPLIVES(ph)CIR 2 4.697 0.78668 S 2 2 1 +
DS(ph)GQVIPLIVES(ph)CIR 12 4.697 0.78668 S 2 2 1 +
DSEDS(ph)LY(ph)NDYVDVFY(ph)NTK 7 4.0314 2.1864 Y 3 3 0.988714 +
DSEDS(ph)LY(ph)NDYVDVFY(ph)NTK 5 4.0314 2.1864 S 3 3 0.941579 +
DT(ph)LSNS(ph)TLT(ph)EFVK 2 0.6235 0.66507 T 3 3 0.961756
DT(ph)LSNS(ph)TLT(ph)EFVK 9 0.6235 0.66507 T 3 3 0.880026
EFGSQS(ph)IAIHEPQCLQK 6 0.78923 0.68849 S 1 3 0.826564
ENTICLLSQHQFMSGYSQDILM(ox)PLWT(ph)S(ph)YT(ph)VDR 29 0.95505 1.0024 T 3 4 0.87502
ENTICLLSQHQFMSGYSQDILM(ox)PLWT(ph)S(ph)YT(ph)VDR 26 0.95505 1.0024 T 3 4 0.805635
EVM(ox)LENY(ph)GNVVS(ph)LGILLR 12 1.7859 0.53794 S 2 3 1 +
EVM(ox)LENY(ph)GNVVS(ph)LGILLR 7 1.7859 0.53794 Y 2 3 1 +
EVMLENYGNLVSVGCQLS(ph)K 18 0.65302 0.63587 S 1 3 0.973629
FPGGSCM(ox)AALTVT(ph)LM(ox)VLSS(ph)PLALAGDTR 13 4.082 2.0966 T 2 3 0.953492 +
FVSIVT(ph)EEEGVY(ph)S(ph)VDYS(ph)K 12 0 0 Y 4 3 0.989888
FVSIVT(ph)EEEGVY(ph)S(ph)VDYS(ph)K 13 0 0 S 4 3 0.972152
FVSIVT(ph)EEEGVY(ph)S(ph)VDYS(ph)K 6 0 0 T 4 3 0.777465
GLLYDS(ph)DEEDEERPAR 6 0.80199 0.71766 S 1 2 1
GLS(ph)LDSFLR 3 1.0269 0.84621 S 1 2 1
GS(ph)FIITLVKIPRMILM(ox)Y(ph)IHS(ph)QLK 2 0.28389 0.34202 S 3 3 0.867587 +
GS(ph)T(ph)VHT(ph)AY(ph)LVLSSLAMFT(ph)CLCGM(ox)AGNSMVIWLLGFR18 0.23937 0.23771 T 5 4 0.924398 +
GS(ph)T(ph)VHT(ph)AY(ph)LVLSSLAMFT(ph)CLCGM(ox)AGNSMVIWLLGFR8 0.23937 0.23771 Y 5 4 0.814082 +
GY(ph)LSETVS(ph)NALGPQGR 2 0.84249 0.94568 Y 2 2 0.865648
GY(ph)QEVIQS(ph)IVQGPGT(ph)LGR 2 0.95576 0.57832 Y 3 3 1
HLPSPPTLDS(ph)IIT(ph)EY(ph)LR 15 0 0 Y 3 3 0.999796
HLPSPPTLDS(ph)IIT(ph)EY(ph)LR 13 0 0 T 3 3 0.999252
HSGLY(ph)LVVTTSENVS(ph)PFS(ph)LLELLSR 18 0 0 S 3 3 0.789984
HSGLY(ph)LVVTTSENVS(ph)PFS(ph)LLELLSR 5 0 0 Y 3 3 0.784338
IAESHLQSIS(ph)NLNENQASEEEDELGELR 10 0.47153 0.41918 S 1 4 0.837253
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IAFLFDS(ph)T(ph)LTAFLM(ox)M(ox)GNLSPNLK 7 0.93878 0.98284 S 1 3 0.999834
IAFLFDS(ph)T(ph)LTAFLM(ox)M(ox)GNLSPNLK 8 0.93878 0.98284 T 1 3 0.999641
IAQFLS(ph)DIPETVPLSTVNR 6 0.91981 0.80601 S 1 3 0.999994
IIFHENYNAGT(ph)YQNDIALIEMK 11 0.90388 0.7692 T 2 3 0.787359
IIFSTLGVCT(ph)FFAVGY(ph)MLLPLFAY(ph)FIR 24 0 0 Y 2 3 0.997899
IIFSTLGVCT(ph)FFAVGY(ph)MLLPLFAY(ph)FIR 16 0 0 Y 2 3 0.994484
IIFSTLGVCT(ph)FFAVGY(ph)MLLPLFAY(ph)FIR 10 0 0 T 1 3 0.902139
ILQQLGLDST(ph)CEDSIVVK 10 0.64662 0.76701 T 2 3 0.753397
IRS(ph)S(ph)LAVLHLENAS(ph)LS(ph)GRP 3 1.0031 1.0551 S 1 3 1
IRS(ph)S(ph)LAVLHLENAS(ph)LS(ph)GRP 4 1.0031 1.0551 S 1 3 1
IS(ph)LDSAQSSRSTSYSPR 2 0.66952 0.79173 S 1 3 0.997764
ITDT(ph)GLS(ph)Y(ph)LS(ph)TM(ox)SSLR 10 0.25479 0.1748 S 1 3 0.972387 +
ITDT(ph)GLS(ph)Y(ph)LS(ph)TM(ox)SSLR 8 0.25479 0.1748 Y 1 3 0.963579 +
ITDT(ph)GLS(ph)Y(ph)LS(ph)TM(ox)SSLR 4 0.25479 0.1748 T 1 3 0.878893 +
ITDT(ph)GLS(ph)Y(ph)LS(ph)TM(ox)SSLR 7 0.25479 0.1748 S 1 3 0.87763 +
IWALKNAFDY(ph)FNNM(ox)R 10 0 0 Y 1 3 1
IYS(ph)GTIK 3 0.80176 0.88136 S 3 2 0.863251
KDYLT(ph)GT(ph)GQDSS(ph)HLVLVTFK 7 0 0 T 2 3 0.758531
KDYLT(ph)GT(ph)GQDSS(ph)HLVLVTFK 12 0 0 S 1 3 0.877501
KY(ph)QM(ox)T(ph)GVEEVT(ph)QIPQEEHAANGPELLR 2 0 0 Y 2 3 1
KY(ph)QM(ox)T(ph)GVEEVT(ph)QIPQEEHAANGPELLR 5 0 0 T 1 3 1
KY(ph)QM(ox)T(ph)GVEEVT(ph)QIPQEEHAANGPELLR 11 0 0 T 1 3 1
LES(ph)Y(ph)LDLM(ox)PNPSLAQVK 3 0.38154 0.3069 S 2 3 0.999889 +
LES(ph)Y(ph)LDLM(ox)PNPSLAQVK 4 0.38154 0.3069 Y 1 3 0.999882 +
LGLLLLS(ph)LS(ph)QGQECGEY(ph)PVT(ph)IPSDLPADFQDFLK 9 1.3789 7.3773 S 1 4 0.999434 +
LGLLLLS(ph)LS(ph)QGQECGEY(ph)PVT(ph)IPSDLPADFQDFLK 7 1.3789 7.3773 S 1 4 0.99942 +
LHT(ph)PMYFFISQLALM(ox)DLMY(ph)LCVTVPK 19 0 0 Y 4 3 0.950056
LIMIPVELLLCY(ph)LLLHPVDAT(ph)S(ph)Y(ph)GK 21 0 0 T 2 3 1
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LIMIPVELLLCY(ph)LLLHPVDAT(ph)S(ph)Y(ph)GK 12 0 0 Y 2 3 1
LIMIPVELLLCY(ph)LLLHPVDAT(ph)S(ph)Y(ph)GK 22 0 0 S 1 3 1
LIMIPVELLLCY(ph)LLLHPVDAT(ph)S(ph)Y(ph)GK 23 0 0 Y 1 3 1
LLEPGTHQFAS(ph)VPVR 11 0.51573 3.4313 S 3 3 0.999999 +
LLQT(ph)IS(ph)DLM(ox)MS(ph)LPSGSSLQQM(ox)ALR 4 0 0 T 2 3 0.817507
LLQT(ph)IS(ph)DLM(ox)MS(ph)LPSGSSLQQM(ox)ALR 6 0 0 S 1 3 0.820288
LLS(ph)HPFLS(ph)THLGSS(ph)M(ox)AR 3 0.40429 0.19312 S 2 3 0.95699 +
LLS(ph)HPFLS(ph)THLGSS(ph)M(ox)AR 8 0.40429 0.19312 S 1 3 0.95699 +
LLS(ph)HPFLS(ph)THLGSS(ph)M(ox)AR 14 0.40429 0.19312 S 1 3 0.788614 +
LNDCS(ph)CLAS(ph)QAILLGILLK 5 0.23268 0.60836 S 1 3 1 +
LNDCS(ph)CLAS(ph)QAILLGILLK 9 0.23268 0.60836 S 1 3 1 +
LPAPLIS(ph)KQQFLS(ph)NS(ph)S(ph)R 7 1.3606 1.6391 S 4 3 1 +
LPAPLIS(ph)KQQFLS(ph)NS(ph)S(ph)R 13 1.3606 1.6391 S 4 3 1 +
LPEFLS(ph)LGNT(ph)FNS(ph)ITLQDEIHDDQGT(ph)TVIFQER 6 0.72807 2.9788 S 1 4 0.930955 +
LPEFLS(ph)LGNT(ph)FNS(ph)ITLQDEIHDDQGT(ph)TVIFQER 13 0.72807 2.9788 S 1 4 0.805934 +
LPEFLS(ph)LGNT(ph)FNS(ph)ITLQDEIHDDQGT(ph)TVIFQER 10 0.72807 2.9788 T 1 4 0.805934 +
LPVAT(ph)IFTT(ph)HAT(ph)LLGR 5 0.33658 0.75037 T 2 3 0.999966 +
LS(ph)ENAT(ph)IQLDVVEAET(ph)EEIT(ph)QGNT(ph)LLR 2 0 0 S 3 3 1
LS(ph)ENAT(ph)IQLDVVEAET(ph)EEIT(ph)QGNT(ph)LLR 6 0 0 T 3 3 1
LS(ph)ENAT(ph)IQLDVVEAET(ph)EEIT(ph)QGNT(ph)LLR 16 0 0 T 3 3 1
LS(ph)ENAT(ph)IQLDVVEAET(ph)EEIT(ph)QGNT(ph)LLR 24 0 0 T 2 3 1
LS(ph)ENAT(ph)IQLDVVEAET(ph)EEIT(ph)QGNT(ph)LLR 20 0 0 T 1 3 1
LS(ph)VLSALQDTFFAKLHR 2 0.83668 0.74408 S 1 3 0.99507
LSCHVLS(ph)ASVGSSAVMS(ph)T(ph)AIM(ox)AT(ph)LLLFK 23 0 0 T 1 3 0.982996
LSCHVLS(ph)ASVGSSAVMS(ph)T(ph)AIM(ox)AT(ph)LLLFK 18 0 0 T 1 3 0.864788
M(ox)DIGTLIWDGGPVPNT(ph)HINKCKNY(ph)Y(ph)EVLGVTK 25 0.3768 0.17034 Y 2 4 0.914605 +
M(ox)FFIQNYVVSEGQLEDS(ph)S(ph)LLEVDGPAM(ox)K 18 0 0 S 2 3 0.938655
M(ox)FFIQNYVVSEGQLEDS(ph)S(ph)LLEVDGPAM(ox)K 17 0 0 S 2 3 0.794356
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M(ox)GRTPT(ph)AVQVKS(ph)FTK 12 3.7885 1.5436 S 4 3 0.990097 +
M(ox)S(ph)GEFPSPVS(ph)IS(ph)IISSTSGGS(ph)GYGFR 2 0 0 S 3 3 0.772995
M(ox)SM(ox)PEALAAAT(ph)INAAYALGK 11 0.85343 0.63642 T 1 3 0.986677
M(ox)T(ph)CT(ph)AFGNPKPIVT(ph)WLK 14 0.67662 2.7014 T 4 2 1 +
M(ox)T(ph)VFQT(ph)TMCSILTR 2 1.0903 0.794 T 4 2 0.966739
MAPAFLLLLLLWPQGCVSGPS(ph)ADS(ph)VY(ph)T(ph)K 27 0.18958 1.0006 T 3 3 0.999335 +
MAPAFLLLLLLWPQGCVSGPS(ph)ADS(ph)VY(ph)T(ph)K 26 0.18958 1.0006 Y 3 3 0.999285 +
MAPAFLLLLLLWPQGCVSGPS(ph)ADS(ph)VY(ph)T(ph)K 24 0.18958 1.0006 S 3 3 0.997649 +
MAPAFLLLLLLWPQGCVSGPS(ph)ADS(ph)VY(ph)T(ph)K 21 0.18958 1.0006 S 3 3 0.839079 +
MS(ph)NQT(ph)DLLALGT(ph)AVGSILLYSTVK 12 0.91468 0.80016 T 4 4 0.966186
MS(ph)NQTDLLALGT(ph)AVGS(ph)ILLYSTVK 16 0.90513 0.84099 S 4 3 0.780623
NNS(ph)M(ox)NS(ph)NM(ox)GTGTFGPVGNGVHTGPES(ph)R 3 1.2943 0.56317 S 1 4 0.947038
NNS(ph)M(ox)NS(ph)NM(ox)GTGTFGPVGNGVHTGPES(ph)R 6 1.2943 0.56317 S 1 4 0.897224
NNS(ph)M(ox)NS(ph)NM(ox)GTGTFGPVGNGVHTGPES(ph)R 26 1.2943 0.56317 S 1 4 0.894947
NS(ph)QNPALEWNMASSIR 2 1.0189 0.75327 S 1 3 0.999726
PLAPPPQPPASPTHS(ph)PS(ph)FPIPDR 17 0.71038 2.2022 S 2 3 0.999956 +
PLAPPPQPPASPTHS(ph)PS(ph)FPIPDR 15 0.71038 2.2022 S 2 3 0.998423 +
PPALLT(ph)LYPAPDEDEAVERCS(ph)R 21 0 0 S 2 3 1
PPALLT(ph)LYPAPDEDEAVERCS(ph)R 6 0 0 T 2 3 0.84134
PPS(ph)VT(ph)PIFLEPPPK 3 0 0 S 2 2 1
PPS(ph)VT(ph)PIFLEPPPK 5 0 0 T 2 2 1
PRLELMDIIAENVLS(ph)EDR 15 11.696 2.7661 S 1 3 1
PS(ph)T(ph)GLLM(ox)YTLATR 2 0.85225 0.71016 S 5 3 0.996922
PS(ph)T(ph)GLLM(ox)YTLATR 3 0.85225 0.71016 T 1 3 0.996923
PT(ph)S(ph)S(ph)Y(ph)S(ph)MEQDK 2 0 0 T 2 2 1
PT(ph)S(ph)S(ph)Y(ph)S(ph)MEQDK 5 0 0 Y 2 2 1
PT(ph)S(ph)S(ph)Y(ph)S(ph)MEQDK 3 0 0 S 1 2 1
PT(ph)S(ph)S(ph)Y(ph)S(ph)MEQDK 4 0 0 S 1 2 1
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PT(ph)S(ph)S(ph)Y(ph)S(ph)MEQDK 6 0 0 S 1 2 1
PVVCATQM(ox)LESMIT(ph)KPR 14 0.68123 0.82517 T 3 3 0.973748
QFIT(ph)ILEAT(ph)HR 4 9.2751 1.7877 T 1 3 1 +
QFIT(ph)ILEAT(ph)HR 9 9.2751 1.7877 T 1 3 1 +
QGQY(ph)S(ph)PM(ox)AIEEQVAVIY(ph)AGVR 17 0.3762 0.6444 Y 2 3 1 +
QGQY(ph)S(ph)PM(ox)AIEEQVAVIY(ph)AGVR 5 0.3762 0.6444 S 1 3 1 +
QGQY(ph)S(ph)PM(ox)AIEEQVAVIY(ph)AGVR 4 0.3762 0.6444 Y 1 3 1 +
QIHDIVQS(ph)CQPGEVVIR 8 1.4595 0.70571 S 1 3 1
QIVSAVAY(ph)VHS(ph)QGYAHR 11 8.4832 5.4356 S 1 3 0.997785 +
QIVSAVAY(ph)VHS(ph)QGYAHR 8 11.233 6.9786 Y 1 3 0.979815 +
QLEPT(ph)VQSLEMKSKT(ph)AR 15 0.11109 0.11454 T 2 3 0.907779 +
QLEPT(ph)VQSLEMKSKT(ph)AR 5 0.11109 0.11454 T 2 3 0.907754 +
QT(ph)LAQELSLNES(ph)QIK 12 0 0 S 1 3 0.999865
QT(ph)LAQELSLNES(ph)QIK 2 0 0 T 1 3 0.999741
QYEQMHKELT(ph)DKLEHLEQEK 10 0.72529 0.74974 T 1 3 0.999971
RAT(ph)KELLST(ph)ITDPSVIVM(ox)ADWLK 9 0.61388 0.60149 T 1 3 0.870452
RLIAEGDAS(ph)PGEDR 9 0.74168 0.73998 S 3 3 1
S(ph)FTQNYDLLRHERLHMK 1 0.63816 0.19704 S 1 3 0.855715 +
S(ph)KTEADMEEY(ph)IWENSSSERNILET(ph)LLQMK 24 0.65116 0.52321 T 1 4 0.925526
S(ph)KTEADMEEY(ph)IWENSSSERNILET(ph)LLQMK 10 0.65116 0.52321 Y 1 4 0.924293
S(ph)LS(ph)TSHLPGLTT(ph)HS(ph)NKTFTQR 14 0.73791 0.54414 S 1 3 0.784995
S(ph)LS(ph)TSHLPGLTT(ph)HS(ph)NKTFTQR 12 0.73791 0.54414 T 1 3 0.784995
S(ph)LSQSFENLLDEPAYGLIQK 1 1.1582 0.89334 S 5 3 0.995734
S(ph)PEWQVVTQDGT(ph)GALHT(ph)T(ph)Y(ph)LQCK 17 0.82352 0.85004 T 1 3 0.998854
S(ph)PEWQVVTQDGT(ph)GALHT(ph)T(ph)Y(ph)LQCK 18 0.82352 0.85004 T 1 3 0.998854
S(ph)PEWQVVTQDGT(ph)GALHT(ph)T(ph)Y(ph)LQCK 19 0.82352 0.85004 Y 1 3 0.997419
S(ph)PEWQVVTQDGT(ph)GALHT(ph)T(ph)Y(ph)LQCK 12 0.82352 0.85004 T 1 3 0.98088
S(ph)PT(ph)S(ph)SVATPS(ph)STIST(ph)PT(ph)KR 15 0 0 T 2 3 0.833694
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treatments
S(ph)PT(ph)S(ph)SVATPS(ph)STIST(ph)PT(ph)KR 17 0 0 T 1 3 0.96545
S(ph)PT(ph)S(ph)SVATPS(ph)STIST(ph)PT(ph)KR 1 0 0 S 1 3 0.858673
S(ph)SHETLNIVEEK 1 1.3562 1.0807 S 1 3 0.848773
SHLS(ph)T(ph)AGGLAVPSLPT(ph)AGPYY(ph)S(ph)PYALYGQR 5 2.509 1.2208 T 1 3 0.851058 +
SHLS(ph)T(ph)AGGLAVPSLPT(ph)AGPYY(ph)S(ph)PYALYGQR 4 2.509 1.2208 S 1 3 0.766145 +
SHLS(ph)T(ph)AGGLAVPSLPT(ph)AGPYY(ph)S(ph)PYALYGQR 16 2.509 1.2208 T 1 3 0.752798 +
STAPLLDVFS(ph)S(ph)MLKDTTS(ph)QHR 11 0.70068 0.61142 S 2 3 0.946406 +
STAPLLDVFS(ph)S(ph)MLKDTTS(ph)QHR 10 0.70068 0.61142 S 2 3 0.941476 +
T(ph)EEEIEM(ox)M(ox)KLMGFASFDSTK 1 0.7057 0.97952 T 4 3 0.997829 +
T(ph)EFLM(ox)QLDT(ph)VLT(ph)SAEDQIVVICATSK 1 0 0 T 4 3 0.990126 +
T(ph)EFLM(ox)QLDT(ph)VLT(ph)SAEDQIVVICATSK 9 0 0 T 1 3 0.884717 +
T(ph)FLHPEGDHFTLISIYK 1 1.1585 0.88084 T 3 3 0.999385 +
T(ph)GT(ph)PAVT(ph)STS(ph)SASSSLGEK 1 0.64191 0.71316 T 3 3 0.998091 +
T(ph)GT(ph)PAVT(ph)STS(ph)SASSSLGEK 3 0.64191 0.71316 T 3 3 0.923683 +
T(ph)GT(ph)PAVT(ph)STS(ph)SASSSLGEK 7 0.64191 0.71316 T 2 3 0.784398 +
T(ph)KSPTDDEVTPSAVVR 1 0.52839 0.61456 T 2 2 0.98241 +
T(ph)LAHGALAQLGS(ph)LQPLS(ph)VGCVEIR 12 0 0 S 1 3 1 +
T(ph)LAHGALAQLGS(ph)LQPLS(ph)VGCVEIR 17 0 0 S 1 3 1 +
T(ph)TEELNEALSAK 1 0.90643 0.75699 T 5 3 0.857802 +
T(ph)Y(ph)T(ph)VNHETS(ph)HPPPS(ph)K 3 0 0 T 1 2 0.997149 +
T(ph)Y(ph)T(ph)VNHETS(ph)HPPPS(ph)K 14 0 0 S 1 2 0.988568 +
T(ph)Y(ph)T(ph)VNHETS(ph)HPPPS(ph)K 1 0 0 T 1 2 0.987583 +
T(ph)Y(ph)T(ph)VNHETS(ph)HPPPS(ph)K 2 0 0 Y 1 2 0.986485
TFLTPS(ph)IFIIM(ox)VWY(ph)WR 6 0.4843 0.93855 S 1 3 0.775677
THNYSM(ox)AIT(ph)Y(ph)Y(ph)EAALK 10 0.67136 2.9971 Y 3 3 0.978973 +
THNYSM(ox)AIT(ph)Y(ph)Y(ph)EAALK 11 0.67136 2.9971 Y 1 3 0.978973 +
THNYSM(ox)AIT(ph)Y(ph)Y(ph)EAALK 9 0.67136 2.9971 T 1 3 0.975938 +
TLLTPHT(ph)GVT(ph)S(ph)QVLGVAAAVM(ox)TPLPGGHAAGR 7 0.14675 0.30174 T 2 5 0.788483 +
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TLLTPHT(ph)GVT(ph)S(ph)QVLGVAAAVM(ox)TPLPGGHAAGR 10 0.14675 0.30174 T 1 5 0.788483 +
TLLTPHT(ph)GVT(ph)S(ph)QVLGVAAAVM(ox)TPLPGGHAAGR 11 0.14675 0.30174 S 1 5 0.788208 +
TSIIDAVELAKDHS(ph)DLSR 14 0.6999 0.83091 S 2 3 0.918179
TT(ph)LNQGS(ph)CLHNPPRLGEIFM(ox)LK 7 0.674 0.72307 S 1 3 0.808808
TVLFGVQPKFT(ph)NVDIR 11 0.85867 0.89044 T 2 3 0.998902
TVTGT(ph)T(ph)M(ox)T(ph)LIPSEMPTPPK 8 0.25593 0.24376 T 2 3 0.865637 +
VS(ph)PVIINT(ph)MITITSALY(ph)T(ph)T(ph)K 19 0.51028 1.0429 T 4 3 0.990055
VS(ph)PVIINT(ph)MITITSALY(ph)T(ph)T(ph)K 17 0.51028 1.0429 Y 4 3 0.986243
VS(ph)PVIINT(ph)MITITSALY(ph)T(ph)T(ph)K 18 0.51028 1.0429 T 2 3 0.990058
VT(ph)VNYYDEEGS(ph)IPIDQAGLFLT(ph)AIEIS(ph)LDVDADR 2 0.51581 10.971 T 3 4 0.841158 +
VT(ph)VNYYDEEGS(ph)IPIDQAGLFLT(ph)AIEIS(ph)LDVDADR 27 0.52948 7.0426 S 2 4 0.999879 +
VT(ph)VNYYDEEGS(ph)IPIDQAGLFLT(ph)AIEIS(ph)LDVDADR 11 0.51581 10.971 S 2 4 0.966652 +
VT(ph)VNYYDEEGS(ph)IPIDQAGLFLT(ph)AIEIS(ph)LDVDADR 22 0.52948 7.0426 T 1 4 0.999921 +
VTIS(ph)VHEKGFIEIK 4 0.76744 0.54445 S 3 3 0.999196
VVLAAASHFFNLM(ox)FT(ph)T(ph)NM(ox)LES(ph)K 16 0.48894 0.36648 T 2 3 0.995543 +
VVLAAASHFFNLM(ox)FT(ph)T(ph)NM(ox)LES(ph)K 21 0.48894 0.36648 S 2 3 0.990395 +
VVLAAASHFFNLM(ox)FT(ph)T(ph)NM(ox)LES(ph)K 15 0.48894 0.36648 T 1 3 0.995543 +
WLIGGPNPNS(ph)LS(ph)GIRTSK 10 0.65487 1.3571 S 5 3 0.996741
WLIGGPNPNS(ph)LS(ph)GIRTSK 12 0.65487 1.3571 S 5 3 0.971689
WPDLLT(ph)EM(ox)VNRFQSGDFHVINGVLR 6 0.83567 0.74258 T 5 3 0.999331
WY(ph)LAT(ph)GDDIY(ph)DVPHIR 5 0 0 T 4 3 1
WY(ph)LAT(ph)GDDIY(ph)DVPHIR 2 0 0 Y 4 3 1
WY(ph)LAT(ph)GDDIY(ph)DVPHIR 10 0 0 Y 1 3 1
Y(ph)ILQGVT(ph)SWGLGCARPNKPGVY(ph)AR 1 0.56516 0.73067 Y 2 4 0.899308
Y(ph)IWGGFAY(ph)LQDM(ox)VEQGIT(ph)R 18 0.70745 2.8826 T 2 3 1 +
Y(ph)IWGGFAY(ph)LQDM(ox)VEQGIT(ph)R 1 0.70745 2.8826 Y 2 3 1 +
Y(ph)IWGGFAY(ph)LQDM(ox)VEQGIT(ph)R 8 0.70745 2.8826 Y 2 3 1 +
Y(ph)VM(ox)T(ph)FLNVLNFGDQGVYDIVNNLGSLVAR 1 0 0 Y 1 3 0.998426
Y(ph)VM(ox)T(ph)FLNVLNFGDQGVYDIVNNLGSLVAR 4 0 0 T 1 3 0.995058
YILQGVT(ph)S(ph)WGLGCARPNKPGVY(ph)AR 7 0.97795 0.48898 T 1 4 0.836514
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Appendix 2 DAVID analysis of the regulated phosphopeptides in 
LC-FAIMS-MS/MS  
 
Category Term 
KEGG_PATHWAY Insulin signalling pathway 
KEGG_PATHWAY Endocytosis 
KEGG_PATHWAY Regulation of actin cytoskeleton 
KEGG_PATHWAY Fc gamma R-mediated phagocytosis 
KEGG_PATHWAY Tight junction 
KEGG_PATHWAY G protein coupled receptors 
KEGG_PATHWAY ErbB signalling pathway 
KEGG_PATHWAY Base excision repair 
KEGG_PATHWAY mTOR signalling pathway 
KEGG_PATHWAY Thyroid cancer 
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Appendix 3 Peptide details of the SRM assay 
Set 1 
 
Peptide sequence
Precursor ion
(m/z)
Transition ion
(m/z)
Ion type
Collision
energy (eV)
RT
window(min)
RLS(ph)STSLASGHSVR 513.254 437.19 b3 26 12.8 - 14.2
RLS(ph)STSLASGHSVR 513.254 480.595 precursor-98 26 12.8 - 14.2
RLS(ph)STSLASGHSVR 513.254 1268.563 y12 23 12.8 - 14.2
RLNSS(ph)PRAPVSPLK 534.622 501.963 precursor-98 27 13.6 - 14.7
RLNSS(ph)PRAPVSPLK 534.622 964.593 y9 27 13.6 - 14.7
RLNSS(ph)PRAPVSPLK 534.622 1131.592 y10 26 13.6 - 14.7
GAQASSGS(ph)PALPR 639.795 553.345 y5 25 13.8 - 15.1
GAQASSGS(ph)PALPR 639.795 590.807 precursor-98 25 13.8 - 15.1
GAQASSGS(ph)PALPR 639.795 777.365 y7 25 13.8 - 15.1
DINNIDY(ph)Y(ph)KK 723.291 761.266 y4 28 14.2 - 15.5
DINNIDY(ph)Y(ph)KK 723.291 876.293 y5 28 14.2 - 15.5
DINNIDY(ph)Y(ph)KK 723.291 989.378 y6 28 14.2 - 15.5
NFSAAKS(ph)LLNKK 467.583 434.923 precursor-98 24 14.5 - 16.3
NFSAAKS(ph)LLNKK 467.583 782.417 y6 24 14.5 - 16.3
NFSAAKS(ph)LLNKK 467.583 910.512 y7 24 14.5 - 16.3
STS(ph)WHTALR 569.756 520.767 precursor-98 23 14.7 - 15.7
STS(ph)WHTALR 569.756 783.426 y6 23 14.7 - 15.7
STS(ph)WHTALR 569.756 950.424 y7 23 14.7 - 15.7
RPHFPQFSY(ph)SASGRE 615.942 849.313 y7 30 14.7 - 16.2
RPHFPQFSY(ph)SASGRE 615.942 936.345 y8 30 14.7 - 16.2
RPHFPQFSY(ph)SASGRE 615.942 1240.529 b9 28 14.7 - 16.2
VTS(ph)GGVSESPSGFSK 753.33 704.341 precursor-98 29 14.7 - 16.2
VTS(ph)GGVSESPSGFSK 753.33 925.426 y9 29 14.7 - 16.2
VTS(ph)GGVSESPSGFSK 753.33 1305.535 y13 26 14.7 - 16.2
TPKDS(ph)PGIPPSANAHQLFR 705.012 442.229 b4 34 14.9 - 17.2
TPKDS(ph)PGIPPSANAHQLFR 705.012 609.227 b5 34 14.9 - 17.2
TPKDS(ph)PGIPPSANAHQLFR 705.012 672.354 precursor-98 34 14.9 - 17.2
RES(ph)VVNLENFRK 524.263 491.604 precursor-98 26 15 - 16.2
RES(ph)VVNLENFRK 524.263 552.217 b4 26 15 - 16.2
RES(ph)VVNLENFRK 524.263 920.494 y7 26 15 - 16.2
TPKDS(ph)PGIPPSAGAHQLFR 686.007 442.229 b4 33 15 - 17.2
TPKDS(ph)PGIPPSAGAHQLFR 686.007 609.227 b5 33 15 - 17.2
TPKDS(ph)PGIPPSAGAHQLFR 686.007 653.346 precursor-98 33 15 - 17.2
RNS(ph)FTPLSSSNTIR 553.933 521.274 precursor-98 28 15.1 - 16.5
RNS(ph)FTPLSSSNTIR 553.933 585.217 b4 28 15.1 - 16.5
RNS(ph)FTPLSSSNTIR 553.933 1222.642 y11 25 15.1 - 16.5
NYSVGSRPLKPLS(ph)PLR 622.001 589.341 precursor-98 31 15.5 - 16.7
NYSVGSRPLKPLS(ph)PLR 622.001 665.338 y5 31 15.5 - 16.7
NYSVGSRPLKPLS(ph)PLR 622.001 762.39 y6 31 15.5 - 16.7
EHIEIIAPS(ph)PQR 735.361 664.281 y5 28 15.6 - 16.8
EHIEIIAPS(ph)PQR 735.361 686.373 precursor-98 28 15.6 - 16.8
EHIEIIAPS(ph)PQR 735.361 961.486 y8 28 15.6 - 16.8
RYS(ph)DHAGPAIPSVVAYPK 669.994 487.17 b3 33 15.7 - 17
RYS(ph)DHAGPAIPSVVAYPK 669.994 602.197 b4 33 15.7 - 17
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Set 1 continued 
 
 
 
 
 
 
 
 
 
 
 
Peptide sequence
Precursor ion
(m/z)
Transition ion
(m/z)
Ion type
Collision
energy (eV)
RT
window(min)
RYS(ph)DHAGPAIPSVVAYPK 669.994 637.336 precursor-98 33 15.7 - 17
NFS(ph)AAKS(ph)LLNKK 494.237 461.578 precursor-98 25 16 - 17.3
NFS(ph)AAKS(ph)LLNKK 494.237 782.417 y6 25 16 - 17.3
NFS(ph)AAKS(ph)LLNKK 494.237 1219.584 y10 23 16 - 17.3
HFM(ox)HQIITGMLYLHS(ph)HGILHR 879.765 732.426 y6 35 16.1 - 17.7
HFM(ox)HQIITGMLYLHS(ph)HGILHR 879.765 847.104 precursor-98 35 16.1 - 17.7
HFM(ox)HQIITGMLYLHS(ph)HGILHR 879.765 1036.483 y8 35 16.1 - 17.7
TTS(ph)FAESCKPVQQPSAFGSMK 771.009 203.102 b2 35 16.3 - 17.6
TTS(ph)FAESCKPVQQPSAFGSMK 771.009 370.1 b3 35 16.3 - 17.6
TTS(ph)FAESCKPVQQPSAFGSMK 771.009 738.35 precursor-98 35 16.3 - 17.6
RSDS(ph)ASSEPVGIYQGFEK 679.639 526.165 b4 33 16.4 - 18
RSDS(ph)ASSEPVGIYQGFEK 679.639 597.202 b5 33 16.4 - 18
RSDS(ph)ASSEPVGIYQGFEK 679.639 646.978 precursor-98 33 16.4 - 18
T(ph)TSFAESCKPVQQPSAFGSM(ox)K 776.341 182.021 b1 35 16.5 - 18
T(ph)TSFAESCKPVQQPSAFGSM(ox)K 776.341 743.682 precursor-98 35 16.5 - 18
T(ph)TSFAESCKPVQQPSAFGSM(ox)K 776.341 840.391 y8 35 16.5 - 18
VADPDHDHT(ph)GFLTEY(ph)VATR 768.65 689.301 y5 35 16.9 - 18.1
VADPDHDHT(ph)GFLTEY(ph)VATR 768.65 735.991 precursor-98 35 16.9 - 18.1
VADPDHDHT(ph)GFLTEY(ph)VATR 768.65 1068.378 b9 35 16.9 - 18.1
THFPQFS(ph)YSASIRE 583.926 551.267 y7 29 17.3 - 18.4
THFPQFS(ph)YSASIRE 583.926 825.409 y9 29 17.3 - 18.4
THFPQFS(ph)YSASIRE 583.926 1139.476 precursor-98 28 17.3 - 18.4
ALGERVS(ph)IL 519.273 470.285 precursor-98 21 18.2 - 19.4
ALGERVS(ph)IL 519.273 667.353 y5 21 18.2 - 19.4
ALGERVS(ph)IL 519.273 796.396 y6 21 18.2 - 19.4
S(ph)HNDFVAILDLPEGEHQYK 764.683 419.107 b3 35 18.6 - 19.9
S(ph)HNDFVAILDLPEGEHQYK 764.683 732.024 precursor-98 35 18.6 - 19.9
S(ph)HNDFVAILDLPEGEHQYK 764.683 1328.648 y11 34 18.6 - 19.9
DALDLSDINSEPPRGS(ph)FPSFEPR 876.066 843.407 precursor-98 35 19.7 - 22
DALDLSDINSEPPRGS(ph)FPSFEPR 876.066 879.435 y7 35 19.7 - 22
DALDLSDINSEPPRGS(ph)FPSFEPR 876.066 1356.609 y11 35 19.7 - 22
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Set 2 
 
 
 
Peptide sequence
Precursor ion
(m/z)
Transition ion
(m/z)
Ion type
Collision
energy (eV)
RT
window(min)
RLSS(ph)TSLASGHSVR 513.256 357.224 y7 26 12.7 - 14
RLSS(ph)TSLASGHSVR 513.256 480.595 precursor-98 26 12.7 - 14
RLSS(ph)TSLASGHSVR 513.256 1181.531 y11 24 12.7 - 14
RLNSSPRAPVS(ph)PLK 534.624 501.963 precursor-98 27 13.9 - 14.7
RLNSSPRAPVS(ph)PLK 534.624 623.316 y5 27 13.9 - 14.7
RLNSSPRAPVS(ph)PLK 534.624 720.369 y6 27 13.9 - 14.7
LSEEAECPNPST(ph)PSK 834.845 512.211 y4 32 14.1 - 15.5
LSEEAECPNPST(ph)PSK 834.845 696.296 y6 32 14.1 - 15.5
LSEEAECPNPST(ph)PSK 834.845 785.856 precursor-98 32 14.1 - 15.5
RRSIQDLT(ph)VTGTEPGQVSSR 756.376 723.717 precursor-98 35 14.1 - 15.7
RRSIQDLT(ph)VTGTEPGQVSSR 756.376 1050.509 b8 35 14.1 - 15.7
RRSIQDLT(ph)VTGTEPGQVSSR 756.376 1149.577 b9 35 14.1 - 15.7
RLNSS(ph)PRAPVS(ph)PLK 561.278 524.247 28 14.4 - 15.6
RLNSS(ph)PRAPVS(ph)PLK 561.278 528.619 28 14.4 - 15.6
RLNSS(ph)PRAPVS(ph)PLK 561.278 1211.558 26 14.4 - 15.6
DINNIDY(ph)YKK 683.308 438.271 y3 27 14.4 - 15.8
DINNIDY(ph)YKK 683.308 909.411 y6 27 14.4 - 15.8
DINNIDY(ph)YKK 683.308 928.344 b7 27 14.4 - 15.8
T(ph)TSQCKSEPPLLR 513.913 182.021 b1 26 14.7 - 16.1
T(ph)TSQCKSEPPLLR 513.913 481.254 precursor-98 26 14.7 - 16.1
T(ph)TSQCKSEPPLLR 513.913 1358.709 y12 22 14.7 - 16.1
RPPGMEY(ph)SYDINR 559.908 533.252 y6 28 15 - 16.2
RPPGMEY(ph)SYDINR 559.908 767.368 y8 28 15 - 16.2
RPPGMEY(ph)SYDINR 559.908 1139.44 y10 27 15 - 16.2
TPKDSPGIPPS(ph)AGAHQLFR 686.009 653.346 precursor-98 33 15.1 - 16.9
TPKDSPGIPPS(ph)AGAHQLFR 686.009 1163.535 y10 32 15.1 - 16.9
TPKDSPGIPPS(ph)AGAHQLFR 686.009 1260.588 y11 31 15.1 - 16.9
LGS(ph)YSGPTSVSR 645.79 501.174 b4 25 15.2 - 16.3
LGS(ph)YSGPTSVSR 645.79 588.206 b5 25 15.2 - 16.3
LGS(ph)YSGPTSVSR 645.79 596.802 precursor-98 25 15.2 - 16.3
KLPS(ph)TTL 420.217 371.229 precursor-98 18 15.3 - 17.3
KLPS(ph)TTL 420.217 501.195 y3 18 15.3 - 17.3
KLPS(ph)TTL 420.217 598.248 y5 18 15.3 - 17.3
RNSFT(ph)PLSSSNTIR 553.935 521.274 precursor-98 28 15.4 - 16.8
RNSFT(ph)PLSSSNTIR 553.935 686.265 b5 28 15.4 - 16.8
RNSFT(ph)PLSSSNTIR 553.935 1155.54 y10 26 15.4 - 16.8
RIS(ph)LSDMPR 577.773 518.239 y4 23 15.8 - 16.9
RIS(ph)LSDMPR 577.773 605.271 y5 23 15.8 - 16.9
RIS(ph)LSDMPR 577.773 718.355 y6 23 15.8 - 16.9
NLQS(ph)PTQFQTPR 748.848 699.86 precursor-98 29 15.9 - 17.2
NLQS(ph)PTQFQTPR 748.848 974.505 y8 29 15.9 - 17.2
NLQS(ph)PTQFQTPR 748.848 1141.503 y9 27 15.9 - 17.2
RPHFPQFS(ph)Y(ph)SASGRE 642.596 609.937 precursor-98 32 16 - 17.5
RPHFPQFS(ph)Y(ph)SASGRE 642.596 849.313 y7 32 16 - 17.5
RPHFPQFS(ph)Y(ph)SASGRE 642.596 1016.312 y8 31 16 - 17.5
VADPDHDHTGFLT(ph)EYVATR 741.995 709.336 precursor-98 35 16.1 - 18.5
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Peptide sequence
Precursor ion
(m/z)
Transition ion
(m/z)
Ion type
Collision
energy (eV)
RT
window(min)
VADPDHDHTGFLT(ph)EYVATR 741.995 738.378 y6 35 16.1 - 18.5
VADPDHDHTGFLT(ph)EYVATR 741.995 919.391 y7 35 16.1 - 18.5
IADPEHDHTGFLT(ph)EYVATR 751.339 718.68 precursor-98 35 16.4 - 18.8
IADPEHDHTGFLT(ph)EYVATR 751.339 738.378 y6 35 16.4 - 18.8
IADPEHDHTGFLT(ph)EYVATR 751.339 1032.476 y8 35 16.4 - 18.8
NYS(ph)VGSRPLKPLS(ph)PLR 648.655 544.18 y4 32 16.7 - 17.7
NYS(ph)VGSRPLKPLS(ph)PLR 648.655 615.996 precursor-98 32 16.7 - 17.7
NYS(ph)VGSRPLKPLS(ph)PLR 648.655 665.338 b5 32 16.7 - 17.7
RPHFPQFS(ph)YSASGTA 866.878 656.288 y7 33 16.7 - 17.8
RPHFPQFS(ph)YSASGTA 866.878 817.889 precursor-98 33 16.7 - 17.8
RPHFPQFS(ph)YSASGTA 866.878 1098.413 y10 32 16.7 - 17.8
IADPEHDHT(ph)GFLTEY(ph)VATR 777.994 751.339 precursor-98 35 16.9 - 18.4
IADPEHDHT(ph)GFLTEY(ph)VATR 777.994 818.344 y6 35 16.9 - 18.4
IADPEHDHT(ph)GFLTEY(ph)VATR 777.994 1153.43 b10 35 16.9 - 18.4
VADPDHDHTGFLT(ph)EY(ph)VATR 768.653 689.301 y5 35 17 - 18.2
VADPDHDHTGFLT(ph)EY(ph)VATR 768.653 741.995 y6 35 17 - 18.2
VADPDHDHTGFLT(ph)EY(ph)VATR 768.653 1316.532 y10 34 17 - 18.2
RVS(ph)LSEIGFGK 636.821 423.175 b3 25 17.4 - 18.3
RVS(ph)LSEIGFGK 636.821 587.833 precursor-98 25 17.4 - 18.3
RVS(ph)LSEIGFGK 636.821 1017.465 y9 25 17.4 - 18.3
S(ph)GGGDLTLGLEPSEEEAPR 997.441 282.048 b3 35 18.3 - 19.5
S(ph)GGGDLTLGLEPSEEEAPR 997.441 948.453 precursor-98 35 18.3 - 19.5
S(ph)GGGDLTLGLEPSEEEAPR 997.441 1156.547 y10 35 18.3 - 19.5
AVLS(ph)PGSVFSPGR 677.332 628.343 precursor-98 26 19.1 - 20.3
AVLS(ph)PGSVFSPGR 677.332 806.415 y8 26 19.1 - 20.3
AVLS(ph)PGSVFSPGR 677.332 903.468 y9 26 19.1 - 20.3
ATDSFS(ph)GRFEDVYQLQEDVLGEGAHAR 1026.459 522.219 precursor-98 35 20 - 21.6
ATDSFS(ph)GRFEDVYQLQEDVLGEGAHAR 1026.459 746.239 y6 35 20 - 21.6
ATDSFS(ph)GRFEDVYQLQEDVLGEGAHAR 1026.459 993.8 b10 35 20 - 21.6
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Set 3 
 
Peptide sequence
Precursor
ion (m/z)
Transition
ion (m/z)
Ion type
Collision
energy (eV)
RT
window(min)
GRNS(ph)ATSADEQPHIGNYR 684.968 566.208 b5 33 12.9 - 14.4
GRNS(ph)ATSADEQPHIGNYR 684.968 652.309 precursor-98 33 12.9 - 14.4
GRNS(ph)ATSADEQPHIGNYR 684.968 667.255 b6 33 12.9 - 14.4
RLS(ph)S(ph)TSLASGHSVR 539.91 507.251 precursor-98 27 13.4 - 14.8
RLS(ph)S(ph)TSLASGHSVR 539.91 705.236 b5 27 13.4 - 14.8
RLS(ph)S(ph)TSLASGHSVR 539.91 1014.532 y10 27 13.4 - 14.8
S(ph)TVASMMHR 550.225 269.053 b2 22 14.1 - 15.4
S(ph)TVASMMHR 550.225 501.236 precursor-98 22 14.1 - 15.4
S(ph)TVASMMHR 550.225 932.443 y8 22 14.1 - 15.4
DINNIDYY(ph)KK 683.31 518.237 y3 27 14.1 - 15.6
DINNIDYY(ph)KK 683.31 848.378 b7 27 14.1 - 15.6
DINNIDYY(ph)KK 683.31 909.411 y6 27 14.1 - 15.6
NFS(ph)AAKSLLNKK 467.581 429.116 precursor-98 24 14.4 - 16.3
NFS(ph)AAKSLLNKK 467.581 434.923 b3 24 14.4 - 16.3
NFS(ph)AAKSLLNKK 467.581 500.154 b4 24 14.4 - 16.3
S(ph)GEQITSSPVSPK 698.821 354.069 b3 27 14.6 - 15.8
S(ph)GEQITSSPVSPK 698.821 649.833 precursor-98 27 14.6 - 15.8
S(ph)GEQITSSPVSPK 698.821 802.43 y8 27 14.6 - 15.8
RPHFPQFS(ph)YSASGRE 615.94 583.282 precursor-98 30 14.7 - 16.4
RPHFPQFS(ph)YSASGRE 615.94 1077.466 b8 30 14.7 - 16.4
RPHFPQFS(ph)YSASGRE 615.94 1083.414 y9 30 14.7 - 16.4
RPPGMEYS(ph)YDINR 559.91 527.249 precursor-98 28 14.8 - 16.6
RPPGMEYS(ph)YDINR 559.91 680.336 y5 28 14.8 - 16.6
RPPGMEYS(ph)YDINR 559.91 1010.397 y7 28 14.8 - 16.6
T(ph)PKDSPGIPPSAGAHQLFR 686.005 279.074 b2 33 14.9 - 17
T(ph)PKDSPGIPPSAGAHQLFR 686.005 407.168 b3 33 14.9 - 17
T(ph)PKDSPGIPPSAGAHQLFR 686.005 653.346 precursor-98 33 14.9 - 17
EKFS(ph)FEPK 546.244 497.256 precursor-98 22 15 - 16.3
EKFS(ph)FEPK 546.244 687.274 y5 22 15 - 16.3
EKFS(ph)FEPK 546.244 834.343 y6 22 15 - 16.3
KLPST(ph)TL 420.219 371.229 precursor-98 18 15.3 - 17.1
KLPST(ph)TL 420.219 414.163 y3 18 15.3 - 17.1
KLPST(ph)TL 420.219 598.248 y5 18 15.3 - 17.1
SGS(ph)PSDNSGAEEMEVSLAKPK 733.987 312.059 b3 35 15.6 - 16.9
SGS(ph)PSDNSGAEEMEVSLAKPK 733.987 409.111 b4 35 15.6 - 16.9
SGS(ph)PSDNSGAEEMEVSLAKPK 733.987 701.328 precursor-98 35 15.6 - 16.9
TPKDS(ph)PGIPPS(ph)ANAHQLFR 731.668 609.227 b5 35 15.6 - 18
TPKDS(ph)PGIPPS(ph)ANAHQLFR 731.668 699.009 precursor-98 35 15.6 - 18
TPKDS(ph)PGIPPS(ph)ANAHQLFR 731.668 1220.557 y10 33 15.6 - 18
NYS(ph)VGSRPLKPLSPLR 622 544.18 b4 31 15.7 - 16.9
NYS(ph)VGSRPLKPLSPLR 622 589.341 precursor-98 31 15.7 - 16.9
NYS(ph)VGSRPLKPLSPLR 622 601.201 b5 31 15.7 - 16.9
TPKDS(ph)PGIPPS(ph)AGAHQLFR 712.661 680.002 precursor-98 35 15.9 - 18
TPKDS(ph)PGIPPS(ph)AGAHQLFR 712.661 706.28 b6 35 15.9 - 18
TPKDS(ph)PGIPPS(ph)AGAHQLFR 712.661 1163.535 y10 33 15.9 - 18
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Set 3 continued 
 
 
 
 
 
 
 
 
Peptide sequence
Precursor
ion (m/z)
Transition
ion (m/z)
Ion type
Collision
energy (eV)
RT
window(min)
VADPDHDHTGFLTEY(ph)VATR 741.997 446.272 y4 35 16 - 18.4
VADPDHDHTGFLTEY(ph)VATR 741.997 689.301 y5 35 16 - 18.4
VADPDHDHTGFLTEY(ph)VATR 741.997 715.34 y7 35 16 - 18.4
IADPEHDHTGFLTEY(ph)VATR 751.341 689.301 y5 35 16.3 - 17.3
IADPEHDHTGFLTEY(ph)VATR 751.341 724.683 y6 35 16.3 - 17.3
IADPEHDHTGFLTEY(ph)VATR 751.341 818.344 y7 35 16.3 - 17.3
RS(ph)DSASSEPVGIYQGFEK 679.637 324.106 b2 33 16.4 - 17.8
RS(ph)DSASSEPVGIYQGFEK 679.637 439.133 b3 33 16.4 - 17.8
RS(ph)DSASSEPVGIYQGFEK 679.637 646.978 precursor-98 33 16.4 - 17.8
IADPEHDHTGFLT(ph)EY(ph)VATR 777.996 751.339 y6 35 16.8 - 18.3
IADPEHDHTGFLT(ph)EY(ph)VATR 777.996 818.344 y7 35 16.8 - 18.3
IADPEHDHTGFLT(ph)EY(ph)VATR 777.996 1112.442 y8 35 16.8 - 18.3
GLCTSPAEHQYFMTEY(ph)VATR 795.341 689.301 y5 35 16.9 - 18.4
GLCTSPAEHQYFMTEY(ph)VATR 795.341 768.686 precursor-98 35 16.9 - 18.4
GLCTSPAEHQYFMTEY(ph)VATR 795.341 818.344 y6 35 16.9 - 18.4
GAILTTM(ox)LVS(ph)R 629.317 580.329 precursor-98 25 17.4 - 18.5
GAILTTM(ox)LVS(ph)R 629.317 701.305 y5 25 17.4 - 18.5
GAILTTM(ox)LVS(ph)R 629.317 802.352 y6 25 17.4 - 18.5
GFS(ph)FVATGLM(ox)EDDGKPR 641.617 608.958 precursor-98 32 18.5 - 19.8
GFS(ph)FVATGLM(ox)EDDGKPR 641.617 618.232 b5 32 18.5 - 19.8
GFS(ph)FVATGLM(ox)EDDGKPR 641.617 1076.504 y9 31 18.5 - 19.8
LQPFHST(ph)ELEDDAIYSVHVPAGLYR 979.799 710.361 b6 35 19.4 - 20.6
LQPFHST(ph)ELEDDAIYSVHVPAGLYR 979.799 947.14 precursor-98 35 19.4 - 20.6
LQPFHST(ph)ELEDDAIYSVHVPAGLYR 979.799 1020.418 b8 35 19.4 - 20.6
S(ph)VVGTPAYLAPEVLR 826.426 366.142 b3 31 19.7 - 21
S(ph)VVGTPAYLAPEVLR 826.426 777.438 precursor-98 31 19.7 - 21
S(ph)VVGTPAYLAPEVLR 826.426 1128.641 y10 30 19.7 - 21
EYGS(ph)PLKAYT(ph)PVVVTQWYR 806.371 614.185 b5 35 20.3 - 22
EYGS(ph)PLKAYT(ph)PVVVTQWYR 806.371 773.712 precursor-98 35 20.3 - 22
EYGS(ph)PLKAYT(ph)PVVVTQWYR 806.371 1328.639 y10 35 20.3 - 22
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Appendix 4 Quantitation results of SRM assay 
 
Figure 1 Phosphorylation profile of ALGERVpSIL in response to FGF1 
 
Figure 2 Phosphorylation profile of AVLpSPGSVFSPGR in response to FGF1 
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Figure 3 Phosphorylation profile of DALDLSDINSEPPRGpSFPSFEPR in response to FGF1 
  
Figure 4 Phosphorylation profile of EHIEIIAPpSPQR in response to FGF1 
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Figure 5 Phosphorylation profile of EKFpSFEPK in response to FGF1 
 
Figure 6 Phosphorylation profile of KLPpSTTL in response to FGF1 
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Figure 7 Phosphorylation profile of LGpSYSGPTSVSR in response to FGF1 
 
Figure 8 Phosphorylation profile of LSEEAECPNPSpTPSK in response to FGF1 
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Figure 9 Phosphorylation profile of NYpSVGSRPLKPLpSPLR in response to FGF1 
 
Figure 10 Phosphorylation profile of REpSVVNLENFRK in response to FGF1 
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Figure 11 Phosphorylation profile of RIpSLSDMPR in response to FGF1 
 
Figure 12 Phosphorylation profile of RLNSpSPRAPVSPLK in response to FGF1 
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Figure 13 Phosphorylation profile of RLNSSPRAPVpSPLK in response to FGF1 
 
Figure 14 Phosphorylation profile of RLpSSTSLASGHSVR in response to FGF1 
210 
 
 
Figure 15 Phosphorylation profile of RLSpSTSLASGHSVR in response to FGF1 
 
Figure 16 Phosphorylation profile of RNpSFTPLSSSNTIR in response to FGF1 
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Figure 17 Phosphorylation profile of RPHFPQFpSpYSASGRE in response to FGF1 
 
Figure 18 Phosphorylation profile of RPHFPQFpSYSASGTA in response to FGF1 
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Figure 19 Phosphorylation profile of RPPGMEpYSYDINR in response to FGF1 
 
Figure 20 Phosphorylation profile of RRSIQDLpTVTGTEPGQVSSR in response to FGF1 
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Figure 21 Phosphorylation profile of RpSDSASSEPVGIYQGFEK in response to FGF1 
 
Figure 22 Phosphorylation profile of RYpSDHAGPAIPSVVAYPK in response to FGF1 
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Figure 23 Phosphorylation profile of pSGEQITSSPVSPK in response to FGF1 
 
Figure 24 Phosphorylation profile of STpSWHTALR in response to FGF1 
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Figure 25 Phosphorylation profile of pSVVGTPAYLAPEVLR in response to FGF1 
 
Figure 26 Phosphorylation profile of pTTSQCKSEPPLLR in response to FGF1 
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